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Abstract  
 
 
 
 
Peroxisomes represent crucial subcellular compartments for human life and 
health. They are remarkably dynamic organelles which respond to stimulation 
by adapting their structure, abundance, and metabolic functions according to 
cellular needs. Peroxisomes can form from pre-existing organelles by 
membrane growth and division, which results in peroxisome 
multiplication/proliferation. Growth and division in mammalian cells follows a 
well-defined multi-step process of morphological alterations including 
elongation/remodeling of the peroxisomal membrane (by PEX11β), constriction 
and recruitment of division factors (e.g. Fis1, MFF), and final membrane 
scission (by the dynamin-related GTPase Drp1) (Chapter 1). 
 
Although our understanding of the mechanisms by which peroxisomes 
proliferate is increasing, our knowledge on how the division/multiplication 
process is linked to extracellular signals is limited, in particular in humans. The 
classical pathway involved in peroxisome proliferation is mediated by a family of 
ligand-activated transcription factors known as peroxisome proliferator activated 
receptors (PPARs) (Chapter 1). 
 
This project focused on identifying novel signaling pathways and associated 
factors involved in peroxisome proliferation in humans. In this study, a cell-
based peroxisome proliferation assay using the HepG2 cell model with spherical 
peroxisomal forms has been developed to investigate different stimuli and their 
ability to induce peroxisome proliferation (Chapters 2 and 3). In this system, 
peroxisome elongation has been used as the read-out for peroxisome 
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proliferation. We also showed that the number of peroxisomes increased after 
division of elongated peroxisomes indicating peroxisome proliferation. 
 
Different stimuli, such as fatty acids, PPAR agonists and antagonists, have 
been used in this study. PPAR agonists and antagonists had no stimulatory or 
inhibitory effect on peroxisome elongation in our assay, suggesting PPAR-
independent regulatory processes. However, arachidonic acid and linoleic acid 
were able to induce peroxisome elongation, whereas palmitic acid and oleic 
acid were not effective. These findings 
 
indicate that general stimulation of fatty acid β-oxidation is not sufficient to 
induce peroxisome elongation/proliferation in HepG2 cells. Moreover, mRNA 
expression levels of peroxismal genes have been monitored during a time 
course in the HepG2 cell-based assay by qPCR. This analysis shows a 
regulation of expression of peroxins during peroxisome proliferation in human 
cells and suggests differences in the regulation pattern of PEX11α and PEX11β. 
 
In Chapter 4, motif binding sites for transcription factors in peroxisomal genes were 
analyzed. An initial map of candidate regulatory motif sites across the human 
peroxisomal genes has been developed (Secondment at the University of Sevilla, 
Spain with Prof. D. Devos). This analysis also revealed the presence of different 
transcription factor binding sites in the promoter regions of PEX11α and PEX11β, 
supporting different regulatory mechanisms. Based on the computational analysis, 
PEX11β contained a putative SMAD2/3 binding site suggesting a novel link 
between the canonical TGFβ signaling pathway and expression of PEX11β, a key 
regulator of peroxisome dynamics and proliferation. 
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Addition of TGFβ to HepG2 cells cultured under serum-free conditions induced 
elongation/growth of peroxisomes as well as peroxisome proliferation supporting a 
role for TGFβ signalling in peroxisomal growth and division (Chapter 5). 
Furthermore, to demonstrate that this induction is through a direct effect of TFGβ 
on the SMAD binding site found in PEX11β, we performed functional studies using 
a dual luciferase reporter assay with PEX11β wild type and mutated promoter 
regions (Secondment at Amsterdam Medical Center, Netherlands with Prof. H. 
Waterham). Whereas luciferase activity was induced by TGFβ stimulation with the 
PEX11β wild type promoter, mutation of the SMAD binding site abolished 
activation. In summary, this study revealed a new signaling pathway involved in 
peroxisome proliferation in humans and provided a tool to monitor peroxisome 
morphology and gene expression upon treatment with defined stimuli. 
 
Furthermore, I contributed to a study revealing that ER-peroxisome contacts are 
important for peroxisome elongation (Chapter 6). Our group identified peroxisomal 
acyl-CoA binding domain protein 5 (ACBD5), ACBD4 and VABP as a molecular 
linker between peroxisomes and the ER (Costello et al., 2017). Motif analysis of 
ACBD4 and ACBD5 promoter regions revealed that unlike PEX11β, these genes do 
not contain a binding site for SMAD, suggesting they are not co-regulated. Also, 
ACBD4 and ACBD5 do not share any common transcription factor binding sites 
suggesting different regulation. An interesting binding motif within the ACBD4 
promoter is a glucocorticoid receptor binding site. In our study, we found potential 
glucocorticoid response elements (GRE) in other peroxisomal genes encoding β-
oxidation enzymes. This may suggest an important role for glucocorticoid receptors 
in activating expression of peroxisomal genes resulting in the stimulation of fatty 
acid breakdown and energy production. 
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Chapter 1 – Introduction 
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          1.1 Peroxisomes 
 
 
Peroxisomes were first described as spherical microbodies found in mouse 
kidney by Rhodin in 1954 and later characterized and renamed by Christian de 
Duve and his group, who identified several enzymes responsible for hydrogen 
peroxide metabolism (De Duve & Baudhuin, 1966)) Peroxisomes are single 
membrane-bound organelles lacking DNA and protein synthesis machinery. For 
this reason, peroxisomal proteins are encoded by nuclear genes and most of 
them are synthesized on free polyribosomes present in the cytoplasm. 
Peroxisomes usually have a spherical or rod-like morphology (0.1 to 0.5 μm in 
diameter), but elongated tubular organelles can be observed (up to 5 μm) 
(Figure 1.1) (Baudhuin et al., 1964; De Duve & Baudhuin, 1966). 
 
Peroxisomes are essential for the breakdown of diverse fatty acids by β-
oxidation. Very long chain fatty acids (VLCFA) for example can only be 
degraded in peroxisomes and not in mitochondria (I. Singh et al., 1984). Defects 
in genes coding for peroxisomal proteins lead to several peroxisomal disorders 
with varying degrees of severity. 
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Figure 1.1. Microscopic views of peroxisomes. (A) Electron micrographs of 
peroxisomes from HepG2 cells. Magnification: x 85,000. (Costello et al., 2017) (B) Highly 
elongated, tubular peroxisomes in Mff-deficient fibroblasts where peroxisomes are able to 
elongate but cannot divide. (C) Regular tubular peroxisome morphology in HepG2 cells in 
normal culture media with serum. (D) HepG2 cells stained with PEX14 (peroxisomal 
marker, green) and Tom20 (mitochondria, red). Bars= 10 µm (ER = endoplasmic 
reticulum, PO = peroxisomes, M = mitochondria) 
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        1.2 Peroxisomal functions 
 
 
Peroxisomes harbour many metabolic functions that vary according to species, 
cell type, developmental stage and environmental conditions (Circu & Aw, 
2010). Peroxisomes in human cells are involved in lipid metabolism pathways 
which include the synthesis of cholesterol, bile acids and ether lipids such as 
plasmalogens (Wanders et al., 1987). The synthesis of the latter, which 
contributes to 80% of the phospholipid content of the white matter in brain and 
∼ 20% of the total phospholipid mass in humans, is initiated in the peroxisomes 
and completed in the ER (Biardi & Krisans, 1996; Krisans, 1992). Oxidation of the 
sterol side chain results in formation of the C27-bile acid intermediates 3α,7α- 
 
dihydroxycholestanoic acid (DHCA) and 3α,7α,12α-trihydroxycholestanoic acid 
(THCA). The C24-bile acids are formed from the C27-bile acid intermediates by 
peroxisomal β-oxidation of the side chain (Schepers et al., 1988; H. Singh et al., 
1994). Peroxisomes also process alpha-oxidation of 3- methyl-branched fatty 
acids, with phytanic acid (3,7,11,15- tetramethylhexadecanoic acid) as the best 
known example. Alpha-oxidation is a process in which fatty acids are shortened 
by one carbon atom (Mannaerts et al., 2000). 
 
Other peroxisomal functions include the oxidation of alcohols, catabolism of 
purines and polyamines, metabolism of prostaglandins, (Wanders et al., 1987), 
photorespiration in plants and penicillin synthesis in fungi (Jedlitschky et al., 
1991; Tolbert & Essner, 1981). In most organisms, peroxisomes play an 
essential role in lipid and reactive oxygen species (ROS) metabolism 
(Ivashchenko et al., 2011). Peroxisomes produce several types of reactive 
oxygen and nitrogen 
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species (ROS/RNS) (e.g. H2O2, O2•  ̅and NO•) (Fransen(Fransen et al., 2012), 
Nordgren (M. Nordgren & Fransen, 2014). For example, H2O2 is produced 
during beta-oxidation through the action of ACOX1, the first enzyme of the fatty 
acid beta-oxidation pathway, which catalyzes the desaturation of acyl-CoAs to 
2-trans-enoyl-CoAs. It donates electrons directly to molecular oxygen, thereby 
producing hydrogen peroxide (Circu & Aw, 2010). 
 
ROS production can be detrimental for the cells, but ROS also act as 
intracellular signalling molecules regulating kinase-driven networks leading to 
cell survival or apoptosis (Circu & Aw, 2010) by acting as messengers in cell 
signalling and homeostasis.The mechanism of redox signaling involves H2O2-
mediated oxidation of cysteine residues within proteins (Rhee et al., 2005). 
Cysteine residues exist as a thiolate anion (Cys-S-) at physiological pH and are 
more susceptible to oxidation compared to the protonated cysteine thiol (Cys-
SH) (Rhee et al., 2005). 
 
It has also been shown that generating ROS inside peroxisomes disturbs the 
mitochondrial redox balance, which may lead to mitochondrial fragmentation 
(Ivashchenko et al., 2011). In order to maintain the cellular redox state, the 
production of ROS/RNS is balanced by antioxidant enzymes, such as catalase, 
peroxiredoxin 5 and superoxide dismutase 1 (Fransen et al., 2012). Recently, 
peroxisomes have been identified as essential signalling platforms, playing key 
roles in antiviral signalling and ROS-dependent regulation of mTORC1 
signalling (Mast, (Mast et al., 2015; Zhang et al., 2013). In one study, Dixit and 
colleagues showed the dual targeting of the mitochondrial antiviral signalling 
(MAVS) protein to both peroxisomes and mitochondria, and its ability to induce 
different signalling cascades at each organelle in response to viral RNA 
recognition by RIG-I-like receptors (Dixit et al., 2010; Odendall & Kagan, 2013). 
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In another recent study, the tuberous sclerosis complex (TSC) was reportedly found at 
the peroxisomal membrane, functioned as a Rheb GTPase-activating protein (GAP), 
where it upregulates autophagy (and pexophagy) by repressing downstream mTORC1 
signalling in response to increases in ROS (Zhang et al., 2013). This ROS-dependent 
response is still not well understood, and further studies will be needed to better 
investigate the targeting of these proteins to peroxisomes and their responses to 
cellular and peroxisomal ROS. 
 
 
1.3 Peroxisomal diseases and disorders 
 
 
The peroxisomal disorders include a group of genetic diseases in which there is 
impairment in one or more peroxisomal functions. The peroxisomal disorders are 
subdivided into two subgroups comprising: (1) the peroxisome biogenesis disorders 
(PBDs) including four different autosomal recessive disorders: Zellweger syndrome 
(ZS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and 
rhizomelic chondrodysplasia punctata (RCDP) type; 
(2) The single peroxisomal (enzyme/transporters) protein deficiencies (Hashimoto et 
al., 1986; Waterham & Wanders, 2012). 
 
PBDs are due to mutation in the PEX genes encoding for peroxin proteins required for 
peroxisome biogenesis. ZS is an inherited peroxisomal disorder characterised by the 
absence of functional peroxisomes; hence, peroxisomal substrates (such as VLCFA, 
THCA and DHCA) accumulate while there is a shortage of essential peroxisomal 
products (such as plasmalogens which are essential for the formation of the myelin 
sheath) in every tissue. The consequences are especially destructive in the brain and 
spinal cord and patients born with Zellweger syndrome will die prematurely 
(Hashimoto et al., 1986; Wanders et al., 2017). 
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Mutations in PEX genes can result in the complete absence of functional peroxisomes 
or the ormation of empty peroxisomal membranes, so called “ghostes”, which are 
often enlarged and decreased in number. Ebberink et al. described the first patient 
with defective PEX11β resulting in a defect of peroxisome division (Ebberink et al., 
2012). The patient showed mild intellectual disability, congenital cataracts, progressive 
hearing loss and polyneuropathy. These clinical features are also observed in patients 
with a mild peroxisome biogenesis disorder (Ebberink et al., 2012). 
 
Single-enzyme deficiencies include disorders of peroxisomal beta-oxidation, and X-
linked adrenoleukodystrophy (X-ALD). X-ALD is caused by mutations in the ATP 
binding cassette transporter (ABCD1) gene involved in the uptake of VLCFA in 
peroxisomes (Biardi & Krisans, 1996). Clinical presentations are diverse, from the 
cerebral childhood form with difficulty in understanding speech and writing, lethal 
seizures to symptoms like schizophrenia or other psychiatric disorders in adult 
cerebral ALD (Waterham & Wanders, 2012). It has been shown that peroxisomes 
have a role against the development of pulmonary fibrosis (Oruqaj et al., 2015). In 
idiopathic pulmonary fibrosis, lung injury leads to the production of proinflammatory 
mediators such as TNF-α, IL-6, and ROS results in the activation of profibrogenic. This 
damage leads to down-regulation of peroxisomes specifically PEX13, which generates 
more ROS, thus enabling the persistence of fibrotic phenotype (Oruqaj et al., 2015). 
The existence of such serious peroxisomal diseases highlights the essential need for 
correctly functioning peroxisomes in humans. In many cases peroxisome numbers are 
reduced and stimulation of peroxisome proliferation may help to treat milder cases. 
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1.4 Biogenesis of peroxisomes 
 
Proteins specifically engaged in peroxisomal biogenesis are referred to as peroxins 
(encoded by PEX genes). More than 36 PEX genes have been identified in 
evolutionarily diverse organisms, however, not all organisms possess the full range of 
PEX genes (32 in yeast, 16 mammalian and 23 plant homologs) (Agrawal et al., 2011; 
Agrawal & Subramani, 2016; Mano & Nishimura, 2005; Yuan et al., 2016) (Figure 1.2). 
 
Peroxisome biogenesis is a multistep process and can be considered in three 
key stages: 1) matrix protein import, 2) membrane biogenesis, 3) 
proliferation of peroxisomes (Schrader & Fahimi, 2008). 
 
 
 
 
1.4.1 Matrix protein import 
 
 
Peroxisomal matrix proteins are synthesised in the cytosol and transported to the 
organelle by the shuttling receptors PEX5 and PEX7 (Braverman et al., 1998; Dodt 
& Gould, 1996); fully folded, co-factor bound or oligomeric proteins can be 
transported across the peroxisomal membrane. Matrix proteins have specific 
peroxisome targeted signal sequences (PTS1 and PTS2), which are recognized by 
the shuttling receptors PEX5 and PEX7, respectively (Eckert & Erdmann, 2003; 
Platta & Erdmann, 2007). PEX7 needs to interact with PEX5 for targeting to the 
peroxisomal membrane. PEX5 and PEX7 receptors form cytosolic complexes with 
their ligands and efficiently ferry them to the peroxisome membrane. The 
receptor/cargo complex binds at the peroxisome membrane to the PEX13 and 
PEX14 docking complex (Schueller et al., 2010). Following cargo release, these 
receptors are recycled back to the cytosol by an ubiquitin-dependent pathway, 
which involves PEX2, PEX10 and PEX12, and the AAA ATPases PEX1 and PEX6, 
in association with PEX26 for receptor export (Figure 1.2) (reviewed in (Francisco 
et al., 2014; Platta & Erdmann, 2007). 
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Figure 1.2. Overview of peroxisome genes involved in peroxisomes biogenesis, 
metabolism and protein import machinery in humans. Proteins specifically 
engaged in peroxisomal biogenesis are referred to as peroxins. PMPs are recognized 
by the cytosolic chaperone PEX19, which interacts with the PEX3-PEX16 membrane 
complex. Matrix proteins are being sorted by cytosolic receptors PEX5 and 
PEX7.Adopted from KEGG Pathway. 
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1.4.2 Membrane protein import 
 
 
The import of peroxisomal membrane proteins (PMPs) occurs independently of 
matrix import via a different import machinery. Most peroxisome membrane 
proteins (PMPs) are synthesised by free polyribosomes in the cytosol and 
contain one or more membrane peroxisome targeting signals (mPTS) (Halbach 
et al., 2006; Jones et al., 2001) . PMPs are recognised and targeted to 
peroxisomes by the cytosolic chaperone PEX19, which maintains them in a 
stable and import competent conformation, and keeps them from aggregating 
(Fang et al., 2004; Shibata et al., 2004). Most PMPs are recognized by PEX19, 
which then interacts with the PEX3-PEX16 membrane complex (Schmidt et al., 
2012). These three peroxins are essential for peroxisome membrane biogenesis 
in mammals, and loss of either one of them results in the complete loss of 
peroxisomes (Figure 1.2). 
 
The PMP-PEX19 complex docks at the peroxisomal membrane by interacting 
with PEX3 to insert newly formed proteins (Fang et al., 2004; Fujiki et al., 2006; 
Giannopoulou et al., 2016). It has been shown in mammalian cells that PEX3 
and PEX16 target peroxisomes either directly (Jones et al., 2004; Matsuzaki & 
Fujiki, 2008), or indirectly via the ER (Kim et al., 2006; Toro et al., 2009). PEX16 
promotes peroxisomal growth by enabling the PEX3-dependent integration of 
peroxisomal membrane proteins (Figure 1.2). 
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1.4.3 Growth and division vs de novo formation 
 
 
The early steps of peroxisome biogenesis are still controversially discussed 
(Agrawal & Subramani, 2016; Hettema et al., 2014) confronting a classical view 
of peroxisome generation by growth and division and the more recent de novo 
formation from the ER. Direct import of matrix and membrane proteins into the 
peroxisomes led to the classical view that peroxisomes are autonomous 
organelles and the proposal of the “growth and division” model (Fujiki et al., 
2014; Schrader et al., 2016). In this multistep pathway, lipid transfer from the 
ER leads to peroxisome elongation, constriction and fission (Fujiki et al., 2014). 
In contrast, the de novo synthesis model states that several peroxins, such as 
PEX3 and PEX16, are inserted in the ER, and segregate to specific ER exit 
sites and generate pre- peroxisomal vesicles (Agrawal & Subramani, 2016; 
Dimitrov et al., 2013) that may mature towards complete and functional 
peroxisomes. These vesicles have been suggested to i) mature into functional 
peroxisomes, ii) fuse into pre-existing peroxisomes, and iii) fuse with other pre-
peroxisomal vesicles to form mature peroxisomes (Agrawal et al., 2011; Kim, 
2006; van der Zand et al., 2012). 
 
In summary, a combined model where the contributions of both pathways 
depend on the cellular state and organism, is the most current view of 
peroxisome biogenesis. At the moment, growth and division is the major 
pathway but formation from other organelles is formally possible and may occur 
under exceptional conditions (Figure 1.3) (Agrawal & Subramani, 2016; 
Hettema et al., 2014; Sugiura et al., 2017). 
32 
 
 
 
 
1.5 Peroxisome proliferation 
 
 
In mammalian cells, peroxisome proliferation can be regulated by several 
nutritional and environmental changes, such as increases in free fatty acids and 
growth factors, hypoxia and cold exposure (Bagattin et al., 2010; Laurenti et al., 
2011; Schrader et al., 1998b). These stimuli induce an increase in the 
number/size of peroxisomes, and alterations in the expression of several 
peroxisomal proteins, such as ACOX1 or PBFE, in order to increase their 
metabolic activity (Bagattin et al., 2010; Diano et al., 2011; Gurvitz & 
Rottensteiner, 2006). The increase in number/size of peroxisomes could also 
facilitate interactions with other organelles by increasing the available surface 
area and facilitate metabolism. 
 
The known pathway involved in peroxisome proliferation is mediated by a family 
of ligand-activated transcription factors known as peroxisome proliferator 
activated receptors (PPARs) (Rakhshandehroo et al., 2010; Schrader et al., 
2012). These transcription factors are typically activated by lipid-ligands and 
regulate the expression of genes associated with lipid metabolism and 
adipocyte differentiation (Kliewer et al., 1992; Reddy & Hashimoto, 2001; 
Varanasi et al., 1996). Additional pathways independent of PPARs have also 
been described and it is likely that yet unknown mechanisms contribute to the 
regulation of peroxisome proliferation (Gondcaille et al., 2005; Li & Gould, 2002; 
Sexton et al., 2010). 
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1.6 The role of PEX11 in peroxisome proliferation in mammals 
 
 
In mammalian cells, peroxisome formation by growth and division follows 
defined steps of morphological alterations: initial membrane elongation of the 
compartment is carried out by the key peroxisomal membrane protein PEX11pβ, 
combined with the tail-anchored proteins Mff (mitochondrial fission factor) and 
Fis1 (fission protein 1) as well as the GTPase DRP1 (dynamin-related protein 1) 
which mediates final fission into spherical organelles (A. Koch et al., 2005; 
Motley et al., 2008). DRP1 is recruited to peroxisomes by the tail-anchored (TA) 
proteins FIS1 and MFF, which facilitate oligomerisation of DLP1 (A. Koch et al., 
2005; Lazarow & Fujiki, 1985; Otera et al., 2010). 
 
The three mammalian PEX11 isoforms, PEX11α, PEX11β and PEX11γ, 
are able to interact with each other and tend to form either homo-oligomers 
or homo-dimers (Figure 1.3) (J. Koch et al., 2010; Tanaka et al., 2003). 
 
PEX11α is mostly expressed in liver, kidney, heart, and testis (Abe & Fujiki, 1998; Li 
 
& Gould,  2002).  Studies  showed  that  a  PEX11α  knockout  mouse  is 
 
morphologically indistinguishable from the wild-type mouse, with no obvious 
effect on peroxisome number or metabolism (Li & Gould, 2002). Moreover, the 
induction of peroxisome proliferation through PPARα by ciprofibrate does not 
require PEX11α (Li & Gould, 2002). 
 
However, PEX11β knockout mice showed neonatal defects, neuronal apoptosis 
and migration defects similar to Zellweger syndrome phenotypes (Li & Gould, 
2002). This isoform is expressed in most of the tissues and it is not inducible by 
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proliferators. Human PEX11β overexpression leads to peroxisome proliferation 
by tubular peroxisome formation, followed by an increase in peroxisome number 
through division. PEX11α overexpression has no effect on peroxisome 
proliferation (Schrader et al., 1998b). 
 
The third isoform, PEX11γ, is constitutively expressed in liver (Kobayashi et al., 
2007) and might have a redundant function with PEX11β, although it is with 
22% amino acid identity less similar to PEX11β than PEX11α is to PEX11β 
(40% amino acid identity) (Tanaka et al., 2003). 
 
Studies with synthetic peptide corresponding to the N-terminal amphipathic helix 
of Pex11β showed that, this part induces the formation of tubule-like structures 
from artificial membranes in vitro (Opaliński et al., 2011). This membrane-
deforming activity has been shown to be dependent on the amphipathic 
properties of the Pex11pβ α-helical structure by introducing point mutations into 
its sequence (Yumi Yoshida et al., 2015). In summary, PEX11β is required for 
constitutive peroxisome biogenesis. PEX11β localizes to the peroxisomal 
membrane and upon activation assembles in patches at specific sites (Kliewer 
et al., 1992). The mitochondrial TA protein GDAP1 has also been shown to 
dually target peroxisomes and mitochondria, and to regulate organelle division 
(Huber et al., 2013). PEX11β interacts with FIS1 and MFF on the membrane, 
and activates DRP1 by its GTPase activating protein (GAP) activity (Williams et 
al., 2015). A summary of peroxisome proliferation is shown in Figure 1.3 
(Schrader et al., 2016). 
 
A recent study identified a patient with a mutation in PEX11β. Peroxisomes in 
cells derived from this patient appear enlarged and undivided, supporting a role 
for PEX11β in peroxisome proliferation and division (Ebberink et al., 2012). 
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Figure 1.3. Model for peroxisome proliferation. (A) Peroxisomes multiply by 
elongation (growth), constriction, and final fission (division) contributes to peroxisome 
proliferation in mammalian cells. (B) PEX11β is involved in the elongation/tubulation of 
peroxisomes (Schrader et al., 1998a). PEX11β localizes to the peroxisomal membrane 
and upon activation assembles in patches at specific sites (A. Koch et al., 2005). 
PEX11 proteins interact with the adaptor proteins Mff and Fis1, which recruit the fission 
GTPase DRP1 forming a ring-like structure (DLP1) around the organelle (Thoms & 
Erdmann, 2005). Adapted from Schrader (Schrader et al., 2012). 
 
 
 
1.7 Regulation of peroxisome proliferation in different organisms 
 
 
Peroxisome proliferation is supposed to be controlled by different types of signalling 
cascades that trigger the transcription of proliferation related genes. These 
cascades usually start with external stimuli such as fatty acids or fibrates and lead 
to an increase in peroxisome number (Gurvitz & Rottensteiner, 2006; Issemann & 
Green, 1990). Due to their critical metabolic functions, regulation of peroxisomal 
functions and signalling is vital for human health. This has been studied extensively 
in yeast but knowledge of the pathways in humans is scarce. Therefore, a better 
understanding of the signals involved in peroxisome proliferation and metabolic 
activity is necessary, not only to gain a deeper insight 
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into peroxisome biology but also as a potential starting point for generating 
drugs which could be used to treat peroxisome related diseases. 
 
In yeast, peroxisomes are crucial for the primary metabolism of several unusual 
carbon sources and various secondary metabolites such as penicillins, 
polyketides and terpenes. Pip2 and Oaf1p transcription factors form 
heterodimers and activate the transcription of peroxisomal genes containing 
oleate response elements (ORE (Gurvitz & Rottensteiner, 2006). Under glucose 
depression and oleate induction conditions, Adr1p binds to upstream activating 
sequence 1 (UAS1) promoter sites in the proximity of OREs. Adr1p binding 
enhances the affinity of the Pip2/Oaf1p complex to these promoters (Figure 
1.4) (Rottensteiner (Rottensteiner et al., 1996). 
 
Plant peroxisomes are involved in numerous processes, including primary and 
secondary metabolism, development, and responses to abiotic and biotic 
stresses. Like in mammals, PEX11 and DRP1 have a role in peroxisomal 
elongation and division. The proliferation can be induced with ROS, UV 
radiation, light, salt stress and clofibrate (Babu et al., 2003; H. Hu et al., 2008; 
Oikawa et al., 2015). Light induces peroxisome proliferation and up-regulation of 
the PEX11 gene. Activation of PEX11 requires the far-red light receptor phyA, 
as well as the bZIP transcription factor HYH, which binds directly to the 
promoter of PEX11 (J. Hu & Desai, 2008). It has been shown that during 
photomorphogenesis, both the import of leaf-peroxisome enzymes from the 
cytosol and the induction of peroxisome proliferation take place to prepare 
seedlings for photosynthesis and photorespiration (J. Hu & Desai, 2008; 
Issemann & Green, 1990; Lopez-Huertas et al., 2000). 
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In mammals, upon binding of ligand, PPARs hetero-dimerise with its binding 
partner, the 9-cis-retinoic acid receptor, RXRα, and bind to specific cis-acting 
DNA response elements known as peroxisome proliferator response elements 
(PPRE). PPREs consist of tandem repeats of the consensus hexameric motif 
TGACC (T/C) separated by one base pair (DR1). PPREs all have a third half-
site with high homology to the TGACCT consensus half-site either two 
nucleotides 5’ or three nucleotides 3’ to the PPRE (Issemann & Green, 1990). 
 
The sequence specificity of each PPRE is not strict, as the sequence of the 
PPRE can deviate from the consensus sequence by as many as 5 nucleotides 
(Issemann et al., 1993). Despite a study reporting a PPRE shared within the 
PEX11α and perilipin gene, there is no information so far on transcriptional 
regulation of PEX genes in humans/mammals (Shimizu et al., 2004). 
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Figure 1.4: Transcriptional regulation of peroxisome proliferation in different 
organisms (A) In mammals, PPAR and its binding partner RXR form a heterodimer and 
interact with PPAR response elements which lead to transcription of PPAR target genes. 
 
(B) In S. cerevisae Oaf1p and Pip2- form a heterodimer, bind to ORE and induce the 
transcription of peroxisomal genes. (C) In plants, far-red light causes binding of HYH 
transcription factor to light response elements upon Phytochrom A activation. Figure 
from (Schrader et al., 2012). 
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1.7.1 PPAR mechanism of action 
 
 
In mammals, the major known pathway involved in PO proliferation is the 
peroxisome proliferator-activated receptor (PPAR) dependent pathway (Kliewer 
et al., 1992). PPAR represents a family of nuclear receptors composed of three 
members: PPARα, PPARβ and PPARγ. PPARs respond to a broad class of 
structurally diverse ligands, including xenobiotic chemicals called peroxisome 
proliferators and both natural and synthetic fatty acids (Figure 1.5) 
(Rakhshandehroo et al., 2010). 
 
 
 
1.7.2 Role of PPAR and differences between activation in rodents and 
humans 
 
 
Peroxisome proliferation in mammals in response to specific stimuli was first 
described in rats treated with the fibrate ethyl-chlorophenoxy-isobutyrate (Hess 
et al., 1965). Further, PPARα is activated by binding fatty acid ligands, 
especially polyunsaturated fatty acids with 18-22 carbon atoms and 2-6 double 
bounds and forms heterodimers with its binding partner, retinoid X receptor 
alpha (RXRα) (Berger & Moller, 2002; Green, 1995). Endogenous ligands for 
PPARα include linoleic acid, arachidonic acid and leukotriene B4 (Berger & 
Moller, 2002; Schrader & Fahimi, 2006). Binding of these fatty acids and 
synthetic ligands causes a conformational change in PPARα leading to the 
recruitment of its co-activators (CBP-SRC-HAT complex, ASC complex, and 
TRAP-Mediator complex) which initiate the transcription of the target genes. So 
far it has been shown that target genes of PPARα participate in fatty acid 
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transport, fatty acid oxidation, triglyceride clearance, lipoprotein production, and 
cholesterol homeostasis (Kersten et al., 2000). 
 
A comparison of response to PPAR agonists in rat and human cells showed that rat 
hepatocytes responded to PPARα agonist treatment by inducing the mRNA for 
several peroxisome proliferation-related genes including FACO, HD, THIO, CYP4A, 
and PMP-70 and had increased fatty acyl-CoA oxidase (Lawrence et al., 2001b). 
However, there was no change in expression of these genes in human 
hepatoblastoma (HepG2) cells treated with this agonist (Lawrence et al., 2001a). 
 
Mukherjee et al. have observed that WY14,643 (PPARα agonist) was more 
potent at activating the rat PPARα than the human PPARα (Mukherjee et al., 
1997). In addition, they observed that ETYA was more potent on the human 
PPARα than on the rat PPARα. There are two amino acids that differ in the 
ligand-binding domain of PPARα between rat and human. These differences in 
amino acid sequence may explain the differences in the potency of the various 
ligands for each of the species receptors (Rakhshandehroo et al., 2010). 
 
In humans, PPARα plays a role in the regulation of lipid and glucose homeostasis 
and inflammatory responses (Rakhshandehroo et al., 2010). ChIP-seq analysis in 
human hepatoblastoma (HepG2) cells revealed peroxisome proliferator response 
elements (PPREs) in peroxisomal genes such as ACOX1, ACADs (acyl-CoA 
dehydrogenases) and G0S2 (G0/G1 Switch Regulatory Protein 2) (van der Meer et 
al., 2010), suggesting they are regulated by PPARα. Furthermore, studies with the 
synthetic PPAR activator GW7647, demonstrate that ACAD and ACOX1 are up-
regulated upon treatment with this PPARα agonist (P. J. Brown et al., 2001; 
McMullen et al., 2014). Among other slightly up-regulated genes in primary human 
hepatocytes treated with GW7647, are metabolism-related genes 
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such as PLIN1 (Perilipin 1), PDK4 (Pyruvate Dehydrogenase Kinase, Isozyme 
4), as well as PEX11α, highlighting the role of this pathway in regulating 
expression of genes involved in lipid metabolism (McMullen et al., 2014). 
However, none of these studies found an upregulation of genes involved in 
peroxisome dynamics/proliferation. The few peroxisomal related genes found to 
be upregulated by PPARa agonists (ACOX1, ACAD, PEX11a) are related to 
lipid metabolism and their upregulation does not induce peroxisome proliferation 
in humans (McMullen et al., 2014). 
 
The mechanism by which PPARα signalling could stimulate an increase in 
peroxisome numbers in humans remains unclearl. It has been established that 
one of the major factors involved in proliferation is PEX11β (introduction, 1.1.2) 
(Li & Gould, 2002) and currently there is no evidence for up-regulation of 
PEX11β following stimulation with PPARα agonists. 
 
This suggests involvement of PPAR independent pathways in the regulation of 
peroxisome proliferation. 
 
 
 
 
1.7.3 PPAR independent pathways 
 
 
Besides the PPAR dependent pathway, a PPAR independent pathway has 
recently been discovered involving the peroxisome proliferator activated 
receptor γ coactivator-1α (PGC1-α) in humans and mice. PGC1-α can activate 
gene expression by binding to other transcription factors such as NRF2 
(Kemper et al., 2014; Scarpulla, 2008). 
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External signals such as growth factors (GF) can induce peroxisome 
proliferation, suggesting involvement of GF dependent cascades such as mTOR 
in peroxisome proliferation (Schrader et al., 1996). The mTOR protein forms two 
complexes, mTORC1 and mTORC2, each of which contains distinct 
components and signals through a different set of downstream effectors. 
mTORC1 is also induced by growth factors. TSC inhibits the activity of the small 
GTPase Rheb to repress mammalian target of rapamycin complex 1 (mTORC1) 
signalling, a negative regulator of autophagy. Recently, the mTOR pathway has 
been linked to peroxisomes and the localization of TSC1, TSC2 and Rheb 
(major components of mTOR signalling pathway) to peroxisomes has been 
reported. In this study, it has been shown that TSC1 and TSC2 bind PEX19 and 
PEX5, respectively, and that these mTORC1 regulators localize to the 
cytoplasmic surface of the peroxisomal membrane (Zhang et al., 2013). So far, 
it has been shown that peroxisome proliferation in mammals depends on 
PPARα, but there is more to investigate on other extracellular and intracellular 
signalling cascades involved in peroxisome proliferation which can be activated 
by extracellular signals such as ROS and growth factors (Figure 1.5). 
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Figure 1.5: Model for peroxisome proliferation. (A) In mammals, peroxisome 
proliferator-activated receptor alpha (PPARα) is activated by fatty acid-ligands. (B) 
PPARs and retinoid X receptor (RXR) coordinately bind to the PPAR response element 
(PPRE) of peroxisomal genes to initiate gene expression resulting in peroxisome 
proliferation. However, PPARα-independent mechanisms have also been described. 
(C) The activation of PPARα/RxR usually promotes expression of peroxisomal 
enzymes (e.g. for peroxisomal fatty acid β-oxidation) and biogenesis factors (e.g. 
PEX11) (X. Xie et al., 2015). Key division proteins are the Dynamin-like large GTPase 
DLP1 and its receptors Mff and Fis. Other extracellular and intracellular signalling 
cascades involved in peroxisome proliferation in mammals are largely unknown. 
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1.8 Peroxisome degradation 
 
 
The major process for peroxisome degradation in mammalian cells is 
Pexophagy, (reviewed in (Honsho et al., 2016; Marcus Nordgren et al., 2013); 
which allows cells to remove excessive or damaged peroxisomes to maintain 
organelle homeostasis and can be induced by cellular stresses such as altered 
redox state and hypoxia (Iwata et al., 2006; Walter et al., 2014; T. Zhang et al., 
2015). In general, autophagic processes are regulated by conserved ATG 
genes, supported by additional organism-specific factors which specifically 
regulate pexophagy (Meijer et al., 2007; Schroder et al., 2007). Around 30 
proteins have been shown to be involved in these pathways (Platta & Erdmann, 
2007; Sakai et al., 2006). Two distinct mechanisms have been described: 
macropexophagy and micropexophagy. The majority of peroxisomes in 
mammalian cells are degraded by macropexophagy, a process in which a 
double membrane structure, the autophagosome, grows and engulfs the target 
peroxisome and delivers it to lysosomes for recycling (Iwata et al., 2006; 
Mizushima et al., 2011). Organelles tagged for degradation are recognised by 
specific autophagy adaptors that form a bridge between the organelle and the 
growing autophagosomal membrane (Behrends & Fulda, 2012). 
 
Few studies reported the ubiquitination of PEX5 as a signal for pexophagy. 
Nordgren and colleagues showed that an export-incompetent version of EGFP-
tagged PEX5 became mono-ubiquitinated at the membrane and triggered 
pexophagy (M. Nordgren et al., 2015). This study, reported a role for ATM 
kinase in the phosphorylation of PEX5 in response to intracellular ROS. In 
another study, a role for the tail-anchored protein ACBD5 in pexophagy in 
mammalian cells has been suggested (Nazarko et al., 2014). 
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1.9 Peroxisome motility 
 
 
In eukaryotic cells the regulation of organelle movement and distribution is an 
important factor to reach the optimal activity and inheritance during the cell 
cycle (Jongsma et al., 2015). Whereas in yeast and plant cells peroxisomes 
move along actin filaments by interacting with myosin motors (Gao et al., 2016; 
Tower et al., 2011), in mammalian cells, two main populations of peroxisomes 
can be observed by live-cell imaging: the majority of peroxisomes (85-95%) 
exhibits slow oscillatory movement, whereas the remaining 5-15% display fast, 
directional, and microtubule-dependent movement (Costello et al., 2017b; Rapp 
et al., 1996; Wiemer et al., 1997). This low percentage of directed movement is 
sufficient to maintain a homogeneous peroxisomal distribution at minimum 
energy state (Bonekamp et al., 2012). 
 
Cells from patients with peroxisomal disorders possess enlarged and less 
abundant peroxisomes, which later on cluster and detach from microtubules 
(Nguyen et al., 2006). Overexpression of PEX11β in these cells promotes 
peroxisome proliferation and redistribution throughout the cell, suggesting that 
peroxisome dynamics are essential for their activity (Li & Gould, 2002). 
 
Further studies are needed to elucidate the correlation between peroxisome 
motility and function. 
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1.10 Objectives 
 
 
Peroxisomes represent crucial subcellular compartments for human life and 
health. They are remarkably dynamic organelles which respond to stimulation 
by adapting their structure, abundance, and metabolic functions according to 
cellular needs. An inability to multiply or proliferate peroxisomes has been linked 
to severe human disorders, which were only recently discovered. Although key 
players of peroxisomal fission have been identified at the organelle level, it is 
not clear how they are connected to cellular signalling pathways, in particular in 
humans. The well-known regulatory pathway regulating peroxisome-related 
genes such as ACOX1 in humans is the PPAR cascade. However, PPARα-
independent mechanisms have also been described. Hence, the establishment 
and characterization of a cell model which allows reliable monitoring of 
peroxisome dynamics and proliferation after application of a defined, well-
characterized stimulus is desirable. 
 
The aim of this thesis is to address new signalling pathways regulating peroxisome 
proliferation. In chapter 3, the effect of different stimuli on peroxisome proliferation 
was analysed, a cell-based peroxisome proliferation assay has been developed to 
study the effect of this stimuli on peroxisome morphology and peroxisomal gene 
expression. In chapter 4, transcription factor binding sites of peroxisomal genes 
have been identified, a bioinformatic approach has been used to identify these 
regulatory elements and link them to specific signalling networks. In chapter 5, 
functional studies have been performed to investigate the predicted novel signalling 
pathway (TGFβ) in peroxsiome proliferation. Molecular cell biology approaches and 
pharmacological studies have been combined with transcriptome analyses in order 
to identify novel regulatory networks. 
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Our results have led to the identification of a novel signalling pathway triggering 
peroxisome proliferation and may lead to novel leads for therapeutic options to 
improve peroxisome abundance. 
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Chapter 2 – Material and Methods 
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2.1 Buffers and solutions 
 
 
General buffers and solutions used in performed experiments are listed in table 
2.1. All buffers and solutions used were sterilised by autoclaving or filtration prior 
to use. 
 
 
 
 
Buffers and solutions Recipe/Composition 
  
Blocking solution for IMF 1% (w/v) BSA in PBS 
  
Blocking solution for WB 5% (w/v) low-fat milk powder (Marvel) in TBS-T 
  
Bradford Dye reagent 
Biorad) 1.5 dilution in water 
 
  
Cell Freezing media MEM/life technologies, 10% DMSO 
  
Collagen-R solution 
Type I rat tail collagen; 4 mg/ml in 0.1 % acetic acid, 0.4% 
(Serva)  
  
DEAE (50mg/ml) 
25 mg/ml in deionized H2O  
  
ECL reagent ECL prime GE healthcare 
  
FBS 10% Life technologies, south American origin 
  
Fixative for IMF, pH 7.4 4% (w/v) Paraformaldehyde in PBS 
  
LB medium 2.5% (w/v) LB-Broth Miller 
  
LB Agar 
2.5% (w/v) LB-Broth Miller 
1% (w/v) Agar  
  
 25 mM TrisHCl 
Lysis buffer 
150 mM NaCl 
0,5 mM EDTA 
pH 7.5 
Add fresh: 0.5% (w/v) Triton X-100, 1 mM PMSF, 1 mini  
 protease inhibitor cocktail tablet (Roche) 
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 12 g Mowiol 4-88 (Sigma) 
 40 ml PBS, stir over night 
Mowiol mounting media + 20 ml Glycerol, stir over night 
 Centrifuge 1 hour, 15,000 rpm, 4°C 
 Add sodium azide to the supernatant 
  
 0.5mg/ml recombinant human insulin, 0.5mg/ml human 
N1 Supplement 
transferrin (partially iron-saturated), 0.5μg/ml sodium 
selenite, 1.6mg/ml putrescine, and 0.73μg/ml  
 progesterone (Sigma) + 0.25% BSA 
  
 140 mM NaCl 
Phosphate buffered saline (PBS) 2.5 mM KCl 
pH 7.4 6.5 mM Na2HPO4 
 1.5 mM K2HPO4 
  
Permeabilisation solution 0.2% (v/v) Triton X-100 in PBS 
  
 60 mM Tris, pH 6.8 
 2% (w/v) SDS 
Laemmli-buffer 
10% (v/v) Glycerol 
0.005% (w/v) Bromophenol blue  
 20 mM DTT 
 5% (v/v) β-Mercaptoethanol (fresh) 
  
 25 mM Tris 
TGS- running buffer 190 mM Glycine 
 0.1% (w/v) SDS 
  
 48 mm Tris 
Transfer-buffer 
39 mM Glycine 
0.4% (w/v) SDS  
 20% (v/v) Methanol 
  
50x TAE –buffer 
40 mM Tris 
20 mM Acetic acid 
pH 8.0 
1 mM EDTA  
  
 50 mM Tris, pH 7.5 
TBS-T 150 mM Sodium chloride 
 0,05% Tween20 
  
Tris buffer, pH 8.8 (separating 
2 M Tris in water 
gel)  
  
Tris buffer, pH 6.8 (stacking gel) 1 M Tris in water 
  
 
 
 
Table 2.1 list of buffers and solutions and their composition/recipe 
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2.2 Cell culture 
 
2.2.1 Cell passage 
 
 
HepG2 cells were routinely cultured in Dulbecco’s Minimum Essential medium 
(MEM, Life technologies) low glucose (1.5 g/L) supplemented with 10% FBS, 100 
U/ml penicillin and 100 µg/ml streptomycin (all from Life technologies) at 37°C with 
5% CO2 and 95% humidity. Cell passage was performed twice a week, after the 
cells reached 75% confluency. Cells were washed once with 1x PBS and incubated 
for 3 minutes with 1 ml TrypLE Express at 37°C. Upon resuspension in medium, 
cells were centrifuged for 3 minutes at 1000 rpm. Cell pellets were resuspended in 
10 ml of fresh MEM medium and seeded at 1:10 to 1:3 dilution. Cells were routinely 
grown on 10ø cm tissue cell culture dishes (Greiner), for immunofluorescence, cells 
were seeded on round 19ø mm glass coverslips 24 hours prior to fixation. When 
using HepG2 cells, coverslips were coated with collagen (1/10 in d H2O, Serva) 
prior to seeding. To ensure reproducibility between experiments, cell number was 
determined using a Neubauer improved counting chamber or a TC20™ Automated 
Cell Counter (Bio-Rad, USA). 
 
Cell line Organism Tissue Cell type Morphology Source 
      
 Cercopithecus  SV40 Fibroblast- ATCC 
COS7  Kidney    
 aethiops  transformed like (CRL-1651) 
      
     ATCC 
HepG2 Homo sapiens Liver carcinoma Epithelial  
     (HB-8065) 
      
Table 2.2 – Cell lines      
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2.2.2 Cell freezing and thawing 
 
HepG2 cells, early passages, were kept through cryopreservation in liquid 
nitrogen. Cell pellets were resuspended in freezing medium (MEM 
supplemented with 10% FBS and 10% DMSO). 1 ml aliquots in cryovials 
(Greiner) were kept overnight at -80°C, prior to storage in a liquid nitrogen tank 
(Biorack). For thawing, cells were quickly resuspended with pre-warmed culture 
medium and seeded in a 10ø cm tissue cell culture dish. The culture medium 
was change after cell adhesion to remove debris and DMSO. 
 
2.3 Transfection methods 
 
 
Several transfection methods were used, depending on the cell line and 
experimental objective. COS7 cells were routinely transfected with (DEAE)-
dextran. HepG2 cells were transfected using Lipofectamine® 3000 (Invitrogen). 
For all transfection methods used, cells were either seeded in dishes or 19ø mm 
glass coverslips 24 hours prior to transfection. 
 
2.3.1 DEAE 
 
 
For transfection of 10ø cm dishes, 10 µg of DNA and 18 µl of DEAE-dextran were 
diluted in 1.5 ml of complete medium and incubated at room temperature for 20 
minutes. Cells were washed twice with PBS and incubated with the DNA-DEAE-
dextran mixture for 90 minutes, at 37ºC and 5% CO2. During incubation, the dishes 
were shaken every 15 minutes. After 90 minutes, the DNA-DEAE-dextran mixture 
was removed and 10 ml of complete medium supplemented with 10 µl of 
chloroquine were added to the dishes for 3 hours. Lastly, the cells were washed 3 
times with PBS and incubated with fresh medium for 24/48 hours. 
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2.3.2 Lipofectamine® 3000 
 
 
Transfection protocols for lipofectamine were optimized for DNA and siRNA 
following the manufacturer’s protocol and scaled up or down as necessary. For 
DNA transfection in a 6ø cm dish, one tube was prepared with 16.5 µl of 
lipofectamine diluted in 250 µl of Opti-MEM medium, and another with 11 µg of 
DNA and 22 µl of P3000 reagent in 250 µl of Opti-MEM medium (Life 
technologies) and mixed well. The DNA-P3000 mix was added to the diluted 
lipofectamine and incubated for 5 minutes at room temperature. Lastly, the 
DNA-lipid mixture was added to the previously seeded cells and incubated at 37 
0 C, 5% CO2 for 24-48 hours. 
 
2.4 Immunofluorescence (IMF) 
 
 
Cells grown on glass coverslips were processed for IMF 24/48 hours after 
seeding or transfection, and 72h after silencing. Cells were routinely fixed for 20 
minutes with 4% paraformaldehyde (PFA), followed by 3 washes in 1x PBS for 
5 minutes each and permeabilized with 0.2% Triton X-100 for 10 minutes. After 
3 washes in 1x PBS for 5 minutes, cells were blocked with 1% BSA for 10 
minutes. Followed by primary antibody incubation for 1 hour in a humid 
chamber (Table 2.3). Cells were washed with 1x PBS for 5 minutes. This step 
was repeated for the secondary antibody, protected from light. Coverslips were 
washed with dH2O to remove PBS and mounted using 1:4 Mowiol/ Propyl 
gallate mounting medium on glass slides (Fisher Scientific). All 
immunofluorescence steps were performed at room temperature. 
55 
 
 
  Dilution  
Antibodies Type   Source 
  IMF WB  
     
GAPDH mc rb - 1:5000 ProSci, San Diego, USA 
     
PEX14 pc rb 1:1400 1:4000 
Kind gift from D.Crane Griffith 
University, Australia     
     
PMP70 mc ms 1:500 1:5000 
Sigma-Aldrich, Schnelldorf, 
Germany     
     
AlexaFluor 488 
dk   Molecular Probes 
 
1:400 - (ThermoFisher Scientific, 
IgG 
anti-rb 
  
Waltan, USA)    
     
AlexaFluor 488 
dk   Molecular Probes 
 
1:400 - (ThermoFisher Scientific, 
IgG 
anti-ms 
  
Waltan, USA)    
     
HRP IgG 
gt 
- 1:5000 Bio-Rad, Munich, Germany 
anti-ms     
     
HRP IgG 
gt 
- 1:5000 Bio-Rad, Munich, Germany 
anti-rb     
     
 
Table 2.3 – Primary and secondary antibodies. Abbreviations: IMF, 
immunofluorescence; WB, western blot; mc, monoclonal; pc, polyclonal; ms, mouse; rb, 
rabbit; gt, goat; dk, donkey; HRP, horseradish peroxidase. 
 
 
 
 
2.5 Microscopy 
 
 
2.5.1 Epifluorescence and confocal microscopy 
 
 
Routine cell imaging was performed using an Olympus IX81 microscope 
equipped with an UPlanSApo 100x/1.40 oil objective (Olympus Optical, 
Hamburg, Germany). Digital images were taken with a CoolSNAP HQ2 CCD. 
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2.5.2 Image processing 
 
 
Images were adjusted for contrast and brightness using the Olympus Soft 
Imaging Viewer software (Olympus Soft Imaging Solutions GmbH) and 
MetaMorph 7 (Molecular Devices, USA). 
 
2.5.3 Live-cell imaging 
 
 
For live-cell imaging, HepG2 cells labelled with GFP-SKL were plated in 
collagen coated 3,5ø cm glass bottom dishes (Cellvis, USA and MatTek, USA). 
Live-cell imaging data was collected using an Olympus IX81 microscope 
equipped with a Yokogawa CSUX1 spinning disk head, CoolSNAP HQ2 CCD 
camera, 60x/1.35 oil objective. 
 
A controlled-temperature chamber and objective warmer were set-up on the 
microscope stage at 37ºC. During image acquisition, cells were kept at 37ºC 
and in CO2–independent medium (HEPES buffered) (Life Technologies). For 
each cell, 250 stacks of 9 planes (0.5µm thickness, 100ms exposure) were 
taken in a continuous stream. All conditions and laser intensities were kept 
between experiments. Digital images were taken and processed using VisiView 
software (Visitron Systems, Germany). 
 
 
 
 
2.6. Protein assays 
 
 
2.6.1 Cell lysis 
 
 
Routinely, cells were transfected in 6ø cm dishes (Greiner) and collected after 
48/72 hours. For lysis, cells were washed with 1x PBS 2 times, and 0.5 ml of lysis 
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buffer was added. To remove all cells, a cell scraper (Greiner, 25cm) was used 
and the cells were collected in a 1.5 ml micro-centrifuge tube. To improve lysis 
efficiency, cells were incubated at 40 C for 30 minutes, using a rotating shaker. 
Lysate was centrifuged at 15,000 g for 15 minutes at 4ºC to remove debris and 
the supernatant was kept. Protein concentration was determined by Bradford 
assay (Bradford 1976). 
 
2.6.2 SDS-PAGE Electrophoresis 
 
 
Standard 1D-SDS PolyAcrylamide Gel-Electrophoresis (SDS-PAGE) was 
performed with 10-12.5% separating and 4% stacking gels (Table 4). A pre-
stained molecular weight marker (Precision Plus, Biorad) was used to determine 
the protein size. The sample running front was visualized by bromophenol blue 
added to the Laemmli-buffer. Gels were conducted in chambers (Biorad, 
Minicell) containing TGS-buffer for 30 minutes at 80 V until the proteins were 
focused and entered the separating gel, followed by an increase to 130 V for 
approximately 90 minutes. 
 
2.6.3 Immunoblotting 
 
 
Protein transfer to nitrocellulose membrane (GE-Healthcare,) was performed by 
semi-dry western blotting for 60 minutes at 14 V (Transblot, BioRad). After 
protein transfer, membrane was blocked with 5% low fat powdered milk in TBS-
T for 1 hour at room temperature. Membrane was incubated with the primary 
antibody diluted in TBS-T, overnight at 4°C on a rotation shaker (VWR). 
Membrane was washed three times for 10 minutes with TBS-T. Secondary 
antibody incubation was performed for 60 minutes at room temperature, after 
which membrane was washed three times for 10 minutes with TBS-T. 
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 Separating Gel Stacking Gel 
 10% 12.5% 4% 
30% 
3.33 ml 4.17 ml 0.83 ml 
Polyacrylamide    
    
2 M Tris pH 8.8 1.86 ml 1.86 ml - 
    
1 M Tris pH 6.8 - - 0.63 ml 
    
20% SDS (0.1%) 50 µl 50 µl 25 µl 
    
dH2O 4.73 ml 3.89 ml 3.43 ml 
    
10% APS 30 µl 30 µl 40 µl 
    
TEMED 5 µl 5 µl 5 µl 
    
Total volume 10 ml 10 ml 5 ml 
    
 
 
 
Table 2.4 – Recipe for acrylamide gels 
 
 
 
 
2.6.4 ECL detection 
 
 
For protein detection, membrane was incubated for 2 minutes with 1:1 ECL 
prime and ECL (GE-Healthcare) and exposed to photographic film (GE-
Healthcare) for 1 to 10 minutes developed protected from light. 
 
 
 
 
2.7 Molecular biology techniques 
 
2.7.1 Gene synthesis 
 
 
Gene synthesis of PEX11β promoter regions (1302bp for the wild type and 
1296bp for the mutant) of human PEX11β was performed by Eurofins, 
sequences are shown in Table 2.5. 
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PEX11β Wt (1302 bp)   
GAG CTC CCC CAA GCG CAC CCT TTA ACT CAT GCT ATG GAC CCA AAT CCC TGT CCT GCC CGG 
TCC TGA GTC CTA GGT CAC TCA CCT GGG GGA AGG CAA GCA GGA AAC TAA GTC CCC AGG CTG 
CCC CCA GAA GTT TCC TTA CAC CTG AAC GGG ATC CAA GCG GGT TGA GTA CTG CTG CCT GGC 
GGT CCA ATC CAA TGA CCA CAG GCA GGA AAG CTG CAG AAT ACG TGG CCA TTA GTT TCA GGA 
ACA TCA GTG TCC GAC ATG CGA TGT CCA CAG CCA GCC ATT GAA CAG TGA TAT TCC AGG TGG 
CAT CTA GGG GCA TAA CCA CAA AAG TGA CTA GTA AGT CGG CGG CTG CTA AAT GGA TGA AGA 
GTC TCC TGA CCG GAG AGG GGC GGA GCT GGC TGG GTT CCC GCC GTG TCA CTG ACC ACA 
GGA CTG CCA GGT TCC CTC CAG CCG AAG AAA CAA ACA GCA CAA TGG TCA CTC CCA CTC GGA 
CCT TGG CTG CTG CCG AGA AGG TGG GCA GCT CTG AGC CCT CCA CCT CCA CTC CTG ATC CAG 
CCC AGA CCT CCT CCC CCG CTG CTG ACC CCA AGG GGT GCC GTT GCC TGC AGA CAT GGT GGC 
CTG GAG AGA AAC TGA GGA GGA TGA AGT GTG GGT ATG AAG CGG TTA GCT TTG GCC ACT GAT 
TCT TCG CCC TCC TTT TCA GGA TCT GGA GCT GAT TAT TGC GAA TTT CGT TCA CTA AAG CCT 
CTG CTT CTG GAG ACT CTC CAT CTG TTC TGG AGG AGG TCA CTT GTT CAA CTG TCA AGG TTC 
TGC AGG GAA CGA AGA TCT GGT ACC AAT CAC GCT CCT TTT TCC TTG GAC AGA CCA GCC TGG 
GCT TCA GGC CTC TAC TGA CCT AGA CCT CTT TAG CCC CTA CAG CCC TGG ATT CAG TCG GGG 
CCT GCG TGC ATG TGT ATT TGT GAG GTT CTG CCA GGC GCA CAC CTA TGC CGG CGG CCT CCA 
AGA CGT GGA GAT CAC TGC GGC GCT TTC TCG CCC CGC CCC GGC CCC TGC AGG CCC CGC 
CCT TGG TCA TGA ATA  
TTT AAA GAA GAA GGT GCC GCT GGA GGC GTG CTA GGG AGT AGG GGT CGT CTG ATA AGG 
GGA AGC TGT GAC GCA GAC ACG CAC AGT AAT ACA CAG ATG GAG GCT CAA AAG ACA CGA 
GTT TCG CGT CCT GAA ATT CCG CTT CCA GGG CCA AGC TTT CTT TTC TGA TAC TGT TTG 
TCC CTC GCG AGG CAC CGT TGG GTC GCG CAG TAG GCG TGA CTA GGG GCG GGA AGT 
GGG GCG GGA GCA GGG CCG CGG AGC CTG GGC TGC GGC TGT CAT CTC GAG  
 
PEX11β Mut (1296bp)  
 
CGG TCC TGA GTC CTA GGT CAC TCA CCT GGG GGA AGG CAA GCA GGA AAC TAA GTC CCC AGG 
CTG CCC CCA GAA GTT TCC TTA CAC CTG AAC GGG ATC CAA GCG GGT TGA GTA CTG CTG CCT 
GGC GGT CCA ATC CAA TGA CCA CAG GCA GGA AAG CTG CAG AAT ACG TGG CCA TTA GTT TCA 
GGA ACA TCA GTG TCC GAC ATG CGA TGT CCA CAG CCA GCC ATT GAA CAG TGA TAT TCC AGG 
TGG CAT CTA GGG GCA TAA CCA CAA AAG TGA CTA GTA AGT CGG CGG CTG CTA AAT GGA TGA 
AGA TGA CCG GAG AGG GGC GGA GCT GGC TGG GTT CCC GCC GTG TCA CTG ACC ACA GGA 
CTG CCA GGT TCC CTC CAG CCG AAG AAA CAA ACA GCA CAA TGG TCA CTC CCA CTC GGA CCT 
TGG CTG CTG CCG AGA AGG TGG GCA GCT CTG AGC CCT CCA CCT CCA CTC CTG ATC CAG CCC 
AGA CCT CCT CCC CCG CTG CTG ACC CCA AGG GGT GCC GTT GCC TGC AGA CAT GGT GGC CTG 
GAG AGA AAC TGA GGA GGA TGA AGT GTG GGT ATG AAG CGG TTA GCT TTG GCC ACT GAT TCT 
TCG CCC TCC TTT TCA GGA TCT GGA GCT GAT TAT TGC GAA TTT CGT TCA CTA AAG CCT CTG 
CTT CTG GAG ACT CTC CAT CTG TTC TGG AGG AGG TCA CTT GTT CAA CTG TCA AGG TTC TGC 
AGG GAA CGA AGA TCT GGT ACC AAT CAC GCT CCT TTT TCC TTG GAC AGA CCA GCC TGG GCT 
TCA GGC CTC TAC TGA CCT AGA CCT CTT TAG CCC CTA CAG CCC TGG ATT CAG TCG GGG CCT 
GCG TGC ATG TGT ATT TGT GAG GTT CTG CCA GGC GCA CAC CTA TGC CGG CGG CCT CCA AGA 
CGT GGA GAT CAC TGC GGC GCT TTC TCG CCC CGC CCC GGC CCC TGC AGG CCC CGC CCT 
TGG TCA TGA ATA TTT AAA GAA GAA GGT GCC GCT GGA GGC GTG CTA GGG AGT AGG GGT CGT 
CTG ATA AGG GGA AGC TGT GAC GCA GAC ACG CAC AGT AAT ACA CAG ATG GAG GCT CAA AAG 
ACA CGA GTT TCG CGT CCT GAA ATT CCG CTT CCA GGG CCA AGC TTT CTT TTC TGA TAC TGT 
TTG TCC CTC GCG  
AGG CAC CGT TGG GTC GCG CAG TAG GCG TGA CTA GGG GCG GGA AGT GGG GCG GGA 
GCA GGG CCG CGG AGC CTG GGC TGC GGC TGT CAT CTC GAG  
 
 
 
Table 2.5 PEX11β Wt /Mut Sequences, in yellow is binding site for SMAD 
transcription factor. 
60 
 
 
2.7.2 Digestion 
 
 
DNA and vectors were digested with restriction enzymes following the 
manufacturer’s suggested buffers at 37°C, for 4h or overnight. Enzyme 
inactivation was performed at 65°C for 20 minutes. Upon digestion, samples 
were run in an agarose gel to remove unwanted DNA fragments. Vector DNA 
was dephosphorylated with antarctic phosphatase for 40 minutes at 37°C, 
followed by enzyme inactivation for 20 minutes at 65°C. DNA concentration was 
determined using the Qubit2.0 fluorometer (Invitrogen, USA). To calculate the 
exact amount of DNA to be used, the following formula was used: 
 
 
 
 
 
The complementary sticky DNA ends created by digestion of vector and insert 
hybridize with each other and the DNA backbone is ligated by the DNA ligase 
by using T4 ligase (NEB) at 4 °C overnight or at room temperature for 2 hours. 
 
Digestion reactions were run in agarose gels prior to purification. DNA 
electrophoresis was routinely performed in an agarose gel (1% agarose in 1x 
TAE buffer) stained with ethidium bromide (0.5 µg/ml). Separation was 
performed at 75 V for 45 to 60 minutes in TAE 1x buffer. DNA samples were 
mixed with 6x purple loading dye buffer and loaded to individual wells. A DNA 
ladder was also loaded to one well to compare band sizes. Digital images were 
taken using the BioDoc-It Imaging System (UVP, USA). Specific DNA bands 
were excised with a scalpel under UV light and purified using the NucleoSpin 
Extract II kit (Macherey-Nagel, Germany), following the manufacturer’s protocol 
61 
 
 
2.7.3 Transformation 
 
 
Plasmid amplification was performed in competent DH5α Escherichia coli 
(E.coli) following a standard heat shock protocol. For each plasmid, 50 µl of 
competent E.coli bacteria were mixed with 2 µl of ligation mixture and incubated 
for 30 minutes on ice, followed by a 90 seconds heat shock at 42°C, and a short 
incubation on ice. The DNA plasmid binds to the membrane of the competent 
bacteria and the uptake is induced by a heat shock. Cells were incubated with 
950 µl of LB medium at 37°C for 1 hour with low agitation (300rpm). Cells were 
centrifuged for 2 minutes at 5000 rpm and the pellets were resuspended in 100 
µl of LB medium. Cells were spread using glass beads on LB agar plates 
containing Kanamycin (30 µg/ml) or Ampicillin (100 µg/ml). Plates were 
incubated overnight at 37°C. 
 
2.7.4 Plasmid isolation 
 
 
Colonies were tested by DNA digestion following plasmid DNA isolation using 
the NucleoSpin Plasmid Miniprep kit (Macherey-Nagel, Düren, Germany). A 
single positive clone for each plasmid was selected and sequenced (Table 2.6). 
For positive clones, DNA yield was increased by performing midi preparations 
using the NucleoBond Xtra Midi kit (Macherey-Nagel, Düren, Germany) 
according to the manufacturer’s protocol. 
 
Table 2.6 – Primers for cloning and sequencing  
 
 Name Sequence (5’ to 3’) 
   
 PGL3-forward 
5’ CTAGCAAAATAGGCTGTCCC 3’  
(RVprimer3)   
 PGL3- reverse (GL2) 5’ CTTTATGTTTTTGGCGTCTTCC 3’ 
   
 PEX11β- forward 5’ CTAAATGGATGAAGACTCCTGACCGGAGAG 3’ 
 PEX11β- reverse 5’ CTCTCCGGTCAGGAGTCTTCATCCATTTAG 3’ 
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Chapter 3 – Results 
 
 
 
Generation and application of a cell-
based peroxisome proliferation assay 
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Summary: 
 
 
Peroxisomes respond to external signals and changes in the cellular environment 
with alterations in their morphology, number and enzyme composition. How the 
regulation of these processes is integrated into the cell’s response to different 
stimuli, the signaling pathways and factors involved, remains unclear, in particular 
in human cells. Here, a cell-based peroxisome proliferation assay using the human 
hepatoblastoma cell line HepG2 has been developed to investigate different stimuli 
and their ability to induce peroxisome proliferation. This assay allows culture of 
HepG2 cells under serum-free conditions and can be applied for different 
approaches, including studying the expression of peroxisomal genes, the 
correlation between gene expression and peroxisome morphology and 
quantification of peroxisome number. As shown before (Schrader et al., 1998a), 
addition of serum/growth factors stimulated the membrane elongation of 
peroxisomes, which is a pre-requisite of peroxisomal division, multiplication/ 
proliferation, and was used as a morphological read-out via immunofluorescence. 
We demonstrated that growth of HepG2 cells was not affected under serum-free 
culture condition. Furthermore, autophagic processes were not induced. We also 
showed that the number of peroxisomes increased after division of elongated 
peroxisomes which is indicative for peroxisome proliferation. 
 
Different stimuli, such as fatty acids, PPAR agonists and antagonists, have been 
used in this study. PPAR agonists and antagonists had no stimulatory or inhibitory 
effect on peroxisome elongation in our assay, suggesting PPAR-independent 
regulatory processes. However, arachidonic acid and linoleic acid were able to 
induce peroxisome elongation, whereas palmitic acid and oleic acid were not 
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effective. These findings point to a stimulatory mechanism, which is different 
from mere stimulation of peroxisomal fatty acid β-oxidation. 
 
Analysis of peroxisome morphology and peroxisome gene expression during a time 
course showed an increase in PEX11β expression which reaches a maximum at 24 
hours before declining. This correlates very well with the induction of peroxisome 
elongation and subsequent division. No such increase was observed for PEX11α 
and PEX11y, suggesting different roles of PEX11 isoforms. Besides PEX11β there 
are several other factors whose activity could be modified to control peroxisome 
proliferation. Deficiencies in peroxisome proliferation have been associated with a 
variety of disease states, including liver diseases and neurological dysfunction, as 
well as cellular ageing (Cimini et al., 2009; Titorenko & Terlecky, 2011). A clear 
understanding of the mechanisms and signaling pathways that control peroxisome 
plasticity could allow modulation of peroxisome abundance to improve cellular 
function in health and disease. 
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3.1 Introduction 
 
 
3.1.1 Peroxisome plasticity and proliferation 
 
 
Peroxisomes are responsive organelles which show a remarkable plasticity with 
respect to morphology, number, protein composition and metabolic function. All 
those parameters can vary depending upon organism, cell type, developmental 
stage, and environmental conditions (Islinger et al., 2010). Peroxisomes in 
almost all organisms have the ability to proliferate and multiply or be degraded 
in response to nutritional and extracellular environmental stimuli (Schrader et 
al., 2012). 
 
Several morphologically distinct types of peroxisomes have been described in 
mammalian cells either by immunofluorescence or by electron microscopic 
studies (Schrader et al., 1996; Yamamoto & Fahimi, 1987). Peroxisomes can 
appear as spherical organelles, but are also observed to form elongated, tubular 
structures (Figure 3.1). Over the years it became evident, that elongation 
(tubulation) is the first step in a sequence of morphological changes which occur 
during peroxisome proliferation/multiplication. This step contributes to the 
expansion and growth of the peroxisomal membrane, which then constricts and 
divides into new, spherical peroxisomes, which import newly synthesized matrix 
proteins (see Introduction 1.6; Figure 1.3) (reviewed in (Schrader et al., 
2016)). PEX11 proteins are key factors in the elongation and division process. A 
striking increase in elongated peroxisomal forms on expression of PEX11 has 
been observed in all organisms studied including yeast, trypanosomes and 
mammalian cells (Erdmann & Blobel, 1995; Schrader et al., 1996). It is 
supposed that human PEX11β, which is very well studied, remodels and 
deforms the peroxisomal membrane by oligomerisation and 
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interaction with membrane lipids via its amphipathic helixes at the N-terminus of 
the protein (Delille et al., 2010; Opaliński et al., 2011; Y. Yoshida et al., 2015). It 
then recruits and interacts with components of the division machinery such as 
the adaptor proteins Fis1 and Mff, which are involved in the recruitment of the 
fission GTPase Drp1 (reviewed in (Schrader et al., 2016)). Recently, it was 
found that PEX11 also acts as a GTPase activating protein (GAP) towards Drp1 
and stimulates Drp1 GTPase activity and membrane scission (Williams et al., 
2015). Mutations in Drp1 and Mff have been linked to new disorders resulting in 
highly elongated peroxisomes which are unable to divide (Shamseldin et al., 
2012; Wanders & Waterham, 2006; Waterham et al., 2007). Patients with a loss 
of PEX11β function have also been identified (Ebberink et al., 2012; Taylor et 
al., 2017). They present with short stature, eye problems, progressive hearing 
loss and neurological defects. Similar to Drp1 or Mff deficiency, the metabolic 
functions of peroxisomes are either not or only slightly affected in patients with 
defects in peroxisome dynamics. This suggests that the symptoms relate to 
altered peroxisome plasticity, highlighting the importance of proper regulation of 
peroxisome abundance for cell function. In line with this, altered peroxisome 
abundance in PEX11β-deficient epidermal cells resulted in abnormal mitosis 
and organelle inheritance, thus affecting cell fate decisions (Asare et al., 2017). 
 
Elongated peroxisomes can be observed during rapid cellular growth, for 
example, after hepatectomy (Yamamoto & Fahimi, 1987) or in mammalian cells 
under conditions of low cell density (Schrader et al., 1998b). Stimulation of 
cultured cells with defined growth factors, fatty acids or free radicals also 
promotes peroxisome elongation (Schrader et al., 1996; Schrader et al., 1999) 
as well as depolymerisation of microtubules (Passmore et al., 2017; Schrader et 
al., 1996), suggesting the involvement of intracellular signalling in peroxisome 
elongation. Motor-driven pulling forces, e.g. mediated by the Kinesin-adaptor 
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Miro1 along microtubules, can also contribute to peroxisomal membrane 
 
expansion (Castro et al., 2018). 
 
Despite their importance to cell physiology, the mechanisms that mediate and 
regulate peroxisome membrane dynamics and abundance in humans are poorly 
understood. Despite progress in understanding of peroxisomal growth and 
division, the relation of these mechanisms with cellular signalling cascades and 
the transcriptomics behind this action is still not clear (see Introduction 1.7.3; 
Fig. 1.5). 
 
 
3.1.2 Peroxisome proliferator activated receptors (PPARs) 
 
 
The known pathway involved in peroxisome proliferation is mediated by a family 
of ligand-activated transcription factors known as peroxisome proliferator 
activated receptors (PPARs) (Rakhshandehroo et al., 2010; Schrader et al., 
2012; Y. X. Wang, 2010). 
 
PPARs are ligand-activated nuclear receptors which function in the regulation of 
genes involved in glucose and lipid homeostasis. PPARs represent a family of 
nuclear receptors composed of three members: PPARα, PPARβ, PPARγ which 
have tissue -specific expression, and vary in the responses they mediate 
through binding to their interaction partners. The PPAR:RXR heterodimer binds 
peroxisome proliferator receptor elements (PPREs) in and around target genes 
(Berger & Moller, 2002). These transcription factors are typically activated by 
lipid- ligands and regulate the expression of genes associated with lipid 
metabolism and adipocyte differentiation (Kliewer et al., 1992; Reddy & 
Hashimoto, 2001). 
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Additional pathways independent of PPARs have also been described and it is 
likely that yet unknown mechanisms contribute to the regulation of peroxisome 
proliferation (Gondcaille et al., 2005; Li & Gould, 2002; Sexton et al., 2010). 
 
 
 
3.1.3 PPAR independent mechanisms 
 
 
Even though there is evidence that peroxisome proliferation is regulated by 
PPARs it is likely that other regulatory mechanisms also play a role. 
Interestingly, peroxisome numbers have been shown to increase in response to 
external stimuli in a PPAR-independent manner. A set of chemical compounds 
(e.g. BM 15766 and 4-phenylbutyrate) was shown to induce peroxisome 
proliferation in mammalian (Ribeiro et al., 2012; Schrader et al., 2012). BM 
15766, an inhibitor of cholesterol biosynthesis at the 7-dehydrocholesterol-Δ7-
reductase step, was shown to induce peroxisome proliferation without 
significantly elevating fatty acid β-oxidation enzyme levels, thus implying a 
PPARα-independent signal transduction (Baumgart et al., 1990). 
 
Phenylbutyrate was also shown to induce peroxisome proliferation in mice in the 
absence of the nuclear receptor PPARα although a potential role for PPARγ has 
not been ruled out (Baumgart et al., 1990; Gondcaille et al., 2005; Song et al., 
2013). In a high content screen probing more than 15,000 drugs, 10 new 
compounds were reported to induce peroxisome proliferation in HepG2 cells, which 
are supposed to be refractory to PPARα-mediated peroxisome proliferation (Sexton 
et al., 2010). Thus, there is increasing evidence for the existence of numerous 
PPARα independent pathways controlling peroxisome abundance, which could be 
exploited for therapeutic use in humans. For most of the chemicals 
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described so far in the literature, the mechanism of action remains unknown 
(Ahmadian et al., 2013) However, unlike PPARα-ligands, which induce 
peroxisome proliferation in the absence of PEX11α, 4- phenylbutyrate does 
require PEX11α to induce peroxisome proliferation indicating the existence of 
alternative pathways involving different molecular players in order to control 
peroxisome abundance (Li & Gould, 2002). Besides the peroxisome 
proliferators reported up to now, other factors such as growth factors, 
polyunsaturated fatty acids (e.g. arachidonic acid) and ROS have been shown 
to induce peroxisomal elongation (a pre-requisite for proliferation) in human 
cells (Diano et al., 2011; Schrader et al., 1998a). 
 
Another PPAR independent pathway has recently been discovered involving 
PPARγ coactivator-1α (PGC1-α) in humans and mice (Bagattin et al., 2010). 
Although, as the name suggests, the obvious receptor for PGC1-α would indeed 
be PPARγ, this was excluded in this case. PGC1-α can activate gene 
expression by binding to other transcription factors such as NRF2 (Schrader et 
al., 2012; Vega et al., 2000). 
 
External signals such as growth factors can also induce peroxisome 
proliferation, suggesting the involvement of growth factor-dependent cascades 
such as mTOR (Schrader & Fahimi, 2006). Indeed, the mTOR pathway has 
recently been linked with peroxisomes (Zhang et al., 2013; J. Zhang et al., 
2015). The mTOR protein forms two complexes, mTORC1 and mTORC2, each 
of which contains distinct components and signals through a different set of 
downstream effectors. A key function of mTORC1 is to coordinate nutrient 
availability with autophagy. When growth factors are present, the action of 
mTORC1 ensures that autophagy is inhibited, whilst under starvation 
conditions, or in response to ROS, mTORC1 
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inhibition causes upregulation of autophagy (Sengupta et al., 2010). The tuberous 
sclerosis complex (TSC) is a signalling node which represses mTOR1 signalling by 
inhibiting the activity of the small GTPase Rheb, leading to activation of autophagy 
(Watanabe et al., 2011; Zhang et al., 2013). Recently, the peroxisomal localization 
of TSC1, TSC2 was reported (J. Zhang et al., 2015). The authors also suggest that 
the peroxisomal TSC functions as a signalling node which is able to repress 
mTORC1 and to induce autophagy when peroxisomal ROS production exceeds 
tolerable levels (Zhang et al., 2013). 
 
 
 
 
3.1.4 Human hepatoblastoma cells (HepG2) as a model to study 
 
peroxisomes 
 
In the past decades, huge efforts have been made to establish cell lines that 
express differentiated hepatic functions. Among them, a number of human 
hepatoma cell lines, including HepG2, Hep3B, HuH7, and HepaRG, are 
commonly used for drug metabolism and hepatotoxicity studies (Costantini et 
al., 2013). Although the metabolic functions of hepatoma cells are more limited 
than those of primary hepatocytes, they offer advantages for in vitro studies, 
such as high availability, easy handling, and stable phenotype. 
 
The hepatoblastoma cell line HepG2 is a perpetual cell line consisting of human 
liver carcinoma cells, derived from the liver tissue of a 15-year-old Caucasian 
male who had a well-differentiated hepatocellular carcinoma (Aden et al., 1979; 
Donato et al., 2015). HepG2 is the most widely used human hepatoma cell line 
in pharmaco-toxicological research (Natarajan & Darroudi, 1991). These cells 
are non-tumorigenic and highly proliferative and have been grown successfully 
in large-scale culture systems. HepG2 cells secret many plasma proteins, such 
as 
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transferrin, fibrinogen, plasminogen and albumin (Knowles et al., 1980). They 
are adherent, epithelial-like cells growing as monolayers and in small 
aggregates. HepG2 cells can also form bile canaliculi-like structures between 
adjacent cells (Sormunen et al., 1993). Bile canaliculus formation in cultured 
HepG2 cells (Bader et al., 1992; Natarajan & Darroudi, 1991) indicating the 
potential for differentiation (Stier et al., 1998). 
 
Due to their important role in lipid metabolism, peroxisomes are very prominent 
in hepatocytes in the liver. The peroxisomal compartment in HepG2 cells has 
been well characterised (Schrader et al., 1996), and the cell line has been used 
in several studies on peroxisome dynamics (A. Koch et al., 2003; Schrader et 
al., 2000). HepG2 cells contain an elaborate peroxisomal compartment with 
high plasticity, showing distinct peroxisome morphologies (Grabenbauer et al., 
2000; Schrader et al., 1996). Furthermore, peroxisome elongation can be 
stimulated in HepG2 cells by low cell density or microtubule depolymerisation 
(Schrader et al., 1996). Furthermore, addition of growth factors, fatty acids or 
UV irradiation has been shown to promote peroxisomal tubule formation in 
HepG2 cells (Schrader et al., 1998b; Schrader et al., 1999). In addition, 
peroxisomal enzyme activities are comparable in HepG2 and human liver 
(Wanders et al., 1991), and peroxisomes can be isolated from HepG2 cells 
using density gradient centrifugation (Manner & Islinger, 2017). Hence, HepG2 
cells represent a suitable model system for the investigation of peroxisome 
proliferation and the identification of additional stimuli which alter peroxisome 
morphology and numbers in human cells. 
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3.2 Specific Methods 
 
 
3.2.1 Cell culture and cell-based peroxisome proliferation assay 
 
 
HepG2 cells (ATCC HB8065) were maintained under standard conditions in 
Eagle’s minimum essential medium (MEM) (Gibco) supplemented with 10% 
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C in a 5% CO2-
humidified incubator. To test certain stimuli and their effect on peroxisome 
dynamics and proliferation, a serum-free cell culture assay was developed, 
which is based on a previous system using HepG2 cells (Schrader et al., 
1998b). Culture conditions were tested and optimised (e.g. cell batches, cell 
culture media, time points, cell density). Cells were incubated in serum-free 
MEM supplemented with N1 (Sigma) containing 0.5 mg/ml recombinant human 
insulin, 0.5 mg/ml human transferrin (partially iron-saturated), 0.5 μg/ml sodium 
selenite, 1.6 mg/ml putrescine, and 0.73 μg/ml progesterone. 
 
For morphology analysis, cells were plated at a defined cell density (2 × 10
5
 
cells/ml) in 6 cm ø dishes with collagen-coated glass coverslips in standard or 
serum-free media. After 6 hours, compounds/inhibitors were added at the indicated 
concentrations. Stimulation with 20% FBS served as a positive control for 
peroxisome elongation/proliferation. HepG2 cells were incubated with 20-80 nM of 
rapamycin for 2 hours upon serum stimulation. PPAR agonists and antagonists 
were also tested in this system. Summary of compounds and the concentrations 
used for this experiment are shown in Table 3.1. Fatty acid stimulation was 
performed by addition of 25-50 µM of arachidonic acid (C20:4(ω-6), linoleic acid 
(C18:2 ω-6), oleic acid (C18:1 ω-9) and palmitic acid (C16:1 ω-7) to cells incubated 
for 6 hours in serum-free media. Fatty acids (Sigma) were dissolved in in isopropyl 
alcohol at a stock concentration of 40 - 80 mM and stored 
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at -20. Prior to the experiment, the stocks were diluted in MEM serum free 
media. Cells were incubated for 6, 24 and 48 hours and processed for 
immunofluorescence or immunoblotting (coverslips were omitted). For 
immunofluorescence, peroxisomes were labelled with a combination of anti-
PEX14 and Alexa-488 antibodies, and at least 100 cells per preparation were 
quantified. YFP-LC3 was transfected into HepG2 cells using Lipofectamine (see 
general methods). All experiments were performed in triplicates. Table 
 
 
Type of Compounds Component Concentration 
   
m TOR inhibitior Rapamycin 
10 nM,15 nM, 
20 nM, 40 nM,80 nM   
   
PPARγ agonist Trosiglitazone 100 nM, 80 nM,40 nM 
   
PPARγ agonist Rosiglitazone 100 nM, 80 nM,40 nM 
   
PPARα agonist Wy-14,643 100 nM,80 nM,40 nM 
   
 
Table 3.1 List of compounds used in cell-based assay 
 
 
3.2.2 Cell density and growth curve 
 
 
HepG2 cells were cultured under serum-free conditions supplemented with N1 
or under standard conditions in MEM/FBS. For analysis of cell growth, cell 
numbers were determined every 24 hours for a period of 4 days after seeding. 
In order to determine the cell density over time, the absorbance of a cell 
suspension at OD600 was measured using a spectrophotometer. The cell 
number was also determined using a Neubauer chamber. Cell growth 
experiments were performed in triplicates. 
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3.2.3 RNA extraction 
 
 
Total RNA was extracted from HepG2 cells cultured under standard conditions 
using the NucleoSpin RNA isolation kit (Macherey-Nagel, Düren, Germany). 
Samples were collected at 6, 12, 24, 48 and 72 hours after cultivation in 
quadruples. The isolation steps were followed according to the manufacturer’s 
protocol. DNA was removed by on-column digestion with rDNase. The 
concentration of the extracted RNA was determined with a Nanodrop-1000 
spectrophotometer (NanoDrop Technologies, Inc). 
 
3.2.4 Quantitative real-time PCR 
 
 
 
First-strand cDNA was synthesized from 2 µg of RNA with random hexamer 
primers using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems) and diluted 1:10 in sterilized miliQ water. The real-time PCR 
reaction was set up in a final volume of 20 µl using 2x light cycler 480 SYBR 
Green I MasterMix (Roche Diagnosis, Mannheim, Germany). PCR reactions 
were performed in duplicate using a Roche LightCycler 480. Thermal cycling 
was carried out with a 5 minutes denaturation step at 95°C, followed by 45 
three-step cycles: 10 sec at 95°C, 10 sec at 60°C, and 10 sec at 72°C. The 
relative mRNA amount was calculated using the comparative threshold cycle 
(CT) method. 18S rRNA was used as the invariant control. The quantitative real-
time RT-PCR was performed in cooperation with Dr. W. Kovacs (ETH Zurich, 
Switzerland). Primers used are listed in Supplementary Figure S 3.1. 
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3.3. Results 
 
 
3.3.1 Implementation of a cell-based peroxisome proliferation assay 
 
 
In order to develop an inducible system for the investigation of peroxisome 
dynamics, proliferation and signalling in human cells, HepG2 cells were used 
and culture conditions tested and optimised (e.g. cell batches, media 
composition, cell density, time points) to reproduce earlier, published results 
(Schrader et al., 1996; Schrader et al., 1998b). When seeded under standard 
culture conditions in MEM/10% FBS at low cell density, peroxisomes in HepG2 
cells undergo a series of morphological alterations, which have been linked to 
peroxisome proliferation/multiplication by growth and division (Schrader et al., 
1996; Schrader et al., 2016; Schrader et al., 1998b). We seeded a selected 
stock of HepG2 cells at a density of 2×105 cells/ml on collagen-coated 
coverslips. Alterations in peroxisome morphology were then monitored and 
quantified over time (4-72 hours) by immunofluorescence microscopy using 
antibodies against the peroxisomal membrane marker PEX14 (Grant et al., 
2013; Nguyen et al., 2006) (Figure 3.1 A, B). As described before, HepG2 cells 
exhibiting tubular, elongated peroxisomes increased in a time-dependent 
manner after seeding reaching a maximum after 24 hours (Figure 3.1 A, B). 
This is due to a stimulation of peroxisomal membrane growth. Then cells with 
elongated peroxisomes declined, giving rise to cells with spherical peroxisomes. 
This decline is due to division of elongated peroxisomes into spherical 
organelles and contributes to peroxisome multiplication/proliferation. These 
findings show that peroxisomes in HepG2 cells respond to growth-stimulating 
culture conditions with peroxisomal growth and division. 
77 
 
 
As shown, peroxisomes change their abundance and morphology in response 
to external stimuli. Formation of tubular peroxisome can be an indicator of 
inducing peroxisome proliferation by adding specific stimuli to the cells. The aim 
was now to develop an inducible cell culture assay to investigate different 
stimuli (or inhibitors) and their effect on peroxisome dynamics and proliferation 
in order to identify signalling pathways involved in these processes. We 
previously showed that HepG2 cells can also be cultured under serum-free 
conditions, where a change in peroxisome morphology from spherical shapes to 
tubular forms can be achieved upon serum stimulation (Schrader et al., 1998b). 
Culturing HepG2 cells under serum-free (but supplemented) culture conditions 
has the advantage that peroxisomes remain spherical under those conditions 
making it possible to readily monitor peroxisome elongation when a specific 
stimulus is added (Schrader et al., 1998b). 
 
This cell-based peroxisome proliferation assay can be used for stimulus or 
inhibitor screening (see chapters 3 and 5) in serum-free conditions, but also for 
the monitoring and analysis of peroxisome dynamics by fluorescence 
microscopy and live cell imaging. In addition, it opens possibilities for RNA 
profiling (e.g. monitoring the RNA level of peroxisomal genes during the time 
course and correlation of expression to peroxisome morphology; see 3.3x), 
metabolomics and proteomics under standard and serum-free culture conditions 
to further study peroxisome dynamics and proliferation (see Figure 3.1 C). 
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    Figure  3.1. Overview of the cell-based  peroxisome  proliferation  assay.  (A) 
 
Quantification of peroxisome morphology over time in HepG2 cells grown under standard 
culture conditions and processed for immunofluorescence. (B) Immunofluorescence of 
HepG2 cells showing tubular peroxisomes. Cells were cultured for 6 and 24 hours under 
standard conditions, processed for immunofluorescence and stained with anti-PEX14 
antibodies. Bars, 5 µm. (C) Cell-based peroxisome proliferation assay and its 
applications under standard and serum-free culture conditions (for example, 
 
stimulus screening, pharmacological approaches, RNA profiling, live cell imaging, 
protein expression, quantification of peroxisome dynamics and number). 
 
 
To establish this assay in our laboratory in Exeter with our current HepG2 cells 
required optimization, including the routine cell culture conditions, serum-free 
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conditions, time-points, and cell density. After testing different types of media, 
the ATCC recommended medium (MEM) was selected based on the healthy 
cell morphology and the highest rate of peroxisomal membrane 
tubulation/proliferation. To select optimal conditions for the serum-free culture, 
we switched to a commercially available N1 supplement (Sigma). For 
optimization, 0.25% BSA was added to the N1 solution (N1 final composition: 
0.5 mg/ml recombinant human insulin, 0.5 mg/ml human transferrin (partially 
iron-saturated), 0.5 μg/ml sodium selenite, 1.6 mg/ml putrescine, 0.73 μg/ml 
progesterone, 0.25% BSA). Addition of BSA to serum-free MEM/N1 medium 
had a beneficial effect on the induction of elongated peroxisomes by stimulation 
with serum (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Morphological changes of peroxisomes with time in culture in HepG2 
cells cultured in MEM/N1 with and without BSA. HepG2 cells were seeded in different 
media, processed for immunofluorescence after 24 hours using anti-Pex14 antibodies, and 
peroxisome morphology quantified. Addition of BSA to serum-free MEM/N1 medium 
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is beneficial for the induction of elongated peroxisomes by the addition of serum. Data 
represent mean ± SEM of 3 independent experiments (n=3 cells). *** p<0.001, ** 0.001 
to 0.01, two-tailed unpaired t-test 
 
 
 
 
For analysis of peroxisome morphology and number, 2 × 105 cells/ml were 
plated in 6 cm dishes with collagen-coated glass coverslips in standard or 
serum-free media. The cells were incubated for 6 hours in serum-free medium 
supplemented with N1 and either stimulated by the addition of 10% FBS or left 
untreated. After 24 hours, the cells were processed for immunofluorescence, 
and peroxisomes were labelled with a combination of anti-PEX14 (pcR) and 
Alexa-488 (DaR). Peroxisome morphology was analysed under the 
fluorescence microscope and at least 100 cells/coverslip were quantified. 
Peroxisomes were either scored as “Rods /Spheres” or “Tubules” based on 
visual analysis (Figure 3.3). The data indicates that in HepG2 cells grown under 
serum-free conditions only around 12% of cells contain tubular peroxisomes 
after 24 hours. However, stimulation with 10% FCS increases the number of 
cells with tubular peroxisomes to 70-80% (Figures 3.2 and 3.3B). Furthermore, 
peroxisome numbers increased almost 3-fold after 48 hours when compared to 
6 hours. This indicates that elongated peroxisomes, which form through serum-
stimulation with a maximum after 24 hours, divide by fission and contribute to 
peroxisome proliferation (Figure 3.3C). These observations indicate that 
peroxisomal growth and division is reduced under serum-free culture conditions, 
and that the peroxisomal compartment is responsive to serum stimulation. 
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Figure 3.3. Peroxisome morphology analysis of HepG2 cells in serum-free N1 
medium upon serum stimulation. (A) Representative images of cells cultured in N1 
and cells stimulated with FBS (N1+FBS) after 24 hours. HepG2 cells cultured in MEM 
media with and without FBS stimulation were processed for immunofluorescence after 
24 h and stained with anti-PEX14 (pcR) and Alexa-488 (DaR) antibodies. Bars, 20 µM 
(B) Quantitative analysis of peroxisome morphology.) (C) Quantitative analysis of 
peroxisome number. Data represent mean ± SEM of 3 independent experiments (n=3 
cells in each condition). *** p<0.001 two-tailed unpaired t-test. 
 
 
 
 
3.3.2 HepG2 cells cultured in MEM/N1 medium grow similar to 
cells cultured in MEM/FBS 
 
 
Cells in conditions of complete nutrient deprivation cease to grow exponentially. 
In our system, the cells are grown under serum-free condition with N1 
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supplement. To test if cellular growth is comparable to standard growth 
conditions or disturbed, we determined and compared cellular growth over time. 
In our assay, two methods (counting number of cells in a Neubauer chamber 
and OD measurement) has been used. Cells cultured in N1 medium (serum-
free medium (MEM) + N1 supplement) display slightly lower growth rates when 
compared to standard conditions. However, the cells are actively proliferating 
and an exponential increase in cell density arises, indicating that the growth 
conditions are suitable for the study of peroxisome dynamics. It should, 
however, be noted that the cells appear smaller and are not as extensively 
spread as HepG2 cells grown under standard conditions (Figure 3.4). 
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Figure 3.4. HepG2 cell density and cellular growth curve. (A) Cellular growth curve 
based on measuring absorbance at OD600 at the indicated time points. (B) Cellular 
growth curve based on counting cell number at the indicated time points (Neubauer 
chamber). An exponential increase in cell density is observed in both N1 and standard 
(FBS) conditions. All measurements were from experiments performed in triplicate. 
Data are expressed as mean ± SD of cell densities determined in three independent 
experiments. 
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3.3.3 Culture of HepG2 cells in MEM/N1 does not induce autophagy 
 
 
In order to exclude increased autophagic processes in HepG2 cells cultured 
under serum-deprived MEM/N1 conditions, which would have an impact on 
peroxisome number and proliferation and reduce the effectiveness of the cell-
based proliferation assay, the autophagic marker LC3 was used. Autophagy can 
be measured by changes in LC3 localization: tracking the level of conversion of 
LC3-I to LC3-II provides an indicator of autophagic activity (Tanida et al., 2005). 
The levels of LC3-II correlate with autophagosome formation, due to its 
association with the autophagosome membrane. These can be detected as 
punctate forms in cells displaying autophagy (Tanida et al., 2004). 
 
HepG2 cells were transfected with an YFP-LC3 plasmid using lipofectamine 
3000, and were examined using fluorescence microscopy (Figure 3.5 A). 
Transfected HepG2 cells with LC3 puncta (as determined by visualisation of 
LC3-YFP) were quantified in MEM/N1 and MEM/N1+FBS as well as after 
treatment with rapamycin. Rapamycin, an inducer of autophagy, was used as a 
positive control. Addition of DMSO (solvent) did not alter LC3 puncta when 
compared to conditions without DMSO (Figure 3.5 B). LC3 puncta were clearly 
observed when rapamycin was added (Figure 3.5 A, c-d). In contrast, only 11% 
of cells in MEM/N1 showed LC3 puncta which was not significantly different 
from controls with FBS (Figure 3.5 B). This clearly shows that growth in 
MEM/N1 does not induce autophagy. 
 
Growth factors induce the activation of p70 S6 kinase and the subsequent 
phosphorylation of the S6 ribosomal protein (An et al., 2003). Phosphorylation 
of S6 correlates with an increase in translation of mRNA transcripts required for 
cell cycle progression and synthesis of ribosomal proteins as well as elongation 
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factors necessary for translation. Inhibition of mTORC1 by rapamycin can cause 
a decrease in PS6 level (An et al., 2003). To determine the level of 
phosphorylated S6, lysates from HepG2 cells cultured in MEM/N1, MEM/N1 + 
FBS or 20 nM rapamycin were analysed by immunoblotting (Figure 3.5 C). As 
described in the literature, the level of PS6 using the phospho-specific PS6 
antibody was decreased by addition of rapamycin (blocking mTOR) compared 
to the control containing FBS. Cells growing in MEM/N1 exhibit the same level 
of phosphorylated S6 ribosomal protein compared to controls containing serum, 
indicating that the translation of proteins involved in cell cycle progression and 
ribosome formation is active under our experimental conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Autophagy is not induced in MEM/N1 condition (A) HepG2 cells 
transfected with YFP-LC3 (lipofectamine transfection) and controls were incubated for 
24 hours in (a) MEM/N1 supplemented with FBS, (b) plain MEM/N1 with no FBS ,(c) 
FBS+rapamycin, (d) MEM/N1 containing rapamycin , (e) FBS+DMSO (solvent), or (f) 
plain MEM/N1 containing DMSO. Cells were fixed and prepared for fluorescence 
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microscopy after 24 hours of treatment. Bar= 5µm (B) Quantitative analysis of cells with 
LC3 puntca under different conditions. Data represent mean ± SEM of 3 independent 
experiments (n=300 cells in each condition). *** p<0.001 two-tailed unpaired t-test. (C) 
Immunoblot of lysates from HepG2 cells cultured as indicated. 40 ug of protein was 
loaded on 10% SDS-PAGE and immunoblots were incubated with anti-Phospho-S6 
Ribosomal Protein (PS6) and anti-ASNA (loading control), an ATPase required for the 
post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. 
 
 
 
 
3.3.4 Investigation of different stimuli and their ability to induce 
peroxisome proliferation in mammalian cells 
 
Following optimization of the cell-based peroxisome proliferation assay, we now 
have an inducible system in hand to test different stimuli and their effect on 
peroxisome dynamics and proliferation. A set of stimulating compounds such as 
fatty acids, PPAR agonists and antagonists have been used in this study. 
Applications of this assay including the testing of inhibitors and stimuli on 
peroxisome proliferation and alterations in peroxisomal gene expression are 
illustrated in Figure 3.1. 
 
 
3.3.4.1 Distinct fatty acids are potent inducers of peroxisome 
elongation/proliferation in HepG2 cells 
 
 
It is known that fatty acids regulate cellular function by modulating the rates of 
transcription of various target genes including the peroxisomal acyl-CoA oxidase 
(ACOX1) through activation of the PPAR-RXR complex (Rakhshandehroo et al., 
2010). Several studies have reported the transactivation of PPAR family members 
through the administration of several fatty acids, in different organisms and cell 
models (Benjamin et al., 2013). However, despite some knowledge 
87 
 
 
on the regulation of peroxisomal enzymes, the effect of different fatty acids on 
peroxisome dynamics and proliferation in humans remains scarce. Making use 
of our cell-based assay, we analysed the effect of saturated and unsaturated 
fatty acids on peroxisome dynamics in HepG2 cells. The fatty acids used were: 
arachidonic acid (AA) (C20:4(ω-6), linoleic acid (LA) (C18:2 ω-6), palmitic acid 
(PA) (C16:1 ω-7) and oleic acid (OA) (C18:1 ω-9). 
 
Arachidonic acid (AA), a 20-C polyunsaturated fatty acid of the 0-6 class, serves as 
a precursor for the synthesis of a number of biologically active lipid mediators 
(Irvine, 1982). Depending on chain length and degree of unsaturation, fatty acid β-
oxidation occurs in either the mitochondria or peroxisomes (Schulz et al., 1991). 
 
Linoleic acid (LA) is a polyunsaturated fatty acid used in the biosynthesis of 
arachidonic acid (AA) and thus some prostaglandins. It has been shown that 
treatment of HepG2 cells with linoleic acid leads to an increase in PPARγ, 
PPARβ and ACOX1 (Lu et al., 2015). 
 
We used AA as a positive control since it has been reported to induce peroxisome 
elongation/proliferation (Schrader et al., 1998b) and indeed our results show that 
 
AA causes a prominent increase in the percentage (45-70%) of cells with tubular 
peroxisomes (Figure 3.6). In fact, when adding 50 µM AA to the medium, the 
percentage of cells with tubular peroxisomes is of the same magnitude as when 
serum is added to the N1 medium. The addition of LA to the medium had a less 
pronounced effect on peroxisome elongation with about 44% of the cells exhibiting 
that phenotype. On the other hand, OA and PA were not able to induce peroxisome 
elongation at the concentrations applied (Figure 3.6). However, as observed for AA 
and LA, the number and size of lipid droplets was increased in 
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the cells (not shown), indicating that the different fatty acids are properly taken 
up and stored by the cells. Whereas PA is a target for mitochondrial β-oxidation, 
OA is supposed to be mainly degraded by peroxisomal fatty acid β-oxidation. 
Even though OA is likely able to trans-activate PPAR family members and to 
undergo peroxisomal β-oxidation in HepG2 cells, it seems that the addition of 
general fatty acid substrates for peroxisomal β-oxidation is not sufficient to 
induce peroxisome elongation. The effect appears to be more specific for LA 
and AA, which link to the synthesis of cellular lipid mediators. 
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Figure 3.6. Arachidonic acid induces the formation of tubular peroxisome in our 
system, whereas palmitic acid and oleic acid have no effect (A) Representative images 
of immunofluorescence preparations with PEX14-Alexa488 antibodies of HepG2 
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cells cultured in MEM/N1 (negative control), MEM/N1 supplemented with FBS (positive 
control) or MEM/N1 supplemented with fatty acids. Bars, 20 µM (B) Quantitative analysis of 
cells with tubular peroxisomes upon fatty acid stimulation in HepG2 cells seeded in 
MEM/N1 (N1). Data represent mean± SEM of 3 independent experiments (n=3). 
 
 
 
 
 
 
 
 
3.3.4.2 PPARα Agonists do not induce peroxisome elongation in 
HepG2 cells cultured in N1 medium 
 
 
 
Previous studies have shown that fibrates such as bezafibrate, fenofibrate, Wy-
14,643 and clofibrate are PPARα agonists and significantly increase 
peroxisome number and the levels of fatty acid β-oxidation enzymes (L. Guo et 
al., 2006; Lazarow & De Duve, 1976; Schrader et al., 2012). The effect of these 
compounds on peroxisome proliferation in mammals is restricted to the 
superfamily of Muroidea, whereas the effect in humans is very mild (Islinger et 
al., 2010; Lawrence et al., 2001a). Testing physiological concentration (10µM, 
15µM and 20 µM) of this agonist in our HepG2 assay did not induce peroxisome 
tabulation. 
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Figure 3.7 The PPARα agonist Wy-14,643 does not induce the formation of 
tubular peroxisome in our cell model. Quantitative analysis of peroxisome 
morphology in HepG2 cells seeded in N1, stimulated with FBS, or 10-15 and 20 µM of 
Wy-14,643. Data represent mean ± SEM of 3 independent experiments) *** p<0.001; 
two-tailed unpaired t-test (n=3). 
 
 
 
The PPARγ ligand troglitazone, one of the thiazolidinediones which are used in 
the treatment of type II diabetes, is a potent and selective activator of PPARγ 
(Blaschke et al., 2006). The role of troglitazone in the growth of cancer cells has 
been elucidated in some studies (Shimada et al., 2002). It has been shown that 
troglitazone has negative effects on the proliferation of malignant tumor cells, 
including colon cancer cells (Lucarelli et al., 2002). The effect of this agonist on 
peroxisome proliferation has not been tested. An effect on fatty acid cycling in 
HepG2 cells has, however, been described (W. N. Lee et al., 1998). Here, 
different concentrations of PPARγ agonist have been tested to induce 
peroxisome elongation/proliferation. Our results showed that the maximal dose 
of PPARγ 
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agonist (15 µM) only induced the number of cells with tubular peroxisomes to 
30% compared to the control group in N1, which is 20% (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 The PPARγ agonist Troglitazone does not induce the formation of 
 
tubular peroxisome in our cell model. Quantitative analysis of peroxisome 
morphology in HepG2 cells seeded in N1, stimulated with FBS, or 5-15 µM of 
Troglitazone. Data represent mean ± SEM of 3 independent experiments) *** p<0.001; 
NS
 p ≥ 0.05; two-tailed unpaired t-test (n=3). 
 
 
 
PPARγ antagonists such as GW9962 inhibit the PPARγ binding to its binding 
elements (X. Liu et al., 2016). In this study, we used 20 - 80 µM of GW9962 to 
monitor the peroxisome morphology in our assay, when the agonist was applied 
in combination with or without FBS. The cells were cultured for 4 hours, pre-
incubated for additional 2 hours with the PPARγ antagonist, and 6 hours after 
cultivation serum stimulation was performed (Figure 3.9). Based on our 
immunofluorescence and quantification data, GW9962did not repress 
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peroxisome elongation/proliferation induced by serum. This implies that serum 
 
contains factors which can induce peroxisome proliferation independently of 
 
PPARγ.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. The PPARγ antagonist GW9962 does not repress serum-induced 
peroxisome elongation/proliferation. Quantitative analysis of peroxisome morphology in 
HepG2 cells seeded in N1, stimulated with FBS, and pre-treated with 20 µM, 40 µM 
and 80 µM of GW9962. Data represent mean ± SEM of 3 independent experiments) *** 
p<0.001; ** p<0.01; two-tailed unpaired t-test (n=3). 
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3.3.4.3 mTOR signalling plays a role in the initiation of 
peroxisome elongation and proliferation 
 
 
Our previous studies revealed a role for serum/growth factors in the elongation 
and proliferation of peroxisomes in mammalian cells (Schrader et al., 1998b) 
and experiments above). We also exploited our cell-based assay for live cell 
analyses of peroxisomal alterations under N1 and serum-stimulated conditions. 
Imaging of peroxisomes in MEM/N1 revealed overwhelmingly spherical 
peroxisome with little elongation or protrusion-forming activity (not shown). 
Interestingly, addition of serum promoted peroxisome elongation and protrusion-
formation as well as overall motility of peroxisomes (data under analysis). 
Overall, these findings clearly demonstrate a role for serum factors in 
peroxisome dynamics and proliferation and suggest the involvement of growth 
factor-dependent pathways like the mTOR pathway. In order to investigate the 
involvement of the mTOR pathway in peroxisome elongation/proliferation in our 
assay, cells were treated with the mTOR inhibitor rapamycin (Rap). HepG2 cells 
were cultured for 4 hours, pre-incubated for additional 2 hours with rapamycin 
(20 – 80 nM), and 6 hours after cultivation serum stimulation was performed. 
Quantification of immunofluorescence preparations (Figure 3.10) revealed that 
rapamycin treatment diminished peroxisome elongation in a dose-dependent 
manner (Figure 3.10 A-B). These data complement our previous observations 
and support our hypothesis that the mTOR pathway plays a role in the initiation 
of peroxisome proliferation during cellular growth. Higher concentration of 
rapamycin (2.5 µM and 5µM) have been used in our laboratory to study 
pexophagy in human fibroblasts. Even with these concentrations no effect on 
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peroxisome number was detected after 24 hours (Josiah Passmore, unpublished 
 
data)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. The mTOR inhibitor rapamycin inhibits peroxisome elongation. (A) 
Representative images of HepG2 cells cultured in MEM/N1 (N1), MEM/N1+FBS and 20 
nM rapamycin+FBS. Cells were processed for immunofluorescence after 24 hours and 
labelled with anti-PEX14/Alexa-488 antibodies. Bars, 20 µM. (B) Quantitative analysis 
of peroxisome morphology after treatment of HepG2 cells with rapamycin (20 nM—80 
nM) and subsequent serum-stimulation. Data represent mean ± SEM of 3 independent 
experiments   (n=3).   ***   p<0.001, 
NS 
p   ≥   0.05 two-tailed   unpaired   t-test.  
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3.4 Correlation of peroxisome morphology and peroxisomal 
gene expression 
 
 
Little is known about the regulation of peroxins and peroxisomal membrane 
proteins and the relation of gene expression with peroxisome proliferation, in 
particular in humans. The only peroxin whose expression has so far been linked 
to peroxisome proliferation in humans is PEX11 (Schrader et al., 2016). As 
indicated before (see Figure 3.1 C), our cell-based assay provides an 
opportunity to monitor peroxisome morphology as well as peroxisomal gene 
expression by RNA analysis. 
 
In order to investigate and correlate alterations in the gene expression (and 
potential signaling factors) with peroxisome proliferation events, we exploited 
our established assay which shows proliferation-associated alterations of 
peroxisome morphology in standard medium over a time course in culture 
(Figure 3.1 A). 
 
As shown before (Figure 3.1 A), the number of elongated peroxisome reaches 
a maximum after 24 hours before declining giving rise to spherical peroxisome 
produced by fission. At each of the time points indicated in Figure 3.11 (6-72 
hours) cell samples were taken, RNA was extracted and then qPCR was 
performed to determine changes in mRNA levels over the time course. The 
experiment was performed in 4 replicates for each time point with the same cell 
number at the start point. For each tested gene the mean Ct value was 
determined for each time point. The change in expression of a subset of 
peroxisomal genes was normalized to18S rRNA. ∆∆Ct was calculated for each 
time point compared to 6 hours (eg, ∆∆Ct=∆Ct12- ∆Ct6). The fold change for 
each time point was calculated using 2-∆∆Ct (Figure 3.11C). Furthermore, 
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morphological changes of peroxisomes over time in the same cohort of cell 
samples (seeded on coverslips) was assessed by immunofluorescence. 
Samples were stained with anti-PEX14 antibodies, and peroxisome morphology 
was quantified (Figure 3.11 A). 
 
Interestingly, an increase in the expression level of PEX11β was observed with a 
maximum at 24 hours and subsequent decline in expression. These alterations 
correlate nicely with the morphological changes of peroxisomes, supporting the 
view that PEX11β expression promotes peroxisome elongation and subsequent 
division (Figure 3.11 A-B). Furthermore, we monitored the PEX11β protein level in 
this assay by immunoblotting, as it is illustrated in Figure 3.11 c. We also observed 
an increase in PEX11β protein up to 24-48 hours before protein levels 
 
declined. In contrast to PEX11β, the mRNA levels of PEX11α and PEX11 were 
not observed to increase and to correlate with peroxisome elongation, but rather 
declined (Figure 3.11). The PEX11 peroxisomal membrane proteins are 
supposed to promote peroxisome proliferation and division in multiple 
eukaryotes. As indicated in the introduction (Section 1.6) in humans/mammals, 
the three PEX11 isoforms PEX11α, β, γ are the only peroxins identified which 
are thought to be involved in peroxisome proliferation. This makes PEX11 an 
ideal candidate for our proliferation studies. As part of our effort to understand 
the molecular and physiological functions of PEX11β in peroxisome 
proliferation, we already revealed that PEX11β expression promotes 
peroxisome elongation prior to fission, whereas PEX11α expression has no or 
little effect (our unpublished observations). We therefore suggest that PEX11α 
is not directly involved in peroxisome multiplication/proliferation, and may fulfill 
other functions, e.g. in peroxisomal metabolism. 
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Interestingly, expression of the early peroxins PEX19 and PEX3 was also 
observed to correlate with peroxisome elongation/proliferation, whereas PEX16 
remained unchanged and declined at later time points. As these early peroxins 
are required for the insertion of peroxisomal membrane proteins including 
PEX11β, an increased expression of those early peroxins would be meaningful. 
 
Other peroxins such as PEX12, PEX10 and PEX14, which are involved in 
peroxisomal matrix import, showed a minor increase after 24 hours followed by 
a decline in expression (PEX10, PEX14) or remained unchanged (PEX12). 
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Figure 3.11. Analysis of peroxisome morphology and peroxisomal gene 
expression during a time course. (A) Quantitative analysis of tubular peroxisomes in 
HepG2 cells monitored over time in standard culture medium and processed for 
immunofluorescence. Data represent mean ± SEM of 3 independent experiments 
(n=300 cells in each condition). (B) qPCR, relative mRNA expression levels of a set of 
peroxisomal genes normalized to 18S rRNA expression in a time course experiment. 
Note that PEX11β expression follows the tubular peroxisome morphology, emphasizing 
its role in peroxisome elongation and division. In contrast, PEX11α expression does not 
correlate with changes in peroxisome morphology. (C) Immunoblot of HepG2 lysates (6 
 
– 72 hours) using anti-PEX11β antibodies. GAPDH was used as a loading control. 
 
Density plot of protein bands normalized to GAPDH. Data represent mean ± SEM of 3 
independent experiments) *** p<0.001; ** p<0.01; two-tailed unpaired t-test. 
 
 
 
 
 
 
The expression profile of the transcription factors PPARα, PPAR1 and PGC-1α 
which are involved in the upregulation of peroxisomal matrix protein expression (in 
particular β-oxidation enzymes) did not correlate with peroxisomal morphology 
alterations, and expression of those transcription factors rather declined over time 
or remained unchanged (Figure 3.12 A). These findings may indicate that the 
observed morphological alterations are independent of those transcription factors. It 
has however been reported that PPARα expression is upregulated in HepG2 cells 
at prolonged incubation times in culture (Baumgart et al., 1990). 
 
Interestingly, the expression of the peroxisomal ABC transporter ABCD3 
(PMP70) follows the morphological changes of peroxisomes, whereas ABCD1, 
the ABC transporter for VLCFA remains unchanged. 
 
Expression of ACOX1b, a key enzyme in the first step of peroxisomal fatty acid 
β-oxidation, remained unchanged, whereas MFP1, which catalyzed the 2nd and 
3rd step, was slightly upregulated after 24 hours. 
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It should be noted that besides PEX11α regulation by PPARα, there is currently 
 
no information available on transcriptional regulation of peroxins in 
 
humans/mammals.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Analysis of peroxisome morphology and peroxisomal gene 
expression during a time course. (A) qPCR, relative mRNA expression levels of a 
set PPARα, PPARγ and PGC1α genes normalized to 18S rRNA expression in a time 
course experiment. (B) qPCR, relative mRNA expression levels of a set of ABCD1 and 
ABCD2 genes, and ACOX1 MFP1, normalized to 18S rRNA expression in a time 
course experiment. Data represent mean ± SEM of 3 independent experiments) *** 
p<0.001; ** p<0.01; two-tailed unpaired t-test. 
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3.5 Discussion 
 
 
Peroxisome can respond to external stimuli such as fatty acids and fibrates with 
an increase in their number or size ((Kaur & Hu, 2009; Platta & Erdmann, 2007). 
Due to their critical metabolic functions, regulation of peroxisomal functions and 
number is vital for human health. Therefore, a better understanding of the 
signals involved in peroxisome proliferation and metabolic activity is necessary. 
It is still not clear how these organelles are connected to cellular signaling 
pathways, particularly in humans. 
 
In this study, HepG2 cells were used as a model system to assess the ability of 
different stimuli to induce peroxisome proliferation in a cell-based approach. As 
previously shown, the well-differentiated human hepatoblastoma cell line HepG2 
has a very plastic peroxisome compartment, displaying small spherical (0.1-0.3 μm) 
and rod-shaped (0.3 μm) peroxisomes as well as elongated-tubular ones (up to 5 
μm and more) (Schrader et al., 1996). In this study, HepG2 cells grown under 
standard cell culture conditions form tubular peroxisomes (around 70% of cells) 24 
hours after cultivation when seeded at a defined density. Elongation of peroxisomes 
is a pre-requisite of peroxisome proliferation and is followed by constriction and 
division of tubular peroxisomal membranes resulting in new spherical peroxisomes 
(Schrader et al., 2016) (Figure 3.1). Formation of tubular peroxisomes can be 
almost completely inhibited by culturing HepG2 cells under serum-free conditions 
(MEM) supplemented with N1, with HepG2 cells still demonstrating cellular growth 
(Figure 3.4) and normal levels of autophagy (Figure 3.5). We have established a 
cell-based assay using the HepG2 cell model with spherical peroxisomal forms to 
analyze peroxisome proliferation upon stimulation. In this system, peroxisome 
elongation has been used as the read-out 
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for peroxisome proliferation, as peroxisomes first form tubular structures and 
then divide (Figure 3.3 C). Cells seeded in MEM/N1 showed similar growth to 
cells cultured under standard conditions (MEM/FBS) (Figure 3.4). Also, based 
on our results with LC3 transfection, this condition does not induce autophagy 
(Figure 3.5 A-C). Thus, the assay is a valuable tool to monitor the effect of 
different stimuli on peroxisome proliferation. 
 
Quantification of different peroxisome morphologies in MEM/N1 and serum-
stimulated conditions showed induction of tubular peroxisomes upon stimulation 
with serum which contains growth factors. One of the main growth factor-
dependent pathways is mammalian target of rapamycin (mTOR) (Guri & Hall, 
2016). In order to investigate the involvement of the mTOR pathway in 
peroxisome elongation/proliferation, rapamycin was used to inhibit this pathway 
through mTORC1 inhibition. Upon serum stimulation, rapamycin-treated cells 
showed a reduced number of tubular peroxisomes compared to non-treated 
cells, suggesting that the mTOR pathway may be involved in the regulation of 
peroxisome proliferation and tubule formation we observe under conditions of 
cellular growth (Figure 3.13). Rapamycin is functional in HepG2 cells, as 
Phospho-S6 Ribosomal Protein was reduced in immunoblots compared to 
controls when rapamycin was added (Figure 3.5 C). 
 
In skeletal muscle tissues and cells, the mTOR inhibitor rapamycin decreases 
the gene expression level of mitochondrial transcriptional regulators, PPARγ 
coactivator-1 (PGC1-α) (Cunningham et al., 2007). This study indicates that 
mTORC1 controls the transcriptional activity of PPARγ coactivator-1 (PGC1a), 
by altering its physical interaction with another transcription factor, yin-yang 1 
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(YY1) initiating expression of genes involved in mitochondrial biogenesis 
 
(Cunningham et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. Schematic diagram of pathways being investigated and how they are 
related. Growth factor stimulation can activate different cascades in the cell. The Ras-
Raf-MEK - cascade is one of the probable pathways which cause MAX-MYC complex 
activation. Activation of ERK1/2 by growth factors depends on the MAPK c-Raf. This 
can inhibit TSC1/TSC2. Rapamycin can block the mTOR pathway through mTORC1 
inhibition. 
 
 
 
Various types of stimuli including fatty acids, PPAR agonists and antagonists were 
used in our system to analyze the effect of these stimuli on peroxisome 
elongation/proliferation. Peroxisomal fatty acid β-oxidation involves the degradation 
of long chain and very long chain fatty acids (Baumgart et al., 1990). It has been 
shown that fatty acids regulate cellular function by modulating the rates of 
transcription of various target genes including acyl-CoA oxidase (ACOX1) 
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through activating the PPAR:RXR complex. As discussed in the introduction 
(See Introduction 1.7.2), PPARs are the known regulators of lipid homeostasis 
and peroxisome proliferation. 
 
The effect of several fatty acids on peroxisome proliferation has been tested in 
our cell-based assay, including arachidonic acid (AA), linoleic acid (LA), palmitic 
acid (PA) and oleic acid (OA). Based on our results, AA and LA, a precursor of 
AA, caused an increase in tubular peroxisomes (from 20% to 70% of total cells), 
comparable to the increase with serum, whereas palmitic acid or oleic acid had 
no effect (Figure 3.6). The addition of LA to the medium had a less pronounced 
effect on peroxisome elongation with about 44% of the cells exhibiting that 
phenotype 
 
PA is a saturated fatty acid found in olive oil and palm oil and it is not a primary 
substrate for peroxisomal β-oxidation and is the target for mitochondrial β-oxidation, 
thus likely does not induce peroxisome proliferation. Although, OA is also 
substrates for peroxisomal β-oxidation but treatment with OA in HepG2 cell-based 
assay did not induce peroxisome elongation (Figure 3.6). This suggests that a 
general stimulation of peroxisomal β-oxidation by fatty acids is not the main trigger 
of peroxisome elongation/proliferation in HepG2 cells. The AA effect may thus not 
be related to peroxisomal β-oxidation. AA is involved in several pathways as a 
signaling molecule – e.g. in inflammation initiating gene expression of the target 
genes or activating the PPAR pathway (Varga et al., 2011). In previous studies, it 
has been shown that AA can act as a second messenger in T-cells through NFκB 
activation. Activation of the oxidative cascade of PUFAs has been associated with 
cancers, including B-CLL (Solomon et al., 2016). B-CLL tumor lymphocytes have 
been shown to produce leukotriene B4 (LTB4). LTB4 binds 
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PPARα, which in turn regulates the oxidative degradation of PUFAs and their 
derivatives, including LTB4. Moreover, PPARγ, another member of the PPAR 
family, contributes to the regulation of inflammation (Stienstra et al., 2007). 
 
Using the cell-based assay, the expression of several peroxisomal genes was 
analyzed in HepG2 cells cultured under standard culture conditions during the 
time course 6-72 hours after cultivation. Cells from the same set of experiments 
were also fixed for peroxisome morphology analysis. According to the q-PCR 
results, PEX11β expression followed the changes in peroxisome morphology, 
whereas PEX11α expression did not. This indicates that PEX11α may not 
directly be involved in peroxisome elongation/proliferation and may have other 
functions in metabolism, e.g. a role in fatty acid b-oxidation or as a pore forming 
protein. It also indicates that different regulatory pathways and different 
transcription factors may control the expression of these genes. 
 
Although our understanding of the mechanisms by which peroxisomes proliferate is 
increasing, our knowledge on how the division process is linked to extracellular 
signals is limited. In mammals, a key player in peroxisome proliferation is PEX11β 
(Itoyama et al., 2012; Schrader et al., 1998b; Y. Yoshida et al., 2015). When 
PEX11β is over-expressed, it causes first elongation and then subsequent division 
of peroxisomes (Delille et al., 2010). This makes PEX11β an ideal target for 
signaling pathways which lead to an increase in peroxisome number. So far, there 
are no studies focusing on transcriptomics of genes inducing peroxisome 
proliferation. The function of PEX11α is less clear (Delille et al., 2010) but may be 
linked to more specialized functions such as in lipid homeostasis or membrane 
contact sites (Dulermo et al., 2015; Mattiazzi Usaj et al., 2015). Further clarification 
of the role of the different PEX11 isoforms is 
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required to understand how transcriptional signal cascades produced by 
external stimuli correlate with an increase in peroxisomal number. Despite an in-
depth, mechanistic understanding of factors involved in peroxisome-related 
signaling, such as the PPARs, there is still some uncertainty as how this 
pathway leads to an increase in peroxisome number. 
 
So far, we established a system which allows us to assess changes in 
peroxisome proliferation/morphology and to correlate this with the expression 
profile of peroxisomal genes involved in the regulation of peroxisome 
proliferation. Future studies are needed, using large scale expression profiling in 
this system which may then allow the identification of novel components 
regulating peroxisome morphology and dynamics. Several key players involved 
in peroxisome dynamics and proliferation have been identified in previous 
studies; however, regulatory mechanisms need further investigation. In this 
study, a possible link between novel regulatory pathways such as NF-κB / 
mTOR and peroxisome proliferation has been suggested based on testing 
different stimuli inducing peroxisome proliferation. There are questions to be 
answered about how external stimulation affects the expression of the three 
mammalian PEX11 isoforms, e.g are they all regulated in a different manner? 
(see chapter 4). This work may also have the outcome of revealing novel 
diagnostics and/or treatment targets for peroxisomal disorders. Further 
investigation is required to validate the involvement of novel PPAR-independent 
pathways in peroxisomal gene expression by computational analysis, e.g. of 
promoter regions and transcription factor binding sites (see chapter 4). 
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Chapter 4 – Results 
 
 
 
Identifying regulatory elements involved in 
peroxisomal gene expression in humans 
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Summary 
 
 
Although our understanding of peroxisome proliferation mechanisms is 
increasing, our knowledge on how this process is regulated and linked to 
signaling pathways is limited. 
 
The known pathway inducing peroxisome proliferation is through peroxisome 
proliferator-activated receptor (PPARS), however the exact mechanism by which 
this pathway regulates expression of peroxisomal genes is not yet known, in 
particular in humans. So far, we established a cell-based assay in which we monitor 
peroxisome proliferation upon extracellular stimulation (Chapter 3). This assay 
gives us the opportunity to study gene expression and its correlation with 
peroxisome morphology. Based on these results, expression of genes such as 
PEX11β, PEX19 and PEX3 correlates with the formation of tubular peroxisomes. In 
this chapter we have employed bioinformatics approaches, including screening of 
promoter regions of 100 promising human candidate peroxisomal genes for 
regulatory elements. A Python-based program has been used to identify regulatory 
elements in the promoter regions of candidate peroxisomal genes. In this initial 
analysis more than 7000 transcription factor binding sites were identified in our 
gene cohort. Furthermore, the chromosome structure for each site identified was 
analyzed for its histone marks. This approach eliminated sites which were located 
on transcriptionally inactive regions. An initial map of candidate regulatory motif 
sites showed a difference between binding sites in PEX11α and PEX11β promoters 
suggesting that these genes are differentially regulated. One of the common 
transcription factors shared by PEX11β and PEX11γ was SMAD2/3. Moreover, 
differences in transcription factor binding sites 
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between metabolic and biogenetic peroxisomal genes suggest differential 
regulation of these genes. 
 
In order to link these motif sites to certain signaling pathways, the Top 10 
shared motifs among our gene cohort were run through the Enrichr database. A 
prominent SMAD2/3 binding site in PEX11β was suggestive for the involvement 
of the TGFβ signalling pathway in the expression of this important gene and in 
peroxisome proliferation and membrane dynamics. 
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4.2 Method pipeline and data filtering 
 
 
4.2.1 Peroxisome proliferator response element (PPRE) search 
 
 
The known pathway involved in peroxisome proliferation in mammals is through 
PPAR. Most of these studies used rodent models and studied the response to 
peroxisome proliferators (Kadowaki, 2001; McMullen et al., 2014). Despite the 
evidence linking PPARα signalling with a variety of other signalling pathways there 
are currently few reports on how this links to peroxisome homeostasis in humans 
(Kadowaki, 2001; McMullen et al., 2014). Treatment with PPAR agonists and 
microarray studies on human hepatocytes showed PPAR binding sites in the 
promoter regions of ACOX1 and PEX11α (Rakhshandehroo et al., 2010). There is 
currently a gap in our understanding of the involvement of this regulatory pathway 
in controlling the transcription of peroxisomal genes for peroxisome proliferation 
under different conditions and precisely how this up-regulation of peroxisome genes 
is linked to peroxisome function (Kadowaki, 2001; McMullen et al., 2014). Here, we 
investigated the promoters of 100 peroxisome genes (Table 4.1) searching for 
PPAR binding sites, starting by extracting -10kb from the TSS (transcription start 
site) and scanning the promoter area. 
 
Ensembl Gene ID 
Associated 
Chromosome Name 
Gene 
Gene End (bp) Strand 
Gene Name Start (bp)     
ENSG00000101986 ABCD1 X 153724868 1.54E+08 1 
      
ENSG00000173208 ABCD2 12 39550033 39619751 -1 
      
ENSG00000117528 ABCD3 1 94418455 94518666 1 
      
ENSG00000119688 ABCD4 14 74285423 74303056 -1 
      
ENSG00000060971 ACAA1 3 38103129 38137242 -1 
      
ENSG00000167315 ACAA2 18 49782167 49813960 -1 
      
ENSG00000240303 ACAD11 3 132558138 1.33E+08 -1 
      
ENSG00000181513 ACBD4 17 45132600 45144181 1 
      
ENSG00000107897 ACBD5 10 27195214 27242130 -1 
      
ENSG00000184227 ACOT1 14 73537114 73543794 1 
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ENSG00000119673 
 
ACOT2 
 
14 
 
73567620 
 
73575658 
 
1 
 
       
             
 ENSG00000177465  ACOT4  14  73591706  73596496  1  
             
 ENSG00000101473  ACOT8  20  45841721  45857406  -1  
             
 ENSG00000161533  ACOX1  17  75941507  75979363  -1  
             
 ENSG00000168306  ACOX2  3  58505136  58537319  -1  
             
 ENSG00000087008  ACOX3  4  8366282  8440723  -1  
             
 ENSG00000176715  ACSF3  16  89088375  89155846  1  
             
 ENSG00000151726  ACSL1  4  184755595  1.85E+08  -1  
             
 ENSG00000123983  ACSL3  2  222860934  2.23E+08  1  
             
 ENSG00000068366  ACSL4  X  109624244  1.10E+08  -1  
             
 ENSG00000197142  ACSL5  10  112374018  1.12E+08  1  
             
 ENSG00000164398  ACSL6  5  131949973  1.32E+08  -1  
             
 ENSG00000281938  ACSL6  5  131807143  1.32E+08  -1  
             
 ENSG00000018510  AGPS  2  177392644  1.78E+08  1  
             
 ENSG00000072210  ALDH3A2  17  19648136  19677598  1  
             
 ENSG00000242110  AMACR  5  33986178  34008108  -1  
             
 ENSG00000276559  BAAT  CHR_HSCHR9_1_CTG5  101371093  1.01E+08  -1  
             
 ENSG00000136881  BAAT  9  101360417  1.01E+08  -1  
             
 ENSG00000121691  CAT  11  34438925  34472062  1  
             
 ENSG00000095321  CRAT  9  129094810  1.29E+08  -1  
             
 ENSG00000005469  CROT  7  87345681  87399795  1  
             
 ENSG00000110887  DAO  12  108858932  1.09E+08  1  
             
 ENSG00000203797  DDO  6  110391771  1.10E+08  -1  
             
 ENSG00000274296  DECR2  CHR_HSCHR16_CTG2  401826  412487  1  
             
 ENSG00000242612  DECR2  16  401826  412487  1  
             
 ENSG00000087470  DNM1L  12  32679200  32745650  1  
             
 ENSG00000113790  EHHADH  3  185190624  1.85E+08  -1  
             
 ENSG00000120915  EPHX2  8  27490779  27545564  1  
             
 ENSG00000197601  FAR1  11  13668670  13732346  1  
             
 ENSG00000064763  FAR2  12  29149103  29340980  1  
             
 ENSG00000214253  FIS1  7  101239458  1.01E+08  -1  
             
 ENSG00000160097  FNDC5  1  32862268  32872482  -1  
             
 ENSG00000116906  GNPAT  1  231241207  2.31E+08  1  
             
 ENSG00000197448  GSTK1  7  143244093  1.43E+08  1  
             
 ENSG00000131373  HACL1  3  15560704  15601852  -1  
             
 ENSG00000101323  HAO1  20  7882981  7940474  -1  
             
 ENSG00000116882  HAO2  1  119368779  1.19E+08  1  
             
 ENSG00000117305  HMGCL  1  23801885  23838620  -1  
             
 ENSG00000133835  HSD17B4  5  119452443  1.20E+08  1  
             
 ENSG00000119912  IDE  10  92451684  92574076  -1  
             
 ENSG00000138413  IDH1  2  208236227  2.08E+08  -1  
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ENSG00000067064 
 
IDI1 
 
10 
 
1039908 
 
1049170 
 
-1 
 
       
             
 ENSG00000148377  IDI2  10  1018907  1025859  -1  
             
 ENSG00000102910  LONP2  16  48244296  48363122  1  
             
 ENSG00000103150  MLYCD  16  83899126  83927026  1  
             
 ENSG00000115204  MPV17  2  27309492  27325680  -1  
             
 ENSG00000110921  MVK  12  109573255  1.10E+08  1  
             
 ENSG00000007171  NOS2  17  27756766  27800499  -1  
             
 ENSG00000112874  NUDT12  5  103548855  1.04E+08  -1  
             
 ENSG00000148832  PAOX  10  133379234  1.33E+08  1  
             
 ENSG00000115425  PECR  2  215996329  2.16E+08  -1  
             
 ENSG00000127980  PEX1  7  92487020  92528531  -1  
             
 ENSG00000157911  PEX10  1  2403964  2413797  -1  
             
 ENSG00000166821  PEX11A  15  89677764  89690783  -1  
             
 ENSG00000131779  PEX11B  1  145911350  1.46E+08  -1  
             
 ENSG00000104883  PEX11G  19  7476875  7497449  -1  
             
 ENSG00000108733  PEX12  17  35574795  35578863  -1  
             
 ENSG00000162928  PEX13  2  61017225  61051990  1  
             
 ENSG00000142655  PEX14  1  10472288  10630758  1  
             
 ENSG00000121680  PEX16  11  45909669  45918812  -1  
             
 ENSG00000162735  PEX19  1  160276812  1.60E+08  -1  
             
 ENSG00000164751  PEX2  8  76980258  77001044  -1  
             
 ENSG00000215193  PEX26  22  18077920  18131138  1  
             
 ENSG00000034693  PEX3  6  143450807  1.43E+08  1  
             
 ENSG00000139197  PEX5  12  7188685  7218574  1  
             
 ENSG00000114757  PEX5L  3  179794958  1.80E+08  -1  
             
 ENSG00000124587  PEX6  6  42963870  42979220  -1  
             
 ENSG00000112357  PEX7  6  136822564  1.37E+08  1  
             
 ENSG00000107537  PHYH  10  13277796  13302412  -1  
             
 ENSG00000179761  PIPOX  17  28950513  29057220  1  
             
 ENSG00000163344  PMVK  1  154924734  1.55E+08  -1  
             
 ENSG00000115138  POMC  2  25160853  25168903  -1  
             
 ENSG00000186951  PPARA  22  46150521  46243756  1  
             
 ENSG00000132170  PPARG  3  12287368  12434356  1  
             
 ENSG00000117450  PRDX1  1  45511036  45523047  -1  
             
 ENSG00000126432  PRDX5  11  64318088  64321811  1  
             
 ENSG00000176894  PXMP2  12  132687606  1.33E+08  1  
             
 ENSG00000101417  PXMP4  20  33702754  33720319  -1  
             
 ENSG00000155366  RHOC  1  112701106  1.13E+08  -1  
             
 ENSG00000116171  SCP2  1  52927229  53051703  1  
             
 ENSG00000172250  SERHL  22  42500579  42512560  1  
             
 ENSG00000197375  SLC22A5  5  132369752  1.32E+08  1  
             
          113  
 
ENSG00000100372 
 
SLC25A17 
 
22 
 
40769630 
 
40819399 
 
-1 
 
       
             
 ENSG00000140284  SLC27A2  15  50182196  50236395  1  
             
 ENSG00000142168  SOD1  21  31659622  31668931  1  
             
 ENSG00000112096  SOD2  6  159669057  1.60E+08  -1  
             
 ENSG00000166575  TMEM135  11  87037844  87323758  1  
             
 ENSG00000108395  TRIM37  17  58982638  59106921  -1  
             
 ENSG00000158125  XDH  2  31334321  31414715  -1  
             
 ENSG00000180011  ZADH2  18  75195108  75209348  -1  
             
 
 
Table 4.1 List of 100 peroxisome genes 
 
 
 
 
 
To study the core promoters and proximal promoters of candidate genes in 
more detail, new databases (such as DECODE) (https://www.decode.com) were 
added to the approach. Ultimately, a program for checking PPREs in our gene 
cohort was generated. This program was used to search for and to assess the 
probability of different forms of PPREs by running through the sequences base 
pair by base pair. Histograms of potential PPREs that have been used for this 
study are shown in Figure 4.1. The results include the position of probable 
binding sites, the PPRE pattern and the percentage of binding efficiency 
(calculated based on the number of base pairs in the gene sequence matching 
the PPRE consensus sequence) (Table 4.2). 
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Figure 4.1. Pictograms of PPAR motif binding sites (JASPAR CORE), position 
weight matrices of PPARα, PPARβ and PPARγ. 
 
 
 
In total, 34 PPAR motif sites were found in 29 peroxisomal genes with a binding 
efficiency higher than 70%, with some genes (PEX1, PEX11γ, ACAA1) containing 
more than one PPRE. An overview of the genes carrying at least one potential 
PPRE is shown in Table 4.2. The PPRE search results reveal the presence of 
PPARγ binding sites in promoter regions of genes involved in peroxisome 
biogenesis such as PEX11β, PEX16, PEX19, or PEX14 and PPARα binding sites 
mostly in the promotor regions of peroxisomal genes involved in metabolic 
functions of peroxisomes such as ACOX1, ACAD, CAT and PGC-1α. 
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Gene Name PPRE Name Binding efficiency PPRE pattern 
    
PEX1 PPAR γ 89 AGGTCANNAGGTCG 
    
PEX1 PPAR β 72 AGGTGANNAGGTCA 
    
PEX2 PPAR γ 75 AGGTCAAGGGTCA 
    
PEX3 PPAR γ 91 AGGCCANNAGGTCA 
    
PEX5 PPAR γ 85 AGGTCCNNAGTTCA 
    
PEX6 PPAR γ 81 AGGTCANNAGTTCA 
    
PEX10 PPAR γ 89 AGGTCANNAGGTCG 
    
PEX11 α PPAR α 100 AGGCCANNAGGTCA 
    
PEX11β PPAR γ 81 AGGTCANNAGTTCA 
    
PEX11 γ PPAR α 72 AGGTCANNAGGTCA 
    
PEX11 γ PPAR γ 81 AGGTCANNAGTTCA 
    
PEX14 PPAR γ 100 AGGCCANNAGGTCA 
    
PEX16 PPAR γ 91 AGGCCANNAGGTCA 
    
PEX19 PPAR γ 89 AGGTCANNAGGTCG 
    
SLC27A2 PPAR γ 81 AGGTCANNAGTTCA 
    
ACSL5 PPAR γ 81 AGGTCANNAGTTCA 
    
ACOX1 PPAR α 100 AGGCCANNAGGTCA 
    
ACOX2 PPAR γ 81 AGGTCANNAGTTCA 
    
EHHADH PPAR γ 81 AGGTCANNAGTTCA 
    
ACAA1 PPAR α 79 TGGTCANNAGGTCA 
    
ACAA1 PPAR γ 91 AGGCCANNAGGTCA 
    
ACOT1 PPAR α 96 GGGGCANNAGGGCA 
    
SLC25A17 PPAR α 100 AGGCCANNAGGTCA 
    
ACBD4 PPAR γ 81 AGGTCANNAGTTCA 
    
BAAT PPAR α 72 AGGTCANNAGGTCA 
    
GSTK1 PPAR α 75 AGGTGANNAGGTCA 
    
ABCD2 PPAR γ 81 AGGTCANNAGTTCA 
    
PPAR α PPAR γ 93 GGGGCANNAGGGCA 
    
ABCD1 PPAR α 96 GGGGCANNAGGGCA 
    
CAT PPAR α 83 AGCTCANNAGGTCA 
    
ACAD PPAR α 83 AGCTCANNAGGTCA 
    
PGC1 PPAR α 100 AGGCCANNAGGTCA  
 
 
 
Table 4.2. Summary of PPREs found in human peroxisomal genes. Binding sites 
for PPARγ appear in the promoter regions of 10 peroxins, while binding sites for 
PPARα were found mostly in promoter regions of genes encoding enzymes involved in 
metabolic pathways. 
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4.2.2 Identification of novel transcriptional regulatory elements 
 
 
In order to search for additional potential non-PPAR regulatory elements in 
peroxisomal genes in humans, we used a Python based program (Gimmemotif). 
(http://gimmemotifs.readthedocs.io/en/master/index.html). The available motif 
sequences were extracted from major transcription factor binding sites in PWS 
(position weight matrices) format JASPARE Core (http://jaspar.genereg.net/). In 
total 700 transcription factor binding sites were represented in the form of PWS 
matrices. For each candidate gene, we analysed -10kb upstream of the start 
codon. The sequences of candidate genes, including 100 peroxisomal r genes 
(PEX genes, genes encoding metabolic enzymes etc), and 100 randomly selected 
control genes were downloaded from Biomart (https://www.ensembl.org/biomart). 
The full list of the selected peroxisomal genes is shown in Table 4.1, and control 
genes in Table 4.3. 
 
Gene stable ID 
Gene 
Gene stable ID 
Gene 
Gene stable ID 
Gene 
name name name    
ENSG00000120437 ACAT2 ENSG00000282513 FMN1 ENSG00000100162 CENPM 
      
ENSG00000153107 ANAPC1 ENSG00000053254 FOXN3 ENSG00000172757 CFL1 
      
ENSG00000149311 ATM ENSG00000116717 GADD45A ENSG00000165410 CFL2 
      
ENSG00000175054 ATR ENSG00000111640 GAPDH ENSG00000149554 CHEK1 
      
ENSG00000089685 BIRC5 ENSG00000105968 H2AFV ENSG00000183765 CHEK2 
      
ENSG00000012048 BRCA1 ENSG00000188486 H2AFX ENSG00000122966 CIT 
      
ENSG00000139618 BRCA2 ENSG00000164032 H2AFZ ENSG00000136108 CKAP2 
      
ENSG00000169679 BUB1 ENSG00000164104 HMGB2 ENSG00000173207 CKS1B 
      
ENSG00000156970 BUB1B ENSG00000198830 HMGN2 ENSG00000123975 CKS2 
      
ENSG00000154473 BUB3 ENSG00000072571 HMMR ENSG00000124207 CSE1L 
      
ENSG00000198668 CALM1 ENSG00000165704 HPRT1 ENSG00000006634 DBF4 
      
ENSG00000110104 CCDC86 ENSG00000144381 HSPD1 ENSG00000155368 DBI 
      
ENSG00000145386 CCNA2 ENSG00000136273 HUS1 ENSG00000168393 DTYMK 
      
ENSG00000134057 CCNB1 ENSG00000125968 ID1 ENSG00000147155 EBP 
      
ENSG00000110092 CCND1 ENSG00000149503 INCENP ENSG00000114346 ECT2 
      
ENSG00000082258 CCNT2 ENSG00000091409 ITGA6 ENSG00000074800 ENO1 
      
ENSG00000010278 CD9 ENSG00000138160 KIF11 ENSG00000174371 EXO1 
      
ENSG00000136807 CDK9 ENSG00000079616 KIF22 ENSG00000106462 EZH2 
      
ENSG00000100526 CDKN3 ENSG00000090889 KIF4A ENSG00000105202 FBL 
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ENSG00000138778 CENPE ENSG00000237649 KIFC1 ENSG00000280548 FBL 
      
ENSG00000117724 CENPF ENSG00000233450 KIFC1 ENSG00000112029 FBXO5 
      
ENSG00000153044 CENPH ENSG00000204197 KIFC1 ENSG00000160752 FDPS 
      
ENSG00000123219 CENPK ENSG00000056678 KIFC1 ENSG00000196924 FLNA 
      
ENSG00000198554 WDHD1 ENSG00000130640 TUBGCP2 ENSG00000136068 FLNB 
      
ENSG00000122952 ZWINT ENSG00000175063 UBE2C ENSG00000248905 FMN1 
      
ENSG00000111057 KRT18 ENSG00000073111 MCM2 ENSG00000037042 TUBG2 
      
ENSG00000106683 LIMK1 ENSG00000135679 MDM2 ENSG00000197275 RAD54B 
      
ENSG00000131899 LLGL1 ENSG00000148773 MKI67 ENSG00000068028 RASSF1 
      
ENSG00000284137 LLGL1 ENSG00000100714 MTHFD1 ENSG00000067560 RHOA 
      
ENSG00000073350 LLGL2 ENSG00000100345 MYH9 ENSG00000175793 SFN 
      
ENSG00000164109 MAD2L1 ENSG00000106631 MYL7 ENSG00000005022 SLC25A5 
      
ENSG00000112062 MAPK14 ENSG00000109805 NCAPG ENSG00000250254 PTTG2 
      
ENSG00000101367 MAPRE1 ENSG00000106268 NUDT1 ENSG00000166974 MAPRE2 
      
ENSG00000173598 NUDT4     
      
 
 
 
Table 4.3 List of 100 control genes 
 
 
Having extracted the promoter sequences for our 100 peroxisomal and 100 
control genes, we then analysed the promoter sequences using Gimmemotif. 
 
Gimmemotif contains commands to collect sequences of known motifs and 
predict and score for motif enrichment on sequences. The commands were 
adopted for the purpose of this research. 
 
The candidate gene sequences were run through the program which displayed a 
potential match to each motif. There are several parameters to be considered 
including the best match of each motif in each sequence, and stringency thresholds 
that were set to maximum to only include the highest probable motifs. The 
threshold for calling a match was fixed at 89%. As controls we used 100 random 
gene sequences (Table 4.3) and in addition, each candidate gene sequence was 
randomized (scrambled 3 times in succession) and run through the same set up as 
an additional control. To select for transcription factor binding motifs which were 
enriched in the peroxisomal genes compared to controls, and 
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to test if the numbers of each motif match were significant, a ratio was obtained 
from the number of sites compared to the control group. These values were 
normalized and the obtained hypergeometric p-value ("log10 (p-value)" >1.3 = 
significant) was used to remove the false positives. This analysis showed the 
set of transcription factor binding sites enriched/over-represented in 
peroxisomal genes compared to the control groups. The results were collected 
as BED or FASTA. The motif search process is summarized in Figure 4.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Schematic view of the bioinformatics approach to scan TF motif sites 
in the promoter region of peroxisomal genes. -10kb of the peroxisomal genes were 
extracted from Biomart, along with JASPAR matrices for transcription factor binding 
sites and run through the GimmeMotif program resulting in 7826 hits. 
 
 
4.2.3 General summary of motif search Data filtering 
 
 
In total, 7826 sites belonging to 105 transcription factors were found to be enriched 
in our gene cohort. Transcription factors such as VDR, TEAD3 or TBX20 did not 
have a binding consensus in the promoter regions of these 100 genes. 
 
In order to eliminate non-active motif binding sites based on chromosome 
structure, we used the USCS transcription factor binding tracks to choose 
transcriptionally active sites in each gene. This database shows probable 
accessible binding sites of the specified transcription factors in the given cell 
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types as determined by chromatin immunoprecipitation followed by high 
 
throughput sequencing (ChIP-seq). 
 
 
Transcriptionally active and silent chromatin is characterized by 
posttranslational modifications on histones. Active genes typically carry high 
levels of lysine acetylation on the histone3 and histone4 tails (H3K27ac), 
trimethylation of lysine 4 histone3 subunit (H3K4me3), trimethylation of H3 
lysine 79, ubiquitylation of H2B, and trimethylation of histone 3 lysine 36 
(H3K36me3). These histone marks may regulate transcription by creating an 
open chromatin structure and recruit effectors that mediate a transcriptionally 
competent state (Bannister & Kouzarides, 2011; T. Zhang et al., 2015). 
 
The presence of H3K4me3, H3K36me3, H3K27ac (histone marks) and absence of 
H3K27m3 near the potential motif was checked with the USCS genome browser as 
indicators of transcriptionally active sites in HepG2 cells. Our cohort of 100 
peroxisomal genes was analyzed by USCS TF binding tracks. Each track shows a 
graph of enrichment for motif binding (signal), along with sites that have the 
greatest evidence of transcription factor binding (Peaks). These tracks are color 
coded by a binding strength score on a scale 0 to 1000, with higher score indicative 
of stronger binding. The peaks were grouped based on the peak height plotted to 
the same scale. From 0 to 200 a low peak was considered, , 200 to 500 as medium 
score, and > 500 was considered as the high binding score. Based on this analysis, 
we selected for a high binding score meaning that among the potential motif sites, 
3271 sites were excluded out of 7826. In total 105 transcription factor binding sites 
among 700 transcription factors were found in our cohort. In the control group only 
1102 binding sites for these 105 transcription factors were identified (instead of 
4555 within the peroxisomal group), indicating 
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these motifs are enriched in peroxisomal genes and may play a role in 
regulating peroxisomal gene expression. 
 
Whilst many transcription factors have multiple binding sites, none bind to the 
promoter regions of all peroxisomal genes, and others have multiple sites in one 
promoter, e.g. FOXA1 has 117 binding sites in the promoter regions of 42 
peroxisomal genes (Table 4.3). However, this was not equally distributed, i.e. 
some genes had 10 FOXA1 binding sites and some had one. 
 
On the other hand, none of the peroxisomal genes showed active motif sites for 
GLI2 (belongs to the C2H2-type zinc finger protein subclass of the Gli family) 
but it was present in the control set. 
 
Motif Name Number of Motif Name Number of Motif Name Number 
 sites  sites  of sites 
FOXA1 117 TBP 68 NFE2L1::MafG 39 
      
SP1 116 GABPA 68 Sox3 39 
      
Gata1 114 JUND 68 Hltf 39 
      
MYC 110 Myc 65 Sox5 39 
      
NFKB1 90 JunD 64 CEBP/A 39 
      
Myb 78 CREB1 61 ELK1 39 
      
JUN::FOS 78 TFAP2A 58 Mafb 39 
      
RUNX1 78 ELK4 56 FOXP2 39 
      
ZEB1 78 STAT1 56 NFATC2 39 
      
SPI1 78 Tcfcp2l1 52 ETS1 39 
      
Nkx2-5 78 HNF4A 50 Ddit3::CEBPA 39 
      
CEBPA 78 Sox2 45 SOX10 39 
      
EBF1 78 E2F1 43 MZF1_5-13 39 
      
Foxa2 77 Gfi1b 39 En1 39 
      
Klf4 77 FOXL1 39 Bhlhe40 39 
      
Zfx 76 RORA_1 39 Sox17 39 
      
MEF2A 76 FOXI1 39 MEF2C 39 
      
GATA2 74 Prrx2 39 HLF 39 
      
MAX 74 ZNF354C 39 MyOg 39 
      
USF1 74 KLF5 39 FOXC1 39 
      
Esrrb 72 BRCA1 39 TCF12 39 
      
GATA3 71 CDX2 39 ATF4 39 
      
YY1 71 HIF1A::ARNT 39 REL 39 
      
NR3C1 69 Erg 39 Nobox 39 
      
Myc-MAX 25 HINFP 17 RREB1 11 
      
NR2C2 23 STAT2::STAT1 16 SRF 10 
      
NR5a2 22 znf143 16 POU5f1::Sox2 8 
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NRF1 22 RXRA 15 HSF1 7 
      
Nr1h3::Rxra 20 TP63 15 MAFF 7 
      
Tal1::Gata1 19 ZNF263 14 Bach1::Mafk 7 
      
NFYB 19 Mecom 13 RORA_2 6 
      
Bcl6 18 PLAG1 13 ESR1 6 
      
PRDM1 18 TP53 12 SMAD2/3 5 
      
TAL1::GATA1 18 RXR::RAR_DR5 12 Rfx1 5 
      
ESR2 18 Pax5 12 Cc 5 
    NFE2::MAF  
 
 
 
Table 4.4 Summary of motif binding sites and number of their repeats in our 
 
peroxisomal gene cohort. 4555 sites in total were found in transcriptionally active parts 
 
of our 100 candidate genes. 
 
 
 
 
 
Interestingly, NR3C1, encoding the glucocorticoid receptor, had 69 motif sites in 
our peroxisomal gene cohort. Upon activation of NR3C1, the expression of 
enzymes involved in fatty acid metabolism is increased (Table 4. 3) (LeBleu et 
al., 2014). 
 
 
4.2.5 The expression of PEX11 isoforms is differentially regulated 
 
 
The PEX11 family of proteins were shown to directly participate in peroxisome 
proliferation in yeasts, plants and mammals (Abe & Fujiki, 1998; Erdmann & 
Blobel, 1995; Lingard & Trelease, 2006; Marshall et al., 1995; Orth et al., 2007). 
In mammalian cells, three PEX11-related genes have been identified, PEX11α, 
PEX11β and Pex11γ. Based on our qPCR results studying the expression of 
PEX11 isoforms in HepG2 cells during a time course, these genes are not 
following the same pattern (Chapter 3, section 3.3.5). PEX11β expression 
follows the tubular morphology pattern of peroxisomes in our assay, with a 
higher expression after 24 hours, during the time course experiment 
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in HepG2 cells, whilst PEX11α and PEX11γ do not. This different expression 
pattern suggests differential regulation; we therefore searched for differences in 
motif sites in these genes. Interestingly, as shown in Figure 4.3, PEX11β and 
PEX11α have no common motifs for transcription factor binding, however, ATF4 
and SMAD2/3 sites were found both in PEX11β and PEX11γ, whilst each gene 
also had other unique motifs. Overall, this suggests differential regulation of the 
three PEX11 genes but also implies potential co-regulation of PEX11β and 
PEX11γ by the ATF4/SMAD2/3 pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Venn diagram of common transcription factor binding sites within the 
promoter regions of human Pex11 isoforms. Potential binding sites for SMAD2/3 
(activated by the TGFβ pathway) in Pex11γ and Pex11β were predicted which are 
located in a transcriptionally active area according to histone marks. 
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4.2.3 Network analysis to compare regulation of peroxisomal genes with 
different functions 
 
 
Gene expression is the result of an organized network of interacting elements in 
signaling pathways and gene regulation networks in the cell (Ling et al., 2013). 
External signals activate signal transduction pathways to initiate transcription 
factor driven gene expression in gene regulatory networks (Schlitt & Brazma, 
2007; D. Xie et al., 2011). Transcription factors are often pleiotropic and 
involved in gene expression profiles of multiple genes and therefore multiple 
biological processes and phenotypes (Franco-Zorrilla et al., 2014; Sureshbabu 
et al., 2016). A list of metabolic genes is shown in Supplementary Table S4.1. 
 
In order to find regulatory pathways involved in expression of our candidate genes, 
the candidate genes were separated into two broad groups based on their known 
function, namely genes involved in metabolic functions of peroxisomes or peroxins, 
which were analyzed for common transcription factor binding sites. The top 10 
common transcription factors for each group were then run through an open source 
network analysis, Enricher (http://amp.pharm.mssm.edu/Enrichr/). The program 
uses the identity of the associated transcription factors to suggest links to specific 
regulatory pathways using data collated on each factor (e.g., KEGG pathways) 
(Kuleshov et al., 2016). Table 4.5 shows the most common transcription factors 
regulating metabolic genes and peroxins. 
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Metabolic Genes Peroxins 
  
NR1H3 ATF1 
  
NR1I2 MAFB 
  
FOXO3A FOXA2 
  
ELK4 HNF4A 
  
ESR1 SOX10 
  
ELK1 NFAT2 
  
VDR IRF2 
  
TFAP2D ATF4 
  
FOXF1 GFI1 
  
MYOD1 SPIB 
  
 
 
Table 4.5. Top 10 motifs found in peroxisomal genes encoding metabolic proteins 
 
and peroxins. 
 
 
 
 
 
As discussed in chapter 3, we established a cell-based assay using HepG2 cells to 
monitor peroxisome morphology and peroxisomal gene expression over a time 
course under standard or serum-free conditions (Chapter 3, Section 3.3.5). Based 
on the qPCR analysis, peroxins which are required early in peroxisome 
formation/proliferation for membrane biogenesis and insertion of membrane 
proteins such as, PEX3, PEX19 or PEX11β are following the tubular morphology 
pattern during a time course of 72 hours upon culture of HepG2 cells. We aimed at 
clarifying whether certain gene clusters following the tubular peroxisome pattern 
during the 6-72 hours are enriched with particular functional categories. 
 
In order to further study their regulatory elements, the set of genes used for 
performing qPCR studies were analyzed for common transcription factor binding 
sites. As illustrated in Figure 4.4, PEX11β and PEX10 have common 
transcription factor binding sites, including those for ATF4 and SNAI2. 
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Figure 4.4. Venn diagram of common transcription factor binding sites within 
the promoter regions of PEX11β, PEX19, PEX16 and Pex10. 
 
 
 
 
The network analysis was performed by using a web-based tool, Enrichr, to link 
these factors to certain regulatory pathways (Kuleshov et al., 2016). Enrichr 
uses all available databases for signaling networks and protein/protein 
interaction, e.g. wikiPathways (Pico et al., 2008), KEGG (Ogata et al., 1998), 
BioCarta, Reactome (Joshi-Tope et al., 2005) and kinase enrichment analysis 
(KEA) (Lachmann & Ma'ayan, 2009) to link certain transcription factors to the 
pathways they are involved in (http://amp.pharm.mssm.edu/Enrichr) and to 
predict relationships between biological and pharmacological processes. The 
results showed that the transcription factors involved in the regulation of 
PEX11β, PEX16, PEX10 and PEX19 are linked to two main pathways, including 
SMAD2/3 and C-MYC 
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signaling  pathways.  However,  ABCD1,  PEX11α,  PPARα  and  PEX11γ  are 
 
regulated by the HIF-1α pathway (Figure 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Venn diagrams of potential regulatory networks involved in the 
regulation of ABCD1, PEX11, PEX11α and PPARα (gene expression does not 
correlate with peroxisome elongation/proliferation in HepG2 cells) and PEX11B, 
PEX19, PEX16, PEX10 (gene expression correlates with peroxisome 
elongation/proliferation in HepG2 cells). 
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4.3 Discussion 
 
 
As highlighted in the introduction, PPARs are the known regulators of lipid 
homeostasis and peroxisome proliferation. Studies with PPAR antagonists 
indicate that unlike many other nuclear receptors, PPARα governs the 
expression of a large set of genes, many of which are involved in fatty acid 
metabolism in human and rodent liver (Berger & Moller, 2002; Desvergne & 
Wahli, 1999; van der Meer et al., 2010). However, PPARα agonists have only 
mild effects on the expression of genes associated with lipid metabolism in 
HepG2 cells (Vanden Heuvel et al., 2003). Here, we focused not only on 
PPARα binding sites but also on PPARβ and γ. 
 
Based on our results, 34 PPAR motif sites were found in 29 peroxisomal genes 
with > 70% binding efficiency, whilst PEX1, PEX11γ and ACAA1 are containing 
more than one PPRE. It has been shown that fatty acids can regulate cellular 
function by modulating the rates of transcription of various target genes 
including acyl-CoA oxidase (ACOX1) through activating PPAR-RXR complex 
(McMullen et al., 2014). Here we used ACOX1 as a control, and as expected, a 
PPARα site was found within the promoter of ACOX1 (McMullen et al., 2014). 
Potential PPARγ sites were identified in the promoter regions of peroxins such 
as PEX11β, PEX16, PEX19, and PEX14. However, PPARα binding sites were 
mainly found in promoter regions of genes involved in metabolic functions of 
peroxisomes. Interestingly, PEX11α, which is likely not directly involved in 
peroxisome proliferation, contains a potential PPARα binding site, which may 
further point to a metabolic role of PEX11α. This suggests different regulatory 
mechanisms for peroxisomal biogenetic and metabolic genes. 
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In the present study, we further searched for other regulatory elements present 
in the promoter regions of peroxisomal genes. As a result, common binding 
sites for transcription factors shared by peroxisomal genes were identified. This 
data can be used to identify the regulatory elements of peroxisomal genes in 
different cell lines considering their active transcription sites. Promoter 
sequences of 100 peroxisomal genes were used to investigate the potential 
target sites for transcription factors. This study resulted in a large amount of 
data and here we focus on some interesting individual examples. Our findings 
showed the difference in regulation of peroxisomal genes involved in metabolic 
or biogenetic functions of peroxisomes. The metabolic genes mostly are 
connected to pathways such as HIF-1α, which is a hypoxia related pathway. 
However, transcription factors which can be activated through cross talk with 
the SMAD2/3 pathway are main regulators for peroxins. 
 
Another interesting motif found in our cohort is the Glucocorticoid Response 
Element (GRE). Our results show that PPARα and γ have an active GRE. 
Glucocorticoids (GR) are a class of steroid hormones that are secreted by 
cortical cells in adrenal glands and modify the immune responses to diverse 
stimuli (Scheschowitsch et al., 2017). In our cohort, a binding element for GR 
was found in 27 genes, including ACOX2, ACAD11, EHHADH and ACBD4. 
Interestingly, there are studies on direct involvement of the mitochondrially 
localized glucocorticoid receptor in the regulation of mitochondrial transcription 
and OXPHOS enzyme biosynthesis by binding to mtDNA and activation of 
mitochondrial gene expression. Also, it has been shown that GR can indirectly 
control expression of mitochondrial genes by induction of genes encoding 
mitochondrial transcription factors (Beato et al., 1996; Psarra & Sekeris, 2008). 
In addition, the mitochondrial localization of several other transcription 
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factors which are involved in activating immune responses including NF-κΒ, 
p53, AP-1, STAT-3 have been reported (Psarra & Sekeris, 2009). Localization 
of GR to mitochondria and existence of GR binding sites in peroxisomal genes 
suggest the involvement of this pathway in the expression of genes contributing 
to energy production and immune responses (Psarra & Sekeris, 2009). 
 
As a key regulator of peroxisome dynamics, the PEX11 promoters were analyzed 
for transcription factor binding sites. Comparison between PEX11α, PEX11β and 
PEX11γ revealed common binding sites for SMAD2/3 and also ATF4, which both 
can be activated by TGFβ signalling. Activation transcription factor 4 (ATF4) can 
also bind to cAMP response element (CRE), which is involved in many pathways 
including activation of autophagy processess upon ER stress (B’chir et al., 2013). 
Other genes containing SMAD2/3 binding sites are FIS1, PEX13 and PEX14, 
further indicating the potential involvement of this pathway in the regulation of 
peroxisome dynamics. Further investigation including functional promoter studies 
using PEX11β vectors are required to validate the direct effect of TGFβ signaling 
via SMAD2/3 on peroxisome dynamics and proliferation (see Chapter 5). 
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Chapter 5 – Results 
 
 
 
 
 
The canonical TGFβ pathway has a role in 
peroxisome proliferation in hepatocytes 
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Summary 
 
 
Our bioinformatic analysis of peroxisomal genes for transcription factor binding 
sites indicated a potential SMAD2/3 binding site in the promoter region of PEX11β. 
As SMAD2/3 can be activated through TFGβ signalling, we investigated whether 
expression of PEX11β is linked to the canonical, SMAD-dependent TGFβ signalling 
pathway. PEX11β is a key protein in the regulation of peroxisome dynamics and 
proliferation, and regulation of PEX11β expression by TGFβ would link this 
signalling pathway to peroxisome proliferation. We first used our developed cell-
based peroxisome proliferation assay to investigate if TGFβ had an effect on 
peroxisome morphology and number. Interestingly, addition of TGFβ to HepG2 
cells cultured under serum-free conditions induced elongation/growth of 
peroxisomes as well as peroxisome proliferation supporting a role for TGFβ 
signalling in peroxisomal growth and division. We also predicted that the putative 
SMAD2/3 binding site in the PEX11β promoter is located in a transcriptionally 
active region with strong binding efficiency for SMAD2/3. To demonstrate that the 
SMAD binding site is indeed functional and can induce PEX11β expression, we 
applied a dual luciferase reporter assay. When we expressed a luciferase reporter 
under control of the PEX11β promoter, luciferase activity was induced by TGFβ 
stimulation. However, a PEX11β promoter mutant with altered SMAD binding site 
was unable to induce luciferase activity after TGFβ stimulation. These findings 
demonstrate that the SMAD binding site within the PEX11β promoter is functional, 
and that TGFβ signalling via the canonical SMAD-dependent pathway can activate 
PEX11β expression, leading to peroxisome growth, division and proliferation in 
HepG2 cells. 
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5.1 Introduction 
 
 
5.1.1 Transforming growth factor β- an overview 
 
 
The transforming growth factor β (TGFβ) superfamily is composed of a large 
group of structurally related polypeptide growth factors, including the 
TGFβ/activin family, bone morphogenetic proteins (BMPs), growth 
differentiation factors (GDFs), and the glial cell line-derived neurotrophic factor 
(GDNF) family (Massague, 2012). 
 
The TGFβ family consist of multifunctional proteins that regulate a diverse range 
of processes during development and tissue homeostasis, such as cell 
proliferation, apoptosis, autophagy, inflammation, angiogenesis, and epithelial-
to-mesenchymal transition (Horbelt et al., 2012; Kitisin et al., 2007; Massague, 
2012; Nagaraj & Datta, 2010). There are three known isoforms of TGFβ 
(TGFβ1, TGFβ2 and TGFβ3) expressed in mammalian tissues; they contain 
highly conserved regions but are different in several amino acid regions. All of 
these isoforms function through the same receptor signalling pathways (Horbelt 
et al., 2012; Kitisin et al., 2007; Massague, 2012; Nagaraj & Datta, 2010). 
 
TGFβ isoforms bind to receptors at the cell surface, and recruit two type I receptors 
and two type II receptors forming a tetrameric complex (Massague, 1998). 
Activated TGFβ superfamily receptors induce a phosphorylation cascade, from 
receptor phosphorylation to subsequent phosphorylation and activation of 
downstream signal transducer R-Smads transcription factors (receptor-activated 
Smads) (Derynck & Akhurst, 2007; Miyazawa & Miyazono, 2017) (Figure 5.1). 
Phosphorylated R-Smads form a hetero-oligomeric (often trimeric) complex with 
Smad4. This R-Smad-Smad4 complex is imported into the nucleus where it 
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regulates the expression of target genes by direct binding to the target gene 
promoter and/or through interaction with transcriptional cofactors in a cell-type-
specific manner (Figure 5.1) (Hariharan & Pillai, 2008; Kamato et al., 2013). 
 
 
5.1.2 TGFβ mechanism of action 
 
 
TGFβ is unique amongst the family of growth factors in that they are synthesized as 
inactive precursors, cleaved into mature ligands and the latency-associated 
peptides (LAP), which are non-covalently linked to the mature ligands, preventing 
binding to their respective receptors The three mammalian TGFβ isoforms are 
normally secreted as part of this inactive complex that consists of an N-terminal 
latency-associated peptide (LAP) and a C-terminal mature TGFβ monomer (Heldin 
& Moustakas, 2016; Kamato et al., 2013). Covalent linkage of LAP to one of three 
latent TGFβ binding proteins (LTBPs) creates a large latent complex that may 
interact with the extracellular matrix (Hariharan & Pillai, 2008; Kamato et al., 2013). 
Activated TGFβ signals through a hetero-tetrameric receptor complex composed of 
two type I and two type II transmembrane receptor subunits with serine/threonine 
kinase domains (Kamato et al., 2013). 
 
The TGFβ family of ligands have different affinities for different type I and II 
receptor combinations. TGFβ protein binds to the constitutively active TGFβ 
type II receptor. In most cell types, following ligand binding, the type II receptor 
(TGFβ RII) phosphorylates the type I (TGFβ RI), leading to recruitment and 
phosphorylation of Smad2 and Smad3 at their C-termini, dissociation from the 
receptor to form a hetero-trimeric complex with other SMAD proteins (Figure 
5.1) (Hariharan & Pillai, 2008; Kamato et al., 2013). 
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Activated Smad proteins associate with Smad4 and translocate to the nucleus, 
where they recruit additional transcriptional regulators, including DNA-binding 
transcription factors, co-activators, co-repressors, and chromatin remodelling 
factors, that control the expression of numerous target genes with Smad 
sequence-specific DNA binding sites (Figure 5.1) (Kamato et al., 2013). 
Differential expression of these factors may be responsible for some of the cell 
type-specific responses to TGFβ (Heldin et al., 1997; Kamato et al., 2013). 
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Figure 5.1. TGFβ signalling and cross talk with other signalling pathways. The 
 
TGFβ pathway is involved in the regulation of cellular proliferation, differentiation, 
embryogenesis, apoptosis, inflammation, immunity and cancer pathways. TGFβ binds 
its receptor type II at the cell surface which then phosphorylates the TGFβ receptor 
Type I. The activated receptor can phosphorylate various SMAD factors. These 
molecules then transfer to the nucleus and act as transcription factors, recruiting their 
co-factors CBP and P300. TGFβ can also activate the AKT/PKB and JNK cascade. 
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5.1.3 The SMAD protein family 
 
 
Eight Smad proteins are encoded in the human and mouse genomes, four in 
Drosophila, and three in C. elegans (Massague, 1998). The Mad protein in D. 
melanogaster, which was the first identified member of this family (Raftery & 
Sutherland, 1999) is the ortholog of mammalian Smad1/5, whereas dSmad2, 
Medea, and Dad are the orthologs of Smad2/3, Smad4, and Smad6/7, 
respectively. The Smad family in C. elegans includes Sma1, Sma2, and Sma3 
(J. Wang et al., 2005). 
 
Smad4 serves as a co-factor for the SMAD2/3 complex (Figure 5.1). The name 
“Smad” was coined with the identification of human Smad1 because of its 
sequence similarity to the Sma and Mad proteins (F. Liu et al., 1997). 
 
 
5.1.4 TGFβ crosstalk with other signalling pathways 
 
 
Accessory proteins such as soluble or membrane-bound regulators or co-
receptors can also affect TGFβ signalling (J. D. Brown et al., 1999; Kamato et 
al., 2013). In addition, TGFβ can activate a number of Smad-independent (non-
canonical) signalling pathways, including Ras/MAPK, PI 3-K/Akt, p38, JNK, and 
RhoA/ROCK in a cell type-specific and context-dependent manner (Figure 5.1). 
Activation of these pathways may also contribute to the cellular responses 
induced by TGFβ (Figure 5.1) (Borggrefe et al., 2016; Ji et al., 2014; Mu et al., 
2012). 
 
So far, several transcription factors, such as AP1, ETS, basic helix-loop-helix 
proteins, C/EBPβ, FOXH1 and FOXO have been identified and validated as 
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important co-factors of TGF-β/BMP signaling pathways (Massague, 2012; 
Miettinen et al., 1994; Seoane et al., 2001) . 
 
TGFβ also induces activation of Ras, RhoB and RhoA, as well as of TAK1 and 
protein phosphatase 2A, which leads to the activation of several MAP kinase 
pathways and the downregulation of S6 kinase activity (Figure 5.1). 
 
There is evidence for a crucial role of TGFβ as cytostatic and apoptotic in 
hepatocytes, which is critical for the control of liver mass (Karkampouna et al., 
2012). Liver is a unique organ with high regenerative capacity which is important for 
homeostasis and tissue repair. As mentioned, this pathway has activator and 
repressor effects on other pathways such as cell growth. Hence, a balanced TGFβ 
signaling in terms of both dosage and spatiotemporal activity is crucial to control 
hepatic gene expression. TGFβ acts in the process of differentiation of hepatoblasts 
to either hepatocytes or cholangiocytes and biliary morphogenesis in the 
developing liver parenchyma during liver regeneration after partial hepatectomy, or 
cholangiocytes in the developing liver parenchyma (Figure 5.2) (Karkampouna et 
al., 2012). This pathway is required at different stages of the process, to allow 
hepatocyte proliferation at the inductive phase followed by an efficient termination 
of the regenerative response afterwards. 
 
In cancer, TGFβ acts as tumour suppressor to induce growth arrest, senescence, 
and apoptosis at the early stages of tumorigenesis, but acts as a tumour promoter 
to induce epithelial-mesenchymal transition (EMT) and to promote angiogenesis in 
addition to loss of growth inhibitory effects at the advanced stages of cancer 
(Katsuno et al., 2013). TGFβ signalling is considered to be an attractive molecular 
target for cancer therapy (Fransvea et al., 2008). 
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Figure 5.2. TGFβ signalling during the progression of chronic liver diseases. Upon 
liver damage, TGFβ ligands in the liver induce the downstream signaling. Depending on the 
disease stage, TGF-β might have a good (+) or bad (−) outcome in the organ. TGFβ 
enhances damage to epithelial cells by inducing apoptosis and oxidative stress, triggers 
myofibroblast (MFB) activation and a wound-healing response, controls or inhibits liver 
regeneration, activates regulatory T cells (TReg) and Th17 differentiation to calm down 
inflammatory responses, inhibits the proliferation of premalignant cells, inhibits tumour-
directed inflammatory responses, facilitates tumour angiogenesis and induces epithelial-
mesenchymal transition (EMT) of tumour cells (Karkampouna et al., 2012). 
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5.1.5 TGFβ target genes 
 
 
In most cell types, TGFβ induces phosphorylation of Smad2 and Smad3 
(activin/TGFβ-specific R-Smads, or AR-Smads) and BMPs induce 
phosphorylation of Smad1, Smad5 and Smad8 (BMP-specific R-Smads, or BR-
Smads). Activated R-Smads form hetero-oligomeric complexes with common-
partner (co)-Smad (Smad4). The complexes translocate into the nucleus where 
they regulate the expression of target genes, such as the genes for Serpine1 
(plasminogen activator inhibitor-1), inhibitory (I)-Smads (Smad6 and Smad7) 
and Id1 (inhibitor of differentiation-1 or inhibitor of DNA binding-1). It has been 
shown that elevated TGFβ signalling is associated with systemic insulin 
resistance and hepatic steatosis by regulating expression of its target genes, 
such as PGC-1α and PPAR-γ (Sohn et al., 2012; Tan et al., 2012; Yadav et al., 
2011). In another study, TGFβ had an inhibitory effect on mRNA production of 
apolipoprotein B (apoB) as well apolipoprotein M (apoM) in less extent in 
HepG2 cells (Xu et al., 2004). 
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5.2 Specific Methods 
 
 
5.2.1 Cell culture, TGFβ and inhibitor treatment 
 
 
HepG2 cells were maintained under standard culture conditions as described (see 
General Methods section 2.2). For stimulation experiments, HepG2 cells were 
cultured in serum-free MEM supplemented with N1 (Sigma) containing 10% BSA. 
For morphological analysis of peroxisomes, HepG2 cells were seeded at a defined 
cell density (2×10
5
 cells/dish) in 6 cm ø culture dishes (Greiner) on collagen 
(Serva)-coated glass coverslips in standard or serum-free media. After 6 hours, 
compounds/inhibitors were added at the indicated concentrations, cells were 
incubated for 24-48 hours and processed for immunofluorescence or 
immunoblotting (coverslips were omitted). Stimulation with 10% FBS served as a 
positive control for peroxisome elongation/proliferation. TGFβ stimulation was 
performed by addition of 1-2 ng of TGFβ recombinant protein (R&D systems). For 
inhibitor studies, cells were treated with 20-80 nM of TGFβ inhibitors LY2109761 
(Cell Signalling) and SIS3 (Cell Signalling) for 2 hours upon TGFβ stimulation. 
 
 
 
 
5.2.2 Cloning of PEX11β promoter region into the pGL3-basic 
luciferase vector 
 
 
For cloning of PEX11β promoter regions, the candidate promoter region (1302bp 
for the wild type and 1296bp for the mutant) of human PEX11β was synthesized 
(Eurofins) and then cloned into the pGL3-basic vector (#E1751, Promega) between 
XhoI and SacI sites. This resulted in the generation of pGL3-Pex11βproWT and 
pGL3-Pex11βproMut. pGL3-promoter (#E1761, Promega) and 
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pGL3-control vector (#E1741) were used as controls. pRL-TK vector (#E2231, 
Promega) was used as internal control vector to normalize luciferase activities. 
All constructs produced were confirmed by sequencing (Eurofins). Vector maps 
are shown in supplementary Figure S.5.1. 
 
 
 
5.2.3 Lipofectamine Transfection and TGFβ treatment 
 
 
For transfection of HepG2 cells for the dual luciferase assay, 2×105 cells/well 
were seeded the day before transfection in 6-well plates (Corning, #3548) in 1.5 
ml complete growth medium (MEM containing serum and antibiotics) and 
incubated at 37°C and 5% CO2. On the day of transfection, pGL3-CMV/ pGL3-
Pex11βproWT /pGL3-Pex11βprMut / pGL3-SMAD (100 ng) and pRL-TK vector 
DNA (4 ng) (ratio 25:1) was diluted in Opti-MEM (Life Technologies) in a 1.5 ml 
microcentrifuge tube, and 5 µl of P3000 was added to a final volume of 100 μl. 
In a second microcentrifuge tube, 2.5 µl Lipofectamine 3000 were added to 100 
µl Opti-MEM. The DNA mix was carefully added to the Lipofectamine mix, 
gently pipetted up and down 3-4 times and incubated for 5 minutes at room 
temperature to allow complex formation. Meanwhile, the growth medium was 
gently aspirated from the plate, the cells were washed once with 200 μl PBS, 
and 100 μl fresh complete growth medium was added. Then, 200 μl of the 
DNA/Lipofectamine mix was added dropwise to the wells, and the plate gently 
swirled to ensure uniform distribution of the transfection complex. The cells 
were incubated in a humidified CO2 incubator (95% air, 5% CO2, 37°C) for 48 
hours to allow expression of the transfected DNA constructs (Figure 5.4). 
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After 48 hours upon transfection, growth media was removed and cells were 
washed with 500 μl of 1×PBS. Cell were were transferred to 96 well 
luminometer plates (Greiner Bio-One Inc, #655083) in 5 columns. Cells were 
seeded in MEM/N1 media in 96 cell plates. After 6 hours incubation in N1, cells 
were treated with TGFβ, FBS or left un treated and were incubated for 24 hours 
prior to performing the dual luciferase assay. 
 
 
 
 
 
5.2.5 Dual Luciferase Reporter Assay (DLR) 
 
 
A dual luciferase assay (Promega, #E1910) was used to measure the luciferase 
and Renilla activity within the transfected cells. Luciferase assays were 
performed with a MicroLumat Plus LB 96V luminometer (Berthold 
Technologies). Cells were incubated in 100 μl of 1× Passive Cell Lysis Buffer for 
20 minutes at room temperature for cell lysis. First, 50 μl of Luciferase Reagent 
II was injected to the lysate and luciferase activity was measured for 10 
seconds. Then, 50 μl of Stop and Glo® reagent was added to the lysate to stop 
the luciferase activity and catalyse the Renilla reaction, incubated for 1.6 
seconds followed by measurement of Renilla activity for 10 seconds. Each 
reaction was measured 3 times. For analysis, luciferase activities were 
normalized to Renilla luminescence in each well (Figure 5.4). 
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Figure 5.4. Experimental design for lipofectamine transfection with luciferase 
 
constructs.  (A)  HepG2  cells  were  transfected  with  PEX11βWT  or  PEX11βMut 
 
luciferase and Renilla control. (B) HepG2 cells were transfected with SMAD luciferase 
and Renilla control. 
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5.3 Results 
 
 
5.3.1 HsPEX11β possesses a SMAD binding site 
 
 
Our analysis of peroxisomal genes for transcription factor binding sites revealed 
the presence of putative SMAD2/3 binding sites in the promoter regions of 
 
PEX11β and PEX11, but not PEX11α. The SMAD binding motif consensus 
sequence was previously defined as two inverted repeats of GTCT (Jonk et al., 
1998), and it was suggested that a single GNCN would be sufficient for SMAD 
DNA-binding (Sandelin et al., 2004). A more complete model of the SMAD binding 
site including the probability of each base pair and its role in the binding efficiency 
has been proposed as position-specific scoring matric on the JASPAR CORE data 
base, which has been used in this study (Figure 5.5) (Sandelin et al., 2004; 
Stormo, 2013) . In our bioinformatic approach, we searched for SMAD2/3 binding 
sites for in promoter of 100 peroxisomal genes (Chapter 4. Section 4.2.3). A 
potential binding site for SMAD2/3 binding site within the PEX11β 
 
promoter was found, this factor also showed a potential binding motif in PEX11 
promoter. For comparison, the known SMAD regulated genes PGC-1α and 
PPAR obtained as control in our system. This indicates that PEX11β 
possesses a strong putative SMAD2/3 binding site. 
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Figure 5.5: Pictogram of SMAD binding motif: Graphical representations of the 
SMAD matrix model, based on information content. The information content of a matrix 
column ranges from 0 (no base preference) and 2 (only 1 base used). This barplot 
shows the total information content in each position, where the bar is replaced by 
stacked letters (A, C, G, T), which are sized and sorted relative to their occurrence 
Taken from (Stormo, 2013). 
 
 
 
To confirm that the SMAD binding sites in the PEX11β and PEX11 promoters 
were located in transcriptionally active regions, the ENCODE Histone mark 
database was consulted indicating that these sites were located in chromatin-
free, transcription-active regions and thus represent feasible locations for 
transcription factor binding in many cell lines including HepG2. (Chapter 4, 
Section 4.2.3) 
 
A comparison of the promoter regions of all three human PEX genes revealed 
that PEX11β and PEX11 shared two putative transcription factor binding sites 
for SMAD and ATF4 (Activating Transcription Factor 4), which belongs to the 
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large ATF/CREB family of transcription factors. In contrast, no transcription 
factor binding sites were shared between PEX11β and PEX11α or PEX11α and 
PEX11γ (Figure 5.5). These findings indicate that PEX11β and PEX11α are 
differently regulated and further support our notion that both proteins fulfil 
different functions at peroxisomes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6 Venn diagram of shared transcription factor binding sites of HsPEX11 
 
genes alpha, beta and gamma. Potential transcription factor binding site for SMAD2/3 
(activated by TGFβ pathway) in PEX11β and PEX11 were predicted which are located 
in the transcriptionally active areas according to histone marks. 
 
 
 
SMAD2/3 can be activated through the TFGβ pathway (Dennler et al., 1998). The 
prediction, with high probability, of SMAD binding sites in the promoter regions of 
 
Pex11β and Pex11 suggests that expression of these two genes might be linked to 
TGFβ signalling. PEX11β is a key protein in the regulation of peroxisome dynamics 
and proliferation; it is involved in all steps of the growth and division process 
including remodelling and elongation of the peroxisomal membrane, recruitment of 
the division machinery, and activation of the fission GTPase Drp1 
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as a GAP (Introduction section 1.6). We therefore focused our studies on the 
 
possible link between TGFβ signalling and peroxisome proliferation. 
 
 
 
 
 
5.3.2 TGFβ induces peroxisome elongation and proliferation in HepG2 
 
cells 
 
 
 
To study the effect of TGFβ on peroxisomes, we used our developed cell-based 
peroxisome proliferation assay (see chapter 3). HepG2 cells cultured under 
serum-free conditions (N1) were mock treated or treated with recombinant 
TGFβ and processed for immunofluorescence 24 hours after treatment using 
anti-PEX14 as a peroxisomal marker (Figure 5.7 A). Recombinant TGFβ has 
been shown to activate TGFβ receptors on the cell surface and to signal 
through the SMAD2/3 complex (Dituri et al., 2013). Whereas control cells (N1) 
showed overwhelmingly spherical peroxisomes (12% ± 0.88), addition of TGFβ 
resulted in a pronounced elongation of peroxisomes (75% ± 0.66), which is a 
pre-requisite of peroxisomal growth and division (Figure 5.7 A-B). As a positive 
control for peroxisomal growth/elongation, the cells were treated with 20% FBS 
(57%±1.6). Interestingly, treatment with TGFβ was as efficent or more efficient 
than with 20% FBS (Figure 5.7 A-B). 
 
To validate that the TGFβ effect was specific to the SMAD-mediated TGFβ 
pathway, we used specific chemical inhibitors which inhibit different steps of the 
TGFβ signalling pathway. The inhibitor SIS3 selectively inhibits TGFβ signalling 
by suppressing SMAD3 phosphorylation (IC50 = 3 µM) without affecting the 
MAPK/p38, ERK, or PI3-kinase signalling pathways (Dituri et al., 2013). We also 
examined the effect of TGFβ receptor type I/II inhibitor LY2109761, which acts 
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upstream of SIS3. LY2109761 has a selective dual inhibitor effect on both TGFβ 
receptors (type I/II) resulting in reduced phosphorylation of SMAD2 (Dituri et al., 
2013). HepG2 cells were pre-treated with TGFβ inhibitors for 2 hours before adding 
recombinant TGFβ, and processed for immunofluorescence as descried above. 
Both inhibitors reduced peroxisome elongation significantly when compared to 
TGFβ-treated controls (Figure 5.7 B) (LY210976 - 33% ± 1.2; SIS3 
- 18% ± 1.3) indicating a specific TGFβ-mediated response. 
 
 
We also quantified the number of peroxisomes in controls and TGFβ-treated 
cells after 6 hours (addition of TGFβ or FBS) and 48 hours using a MATLAB 
script. Whereas in unstimulated control cells no increase in peroxisome 
numbers was observed (6 hours - 131 ± 3.8, 48 hours - 239 ± 5.1), TGFβ-
treatment resulted in a 3-fold increase in peroxisome numbers (6 hours - 131 ± 
3.8, 48 hours - 522 ± 21.32) (Figure 5.7 C-D), which is indicative of peroxisome 
proliferation. Interestingly, peroxisome numbers were less prominently induced 
by treatment with FBS when compared to TGFβ (6 hours - 131 ± 3.8, 48 hours – 
393 ± 17.94) (Figure 5.7 D). Overall, these findings support a role for TGFβ 
signalling in peroxisome proliferation, potentially via SMAD2/3 binding to the 
PEX11β promoter. 
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Figure 5.7. TGFβ increases peroxisome elongation and number in HepG2 cells. (A) 
HepG2 cells were cultured in serum-free αMEM-N1 medium, treated with 10% FBS, or 
TGFβ (2 ng) (with or without inhibitors LY2109761 or SB431542) or mock treated and 
processed for immunofluorescence after 24 hours using anti-PEX14 (pcR) and Alexa-488 
(DaR) antibodies. (B) Quantitative analysis of peroxisome morphology (elongation) for the 
conditions described. Data represent mean ± SEM of 3 independent experiments (n=300 
cells for each condition). *** p<0.001; ** p<0.01; two-tailed unpaired t-test. (C) HepG2 cells 
were cultured in αMEM-N1medium for 6h prior to the addition of TGFβ (2 ng) or 10% FBS, 
incubated for 48 hours and processed for immunofluorescence after 6 and 48 hours as 
described in (A). (D) Quantitative analysis of peroxisome number/cell after 6 and 48 hours. 
Data represent mean ± SEM of 3 independent experiments (n=10 cells for each 
condition).*** p<0.001; ** p<0.01; two-tailed unpaired t-test. Bars, 5 µm. 
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5.3.2 TGFβ induces PEX11β expression through its SMAD binding motif 
 
 
The effect of TGFβ on peroxisome morphology and number is indicative for an 
involvement of TGFβ signalling in peroxisome proliferation via expression of 
PEX11β. To demonstrate that the SMAD binding motif within the PEX11β 
promoter is functional and can activate PEX11β expression after TGFβ 
stimulation, we applied a dual luciferase reporter assay (Figure 5.8). This assay 
relies on the co-expression of two different reporter genes, Renilla and firefly 
luciferase, to evaluate regulated gene expression. The plasmid encoding Renilla 
luciferase (pRL-TK) is under control of a constitutive CMV promoter and served 
as internal control. The PEX11β promoter region was cloned into a pGL3 vector 
encoding firefly luciferase (pGL3-Pex11βproWT). In addition, a construct 
encoding a mutated promoter was generated by site directed mutagenesis 
inducing a two base pair deletion in the putative PEX11β SMAD binding site 
(pGL3-Pex11βproMut) (Figure 5.8). 
 
HepG2 cells were co-transfected with pRL-TK and pGL3-Pex11βproWT, pGL3-
Pex11βproMut, or Basic-pGL3 and treated with recombinant TGFβ. As a positive 
control, cells were co-transfected with pRL-TK and pGL3 encoding the SMAD 
promoter (pGL3-SMAD). It has been shown that TGFβ has a direct effect on SMAD 
protein expression. After 24 hours, the luciferase activity, which reflects promoter 
activity, was measured in cell lysates after addition of luciferin. The dissimilarity in 
the substrates for the two luciferases makes it possible to selectively distinguish 
between the luminescent reactions for each enzyme. The luminescence of the 
firefly luciferase can be measured by addition of the luciferin reagent, and this 
reaction is subsequently quenched while simultaneously activating the 
luminescence of the Renilla luciferase. Thus, one can sequentially 
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measure the luminescence of both reporters in the same well. The data from 
firefly luciferase measurement (FLuc) was then normalised to the Renilla 
luciferase signal (RLuc) and the results expressed as the mean ratio of firefly to 
Renilla luciferase activity (FLuc/RLuc) (Figure 5.8). 
 
We found that TGFβ augmented the luciferase activity in cells transfected with 
wild type PEX11β promoter (pGL3-Pex11βproWT) (20.75 ± 0.32), which 
indicates that TGFβ increases the level of PEX11β expression (Figure 5.8 B). 
However, treatment with TGFβ failed to induce luciferase activity in the PEX11β 
promoter mutant (pGL3-Pex11βproMut) (Figure 5.8 B) (1.1 ± 0.27) . Negative 
controls transfected with basic luciferase vector (pGL3) showed no inducible 
luciferase activity after TGFβ (0.98 ± 0.07) , whereas TGFβ induced luciferase 
activity in cells transfected with the SMAD promoter construct (pGL3-SMAD) ( 
12.95 ± 0.12) (Figure 5.8 B). 
 
When the mean FLuc/RLuc ratios in the absence of TGFβ stimulation were 
compared, only very low basal activity was detected for the empty luciferase vector 
(pGL3) (- control), pGL3-SMAD (+ control) and pGL3-Pex11βproMut (Figure 5.8 C). 
Expression of pGL3-Pex11βproWT resulted in some luciferase activity (1.4 RLU ± 
0.03), suggesting that other factors may be able to trigger signalling via the SMAD 
binding site within the Pex11β promoter in the absence of TGFβ (Figure 5.8 C). 
However, treatment with TGFβ resulted in a prominent increase in luciferase 
activity (24.51RLU ± 0.32). For pGL3-SMAD, an increase from 0.2 ± 0.01 (control) 
to 1.6 RLU ± 0.01 (+ TGFβ) was detected, whereas the FLuc/RLuc ratios remained 
unchanged for pGL3 (- control) (0.28 RLU ± 0.07 to 0.30 ± 0.07) and pGL3-
Pex11βproMut (0.21 RLU ± 0.02 to 0.24 RLU ± 0.02) (Figure 5.8 C). These findings 
indicate that the SMAD binding site within the Pex11β promoter 
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is functional, and that TGFβ signalling via the canonical SMAD-dependent 
pathway can activate PEX11β expression, leading to peroxisome growth, 
division and proliferation in HepG2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. TGFβ activates PEX11β expression by direct binding of SMAD 
transcription factor to the PEX11β promoter. Luciferase reporter assays in HepG2 cells 
transfected with 100 ng/well of SMAD or PEX11β (Wt/Mut) Firefly-Luc reporter and 4 
ng/well of Renilla-Luc reporter. As controls, empty Firefly Luc vector (- Control) was used. 
Cells were treated with TGFβ (2 ng/ml) or left untreated. Data are represented as mean 
±SEM of the ratio firefly/Renilla luciferase, relative to control conditions. Each experiment 
was performed in triplicates (n=3). (A) Reporter vectors include the wild-type or mutant 
PEX11β promoter downstream of the firefly luciferase. The potential SMAD binding motif is 
in red and the mutated base pairs are marked as **. pR-TLK construct with CMV promoter 
downstream of Renilla luciferase was used as an internal control in all the experiments. (B) 
Firefly luciferase activity (FLuc) was first normalized to Renilla 
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luciferase activity (RLuc). Fold increase was then calculated by normalizing the values 
in the presence of TGFβ. (C) The mean ratio of Firefly luciferase and Renilla luciferase 
activity in cells transfected with pGL3-Pex11βproWT in untreated and TGFβ-treated cells 
was approximately 1.4 and 25 RLU (relative light unit), respectively. The mean ratio of 
FLuc/RLuc for cells transfected with the SMAD promoter construct pGL3-SMAD 
(positive control, inducible promoter by TGFβ) in untreated and TGFβ-treated cells was 
approximately 0.2 RLU and 1.6 RLU. 
 
 
 
 
 
5.4 Discussion 
 
 
The canonical TGFβ pathway is involved in peroxisome proliferation in 
HepG2 cells 
 
In this chapter, we provided convincing evidence for a role of the canonical, 
SMAD-dependent TGFβ signalling pathway in the control of peroxisome 
proliferation in HepG2 cells via PEX11β. We showed that i) addition of TGFβ 
induces peroxisome elongation/growth and proliferation in HepG2 cells in our 
cell-based proliferation assay; ii) the stimulatory effect of TGFβ on peroxisomes 
could be inhibited by specific kinase inhibitors which interfere with TGFβ 
signalling; iii) the promoter region of PEX11β contains a SMAD2/3 binding site 
in a transcriptionally active region with a predicted strong binding efficiency; iv) 
the SMAD2/3 binding site is functional and required to induce luciferase activity 
of a reporter after TGFβ stimulation. These findings indicate that TGFβ 
signalling through the canonical SMAD-dependent pathway can activate 
PEX11β expression, leading to peroxisome growth, division and proliferation in 
HepG2 cells. This study therefore links a new signalling pathway to peroxisome 
proliferation in human cells (Figure 5.9). 
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Figure 5.9. Schematic diagram of TGFβ signaling and peroxisome proliferation in 
 
HepG2 cells. TGFβ binds a complex of transmembrane receptor serine/threonine 
kinases (types I and II) at the cell surface and induces phosphorylation of the receptor 
kinases. The activated receptors phosphorylate SMAD2/3 (R-SMAD) at C-terminal 
serines. Activated Smad complexes translocate into the nucleus, where they regulate 
transcription of target genes/PEX11β, through physical interaction and functional 
cooperation with DNA-binding transcription factors. Activation of R-Smads by type I 
receptor kinases can be inhibited by receptor kinase inhibitors or SMAD2/3 inhibitor. 
 
 
The TGFβ superfamily of signalling proteins regulates a variety of biological 
processes including cell growth, differentiation, apoptosis, migration, 
extracellular matrix production, angiogenesis, immunity, and development 
(Massague, 1998; Zhu et al., 2004). The cellular response to many TGFβ 
superfamily members can be variable, and promote as well as antagonise 
responses such as proliferation, apoptosis, and differentiation depending on the 
cell type and stimulation context (Massague, 1998; Massague et al., 2000). A 
well known function of TGFβ is the induction of growth arrest and apoptosis in 
epithelial cells, which suppress carcinogenesis. However, TGFβ can also induce 
epithelial-mesenchymal transition (EMT) and mediate fibroblast 
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activation, thus promoting carcinogenesis and fibrotic diseases (Siegel & 
Massague, 2003). 
 
TGFβ is also a key regulator of liver physiology and pathology. It contributes to 
hepatocyte proliferation and differentiation, but also to all stages of disease 
progression, from initial liver injury through inflammation and fibrosis to cirrhosis 
and hepatocellular carcinoma (Fabregat et al., 2016). 
 
HepG2 cells have been shown to express TGFβ and to respond to TGFβ treatment 
or silencing of TGFβ with alterations in cell growth, apoptosis and cell cycle (X. H. 
Wang et al., 2017). In our experimental set up, HepG2 cells were treated with 
physiological concentrations of TGFβ for short periods of time under serum-free 
conditions. HepG2 cells responded with a pronounced elongation/growth and 
subsequent division and proliferation of peroxisomes. This response was often 
more pronounce than stimulation with FBS indicating that TGFβ initiates a strong, 
peroxisome-specific response. This response is likely mediated by PEX11β 
expression via its SMAD transcription factor binding site. PEX11β is a key protein in 
the regulation of peroxisome dynamics and proliferation, and its expression induces 
peroxisome elongation, division and proliferation (Schrader et al., 1998b). Those 
processes have been linked to cellular growth and are observed under standard 
growth conditions in HepG2 and other cell lines, in particular when the cells are 
seeded at low cell densities (Schrader et al., 1996). It is suggested that 
peroxisomes, which are involved in fatty acid β-oxidation and cellular energy 
control, multiply under those growth-stimulating conditions to support cell 
proliferation and/or differentiation. We therefore assume that TGFβ signalling in our 
experimental system contributes to the proliferation and/or differentiation of HepG2 
cells rather than to growth arrest. 
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It should be noted that peroxisome elongation is usually not observed under 
suboptimal growth conditions and is rather a hallmark of cell growth and 
proliferation (Schrader et al., 1999). 
 
Interestingly, elongated and tubular or constricted peroxisomes are also observed 
after partial hepatectomy in rat liver (Fahimi et al., 1979). These heterogenous 
peroxisome morphologies were as well interpreted as an indicator of peroxisome 
proliferation by elongation/growth and division under conditions of cellular growth 
and proliferation (Schrader & Fahimi, 2008). TGFβ has a crucial role in 
hepatocytes, which is critical for the control of liver mass (Karkampouna et al., 
2012). The TGFβ pathway has activator and repressor effects on other pathways 
such as cell growth, and a balanced TGFβ signaling in terms of both dosage and 
spatiotemporal activity is crucial to control hepatic gene expression (Karkampouna 
et al., 2012). TGFβ acts in the process of differentiation of hepatoblasts to 
hepatocytes during liver regeneration after partial hepatectomy (Karkampouna et 
al., 2012). The TGFβ pathway is required at different stages of the process, to allow 
hepatocyte proliferation at the inductive phase followed by an efficient termination 
of the regenerative response afterwards. 
 
HepG2 cells are hepatoblastoma cells, which can differentiate in culture and 
form bile canaliculi-like structures (Bokhari et al., 2007). Like hepatocytes, they 
secrete the major serum proteins and do not form tumours in nude mice (Wu et 
al., 1994). We therefore assume that similar to regenerating liver, TGFβ induces 
peroxisome proliferation in HepG2 cells under proliferative culture conditions via 
upregulation of PEX11β, a key regulator of peroxisomal growth and 
proliferation. As discussed before (see chapter 3), under standard culture 
conditions, peroxisome elongation has a maximum after 24-48 hours, before the 
elongated peroxisomes divide 
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resulting in the formation of numerous spherical peroxisomes. Peroxisomes do 
not massively elongate at later time points in culture, when the cells are more 
confluent (Schrader et al., 1998b). Ultrastructural studies have shown that the 
peroxisomes in HepG2 cells are now larger and form little groups of organelles, 
possibly changing from a proliferative to a metabolic state (Grabenbauer et al., 
2000). As PEX11β mediates peroxisome elongation and proliferation, it 
represents an ideal target to adapt peroxisome number and function according 
to cellular needs. TGFβ signalling may foster peroxisome proliferation in an 
inductive phase of HepG2/hepatocyte proliferation and differentiation, but may 
also reduce proliferation of peroxisomes afterwards, when the inductive stage is 
completed, and cell growth needs to be terminated (Figure 5.9). As TGFβ 
signalling is complex, it is likely that other, non-canonical signalling pathways as 
well as TGFβ secretion, the concentration of active TGFβ, and the amount of 
TGFβ receptors and spatiotemporal activity contribute to the overall cellular 
response. It should be noted that SMAD transcription factor binding sites were 
 
only detected in PEX11β and PEX11, and not in other peroxisomal genes 
examined, indicating that the PEX11 proteins might be specifically targeted by 
TGFβ signalling (Figure 5.8). 
 
TGFβ signalling has also been linked to carcinogenesis (Chaudhury, 2009), as it 
mediates growth arrest and induces apoptosis preventing tumour formation, but 
also excerts tumour promoting effects at later stages of tumour progression. 
Peroxisomes have been reported to be essential for the viability of liver cancer 
cells, probably through altering metabolism and signaling pathways ((M. Cai et 
al., 2018). Peroxins and associated signalling pathways may thus be potential 
targets of therapeutics against liver cancer. 
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Chapter 6 – Results 
 
 
 
 
 
The VAP–ACBD5 tether is required for 
peroxisome growth 
 
 
 
 
 
 
 
 
 
 
Costello, J., Castro, I., Hacker, C., Schrader, T. A., Metz, J., Zeuschner, D., 
Azadi, A. S., Godinho, L. F., Costina, V., Findeisen, P., Manner, A., Islinger, 
M., and M. Schrader: (2017) ACBD5 and VAPB mediate membrane 
associations between peroxisomes and the ER. J Cell Biol, 216(2), 331-
342. doi:10.1083/jcb.201607055 
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6.1 Overview 
 
 
It has been shown that the ER has a role in peroxisome biogenesis by providing 
peroxisomal proteins such as PEX16, but also for their lipid composition 
(Hettema (Hettema et al., 2014; Hua et al., 2017). Several models have been 
proposed for the lipid/protein exchange between ER and peroxisomes. One of 
these mechanisms includes carnitine transporters, shuttling specific lipids to 
peroxisomes through the cytosol (Lodhi & Semenkovich, 2014). The latest 
suggested mechanism is through ER/peroxisome contact sites (Costello et al., 
2017a; Raychaudhuri & Prinz, 2008; Schrader et al., 2015). Our group identified 
peroxisomal acyl-CoA binding domain protein 5 (ACBD5) and VABP as a 
molecular linker between peroxisomes and the ER (Costello et al., 2017b). 
Absence of ACBD5 or VAPB increased peroxisome motility; this implies that the 
ACBD5/VAPB complex acts as a tether between peroxisomal and ER 
membranes (Costello et al., 2017a). In another study, Hua et al (2017) showed 
that loss of this tether affects cellular plasmalogen and cholesterol levels (Hua 
et al., 2017). There was a decrease in phosphatidylethanolamine (PE) 
plasmalogens and total cholesterol levels in Hela cells treated with ACBD5 or 
VAPB siRNA (Hua et al., 2017). ACBD4 is a member of the ACBD family and 
like ACBD, can also act as a molecular tether, physically linking peroxisomes 
and the ER making this the second protein involved in peroxisome-ER contacts 
in mammals (Costello et al., 2017b). Peroxisomes can form by growth and 
division of pre-existing organelles (Schrader et al., 2015). A key protein in this 
process is Pex11β, which deforms and elongates the PO membrane and 
activates the GTPase DRP1 for membrane scission (Delille et al., 2010; J. Koch 
et al., 2010; Williams et al., 2015). As 
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mentioned in the introduction (See section 1.4.3) peroxisome formation by 
growth and division follows a multistep maturation process involving 
peroxisomal membrane remodelling and elongation, membrane constriction and 
final scission. DRP1 is recruited to peroxisomes by the membrane adaptors Mff 
and Fis1 (Gandre-Babbe & van der Bliek, 2008; A. Koch et al., 2005; Otera et 
al., 2010). Peroxisomes in cells with no Mff lose the ability to divide and have 
highly elongated peroxisomes (and mitochondria) (J. Koch & Brocard, 2012; J. 
Koch et al., 2016; Shamseldin et al., 2012). The elongation step requires 
membrane expansion. Peroxisome-ER contacts are crucial for lipid transfer 
generating a membrane compartment which imports newly synthesised PMPs 
and matrix proteins. 
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Figure 6.1. Schematic view of peroxisome formation in mammalian cells: 
Peroxisomes form by growth and division of pre-existing peroxisomes. The ER delivers 
lipids for membrane growth via membrane contact sites (red arrows). In the absence of 
pre-existing peroxisomes, peroxisomal vesicles can be generated at the ER (EDV) and 
mitochondria (MDV), which may fuse and mature into new import-competent 
peroxisomes. These newly formed peroxisomes then multiply by growth and division. In 
the presence of peroxisomes, pre-peroxisomal vesicles may fuse with growing or 
existing peroxisomes to supply certain proteins and lipids. EDV, ER-derived vesicles; 
MDV, mitochondria-derived vesicles; newly formed peroxisomes are coloured in light 
green (Costello & Schrader, 2018). 
 
 
 
 
6.2 Disrupting peroxisome-ER contacts reduces peroxisome elongation 
 
 
As elongation and growth of the peroxisomal membrane requires lipids, likely 
provided by the ER in a non-vesicular pathway (Raychaudhuri & Prinz, 2008), 
we suggested that the pronounced peroxisome elongation observed in patient 
fibroblasts after loss of Mff reflects a constant transfer of lipids from the ER to 
peroxisome. To investigate a role for ACBD5–VAPB in this process, ACBD5 or 
VAPB were silenced in patient fibroblasts deficient in Mff (Figure. 6.2D-E-G). 
Expression of Mff into control cells (no siRNA) resulted in the formation of 
spherical peroxisomes, restoring the normal organelle phenotype (Figure. 6.2 
B). Knockdown of Pex11β had no effect on peroxisome morphology, however, 
silencing of ACBD5, and to a lesser extent of VAPB, reduced membrane 
expansion, resulting in the formation of shorter peroxisome membrane tubules 
and spherical organelles (Figure. 6.2, C–F). These findings indicate that 
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peroxisomal membrane growth depends on ER-peroxisome membrane contacts 
 
mediated by ACBD5 and VAPB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Loss of ACBD5 or VAPB reduces peroxisomal membrane expansion 
in Mff-deficient fibroblasts. PO morphology in Mff-deficient fibroblasts (control; A) 
after reintroduction of Mff (B) or silencing of Pex11β (C), ACBD5 (D), or VAPB (E). 
Fixed cells were labelled with anti-Pex14 antibodies. (F) Quantification of peroxisome 
morphology in controls and silenced cells (n = 2,500, from three independent 
experiments). Data are presented as mean ± SEM. ***, P < 0.001; ns, not significant. 
(G) Immunoblots of cell lysates. Loading controls used were catalase (Cat), GAPDH, 
and thioredoxin (Thiored). (H–M) Localization of endogenous ACBD5 in Mff-deficient 
fibroblasts. Fixed cells labelled with anti-ACBD5 and anti-catalase antibodies. 
Arrowheads denote ACBD5 concentrated at globular peroxisomes that give rise to 
tubular membranes. Bars, 10 µm (Costello et al., 2017a). 
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6.3 Transcription factor binding site analysis of ACBD4 and ACBD5 
 
 
ER-peroxisome contacts appeared to be important for peroxisome elongation, 
and besides ACBD5 we also identified ACBD4, which is as well involved in ER-
peroxisome membrane contacts (Costello et al., 2017b). To understand how 
ACBD5 and ACBD4 gene expression is regulated, I used my established motif 
search pipeline (Chapter 4) and searched for regulatory elements within the 
promoter regions of these genes. The most prominent transcription binding 
factors in the promoter regions of these genes are summarized in Figure 6.3. 
 
As discussed in Chapter 4, PEX11β, the key modulator of peroxisome 
dynamics, has a SMAD2/3 binding motif, which based on our results (Chapter 
5), is directly regulated by the TGFβ pathway. However, ACBD4 and ACBD5 do 
not have this binding motif or any other binding sites shared with PEX11β, 
suggesting they are not co-regulated. 
 
An interesting binding motif, present in the ACBD4 promoter, is a glucocorticoid 
receptor binding site (Figure 6.3). Glucocorticoids (are a class of steroid hormones 
that are secreted by cortical cells in adrenal glands. Glucocorticoids modify the 
immune responses to diverse stimuli. They produce their effects through their 
actions on the intracellular glucocorticoid receptors (GR). The glucocorticoid 
receptor is a nuclear transcription factor and can activate or repress gene 
expression either through direct binding to glucocorticoid response elements or by 
binding to other transcription factors, e.g., activator protein1 (AP-1), nuclear factor 
(NF)-κB, tumour necrosis factor (TNF)-α (Rao et al., 2011). 
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Interestingly, the ACBD4 promoter also contains an NFkb motif, further 
suggesting a role for GR in modulating ACBD4 gene expression. 
 
In our study, we found potential glucocorticoid response elements (GRE) in 
other peroxisomal genes such as PPARα, PEX5l, AGXT, EHHADH, ISOC1, 
ACOT4, ACAD11, and ACAA1a. This may suggest an important role for GR in 
activating expression of peroxisomal genes resulting in the stimulation of fatty 
acid breakdown and energy production. 
 
For the ACBD5 promoter, E4BP4, PAX-3 and POU2F1 (activates the 
transcription of genes involved in viral immediate response) motifs were found 
in proximity of the transcription start site. These factors have no obvious link to 
peroxisome function or lipid metabolism. This suggests that ACBD5 expression 
at the mRNA level is not controlled by the same signalling cascades as ACBD4 
or other peroxisomal genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Summary of potential transcription factor binding sites in the 
promoter regions of ACBD5 and ACBD4. In promoter of ACBD5, E4BP4, 
PAX-3 and POU2F1 (activates the transcription of genes involved in viral 
immediate response) motifs were found in proximity of the transcription start 
site. Factors in ACBD4 includes PPARγ, GR, NF-κB and C/EBPα. 
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Chapter 7 – General Discussion 
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The mechanism of peroxisome proliferation is well studied, however, there are 
still questions to be answered about how this process is regulated and which 
regulatory cascades are involved in this process. In this study, a cell-based 
assay (HepG2 cells) has been established which allows us to assess changes 
in peroxisome morphology/ proliferation and the expression profile of 
peroxisomal genes involved in regulation of peroxisome proliferation or 
metabolic function after application of a well-defined stimulus. 
 
A well-known pathway for regulating peroxisomal genes (such as ACOX1, 
PEX11α) in mammals is through activation of PPAR (H. Lee & Yoon, 2014; 
Shimizu et al., 2004). However, most of the transcriptomics studies with PPAR 
agonists are in mice (Barish et al., 2008; Guri & Hall, 2016). Despite a large 
body of evidence linking PPARα signalling with a variety of other signalling 
pathways there are currently few reports on how this links to peroxisome 
homeostasis in humans. 
 
Moreover, an increase in peroxisome number in mammals can be induced by 
various compounds in the absence of PPAR such as, endosulfan, 
cyclophosphamid, acetyl salicylic acid, 4-phenylbutyrate, and BM 15,766 
(Abraham & Isaac, 2011; Baumgart et al., 1990; Braunbeck & Volkl, 1991; Y. 
Cai et al., 1994; Gondcaille et al., 2005; Ortiz-Zarragoitia & Cajaraville, 2005). 
Interestingly, peroxisome proliferation induced by BM 15,766 does not change 
peroxisomal β-oxidation implying that both processes can be regulated 
independently. Other environmental factors such as UV light and reactive 
oxygen species (ROS) have been described to induce peroxisome elongation 
which leads to peroxisome division and increase in number in HepG2 cells 
(Schrader et al., 1998). 
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Also, in our HepG2 cell-based assay, growth factors (Chapter 3. Section 
3.3.1), and arachidonic acid (Chapter3, Section 3.3.4.1) can induce 
peroxisome proliferation. This suggests that there are other factors independent 
of PPAR regulating peroxisome abundance. 
 
There is currently a gap in understanding of precisely how this induction of 
proliferation with these tested stimuli is linked to elevation of peroxisomal 
related genes expression (McMullen et al., 2014). 
 
Many studies have examined the effect of PPARα activation or inhibition on hepatic 
gene regulation using PPAR agonists and antagonists followed by transcriptomics 
(Berger & Moller, 2002; Kersten et al., 1999; van der Meer et al., 2010). 
Comparison of the effect of PPARα activation in primary mouse and human 
hepatocytes using a whole genome transcriptomics approach showed the role of 
PPARα as a master regulator of hepatic lipid metabolism in both mouse and human 
liver cells (Bility et al., 2004; L. Guo et al., 2006). However, in recent years, the role 
of PPARα in human liver has been questioned based on the low levels of PPARα 
mRNA expression in human liver compared with mouse liver, indicating the 
involvement of other pathways (Rakhshandehroo, 2009). This conclusion has been 
further supported by the low response to PPARα agonists on expression of lipid 
metabolism genes in HepG2 cells. Based on the lower expression level of PPARα 
in human liver compared to mouse liver, here, we focused on not only PPARα 
binding sites but other PPAR forms (PPARβ and γ). Based on our results, PPARα 
appears to have potential binding sites in genes involved in β-oxidation such as 
ACOX1 and ACAA1, however, 10 peroxins have a PPARγ binding site. (Chapter 4. 
Section 4.1). This highlights the potential role 
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of PPARγ in peroxisomal gene expression encoding proteins involved in 
 
peroxisome comportment. 
 
 
Further, we looked for other regulatory factors in the promoters of the peroxisomal 
and peroxisomal-related genes (Chapter 4. Section 4.2). Binding of a transcription 
factor to DNA at a particular location is influenced by a variety of factors. The first 
factor that was considered in our study is the binding sequence 
 
– i.e. the sequence of bases that appear at a putative binding site. Also, we 
considered the proximity of nucleosomes and the methylation, phosphorylation 
or acetylation states of their constituent histones (Putiri & Robertson, 2011). 
 
Another important factor which can considered for further investigating in 
predicted regulatory motif sites in our system is the distant of each motif to 
transcription start site. The same holds for other transcription co -factors that 
may be bound near these binding sites whose presence can either inhibit 
binding of the transcription factors which we found, or enhance binding by 
modifying its conformation, or the DNA (Aerts et al., 2003; Elkon et al., 2003; 
Elnitski et al., 2006). 
 
Studies have shown a high percentage of functional motifs are found within the 
first 100 base pair (bp) and 2000bp upstream of the TSS (Buckland et al., 2005; 
Cooper et al., 2006; Elkon et al., 2003; Hoogendoorn et al., 2003). However, 
more recent studies have showed that regulatory regions, such as enhancers 
may extend many thousands of bp from the TSS creating complicated 3D 
structures that can influence gene expression by physical interaction with the 
proximal promoter (Angelini & Costa, 2014; Gandolfi & Tramontano, 2017). 
Although in our study these factors were not taken into consideration, our 
analysis still 
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represents a major advancement in our understanding of regulatory elements in 
promoter of peroxisomal genes in HepG2 cells. 
 
The data obtained from our bioinformatics approach revealed that, unlike regulatory 
systems used by other organelles (e.g. lysosomal biogenesis with TFEB 
transcription factor as its master regulator), peroxisomal gene expression in 
humans appears to complex with no single dominant factor present at the majority 
of peroxisomal genes. Whilst for lysosomes it has been shown that TFEB 
coordinates expression of genes encoding lysosomal hydrolases, membrane 
proteins and genes involved autophagy (Settembre & Ballabio, 2014). Here, we 
found different transcription factors regulating expression of metabolic genes and 
peroxins. As discussed before (Introduction, section 1.1) peroxisomes respond to 
external stimuli by increase in number or enzymatic activity and based on our 
results we suggest these are controlled by different pathways. Transcription factors 
such as CEBP and FOXA1 were found in 42, and 32 peroxisomal genes, 
respectively. Both factors are linked to various signalling pathways regulating liver 
development or immune response by cross talk with NFκB, further highlighting the 
role of peroxisomes in these processes (Di Cara et al., 2017; Jin et al., 2015; Moya, 
2012). Previous studies have demonstrated the importance of peroxins in postnatal 
development especially the development of nerve systems. Disruption of these 
signaling functions of peroxisomes can be directly or indirectly linked to a number of 
diseases, such as diabetes, neurodegenerative disease, and cancer (Marcus 
Nordgren et al., 2013). 
 
In a recent study, it has been shown that PEX2 and other peroxins are essential 
for liver cancer cells viability, probably through altering metabolism and 
signaling pathways (M. Cai et al., 2018). Based on this study, peroxins may be 
potential 
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targets of therapeutics against liver cancer (M. Cai et al., 2018). Whilst the 
available epidemiologic and clinical studies on the effect of peroxisome 
proliferators in human are inconclusive they still provide evidence that classical 
peroxisome proliferators used as drugs can promote cancer cell growth 
(Kristiansen et al., 2006; Takeuchi et al., 2016; Youssef & Badr, 2011). 
 
Hence, identification of other signalling pathways regulating one single or a group 
of peroxisomal genes will provide more information of other therapeutical targets. 
 
Alteration in expression of just a single gene or a set of peroxisomal genes has an 
effect on peroxisome abundance. It has been showed that overexpression of 
PEX11β alone can efficiently induce peroxisome proliferation demonstrating that, 
even in the absence of extracellular stimuli, altered expression of only PEX11β can 
induce peroxisome proliferation (Schrader et al., 1998). Hence, we focused on 
regulatory elements present in PEX11 promoters. Based on our results, PEX11β 
possess a SMAD2/3 binding site on its promoter, 200 bp away from the 
transcription start site. (Chapter 4, Section 4.2.5). As discussed in Chapter 5, 
activated TGFβ type I receptor phosphorylates Smads2/3 and initiate the cascade 
which leads to its target gene expression. Hence, we tested the TGFβ in our cell-
based assay to elucidate its ability to induce peroxisome proliferation. As predicted, 
TGFβ induced peroxisome elongation (cells with tubular peroxisomes), followed by 
an increase in peroxisome number compared to non-treated control cells. TGFβ 
also activates the non-Smad pathways, which include Ras, phosphatidylinositol 3-
kinase (PI3K), and Par 6 (X. Guo & Wang, 2009). These molecules regulate the 
activities of glycogen synthase kinase 3 (GSK3) and RhoA, which can increase the 
cancer metastasis in primary liver cancer cells. In order to link TGFβ activation to 
SMAD2/3 activation and PEX11β 
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promoter activity, a functional assay was performed using luciferase vectors and 
co-transfection with Renillla vectors as internal control. As expected, TGFβ 
treatment induce the promoter activity of PEX11βproWT, however, this induction 
was disrupted by a mutation in the SMAD2/3 binding site in the PEX11β 
promoter (PEX11βProMut). Here, we introduced a novel regulatory element 
regulating abundance by direct effect on peroxisomal gene expression. 
 
In order to gain more insight on expression of peroxisomal genes, other 
functional studies can be used, e,g by performing ChIP-qPCR, we will be able to 
test some of the transcription factors candidates (such as PPARγ, GRC and 
FOXA1) , to see if they directly are associated with our gene(s) of interest. 
Future studies using large scale expression profiling in this system will 
contributes to the identification of more novel components regulating 
peroxisome morphology and dynamics. 
 
In conclusion, in this study we provide a data set of regulatory elements in 
peroxisomal genes We introduced a new signalling pathway controlling 
peroxisome proliferation by regulating PEX11b gene expression this opens a 
possibility for therapeutical approaches controlling regulation of PEX11β in 
patient where peroxisome abundance / activity reduced. 
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Table S 3.1. Human primers for quantitative real-time RT-PCR 
 
 
h18S_F1 CCATCCAATCGGTAGTAGCG 21   
h18S_R1 GTAACCCGTTGAACCCCATT 20 
hCyclophilin_F CCCACCGTGTTCTTCGACATT 21 
275 NM_021130 
hCyclophilin_R GGACCCGTATGCTTTAGGATGA 22 
hPEX11a_F GAGAAGGTGGTAATGAAGCTCAA 23 
108 NM_003847 
hPEX11a_R GCTCTGCTCAGTTGCCTGT 19 
hPEX11b_F CGCCCAGTATGCTTGCTCTC 20 
220 NM_003846 
hPEX11b_R TCGATTGAGGTGACTAACAGTGA 23 
hPEX11g_F GGGGACACGTCTGTTGGTG 19 
184 NM_080662 
hPEX11g_R ACAGGGGTAGTAGAGCTGGTC 21 
hPEX1_F GGGGACAGGTATTTCTCAAGC 21 
243 NM_000466 
hPEX1_R CCAGCCTTCCATAAGAGGCAG 21 
hPEX6_F CCCTTTCCGACCGAGACAC 19 
205 NM_000287 
hPEX6_R CGCGGCTAACCAGTAGCTG 19 
hPEX26_F GTGCTCCCTGTGTGTTGTG 19 
93 NM_001199319 
hPEX26_R GGGACCTGGTAATACTGAAGGAC 23 
hPEX5_F AAGCCTTTGGGAGTAGCTTCT 21 
75 NM_001131024 
hPEX5_R GGACACAAGGGGTGCATTC 19 
hPEX2_F1 GAGAATGCGAAGAGTGCAAACA 22 
148 NM_000318 
hPEX2_R1 CTGGCTCAAAGCGAGCTAACA 21 
hPEX14_F GCCACGGCAGTGAAGTTTCTA 21 
119 NM_004565 
hPEX14_R TGCTGGAAGGCCATATCAATCT 22 
hPEX3_F TGGCTGAGTTCTTTCGACCTA 21 
131 NM_003630 
hPEX3_R ACTGCAAACTGAATGGATCTGTC 23 
hPEX13_F ACCTGGACAACCAGCACTTAC 21 
187 NM_002618 
hPEX13_R GCCCAGCCCATTATATCCATAAC 23 
hPEX19_F GCTGAGGAAGGCTGTAGTGTC 21 
157 NM_002857 
hPEX19_R CTGGCGATCTCTTCTGGGG 19 
hPEX16_F GTGCGGGGCTTCAGTTACC 19 
82 NM_004813 
hPEX16_R GGTTAGAGGCAGAGTACACCA 21 
hPGC1a_F TCTGAGTCTGTATGGAGTGACAT 23 
112 NM_013261 
hPGC1a_R CCAAGTCGTTCACATCTAGTTCA 23 
hPGC1b_F GATGCCAGCGACTTTGACTC 20 
186 NM_001172698 
hPGC1b_R ACCCACGTCATCTTCAGGGA 20 
hPex10_F TCTGCTGGGAGTGCATCAC 19 
94 NM_153818 
hPex10_R CGAAGGTAGATGAGCTTCTGGG 22 
hPex12_F TTGAGGTGGTAGCACAGGACA 21 
88 NM_000286 
hPex12_R GTGGGATTTGATTCTGCAAGAAC 23 
 hPPARa_F1 ACACTGTGTATGGCTGAGAAGA 22 
117 NM_005036 
hPPARa_R1 GACGGTCTCCACTGACGTG 19 
hPPARg1_F AAAGAAGCCGACACTAAACC 20   
hPPARg1_R CTTCCATTACGGAGAGATCC 20 
hABCD1_F GCTGGCATGAACCGGGTATT 20 
143 NM_000033 
hABCD1_R GCCACATACACCGACAGGAA 20 
hABCD3_F GCCTGCACGGTAAGAAAAGTG 21 
100 BT006644 
hABCD3_R AGCCTTGAGAAAAACACCTTGTC 23 
hAcox1a_F1 CCTGAACGACCCAGACTTCC 20 
227 NM_004035 
hAcox1a_R1 TTGCCTGGTGAAGCAAGGTG 20 
hAcox1b_F1 GGGCCTCAATTACTCCATGTTT 22 
114 NM_007292 
hAcox1b_R1 TGGGCGTAGGTGCCAATTATC 21 
hMFP1_F1 GGTCAACGCGATCAGTACGAC 21 
104 NM_001966 
hMFP1_R1 CCTCTGCTCCACAAATCACAATG 23 
hACAA1_F GCGGTTCTCAAGGACGTGAAT 21 
128 NM_001607 
hACAA1_R GTCTCCGGGATGTCACTCAGA 21 
 
 
 
Table S 4.1 List of genes encoding metabolic enzymes 
 
Gene Name Gene Description 
ACOT1 acyl-CoA thioesterase 1 
ACOT2 acyl-CoA thioesterase 2 
ACOT4 acyl-CoA thioesterase 4 
ACOT8 peroxisomal acyl-CoA thioesterase 1 
ACOX1 acyl-Coenzyme A oxidase 1 
ACOX2 acyl-Coenzyme A oxidase 2 
ACOX3 acyl-Coenzyme A oxidase 3 
ACSF3 acyl-CoA synthetase family member 3 
ACSL1 acyl-CoA synthetase long-chain family member 1 
ACSL3 acyl-CoA synthetase long-chain family member 3 
ACSL4 acyl-CoA synthetase long-chain family member 4 
ACSL5 acyl-CoA synthetase long-chain family member 5 
ACSL6 acyl-CoA synthetase long-chain family member 6 
AGPS alkyldihydroxyacetone phosphate synthase 
AGTX alanine-glyoxylate aminotransferase 
ALDH3A2 aldehyde dehydrogenase 3A2 
 AMACR alpha-methylacyl-CoA racemase 
BAAT bile acid Coenzyme A: amino acid N-acyltransferase 
CAT Catalyse 
CRAT carnitine acetyltransferase 
CROT peroxisomal carnitine O-octanoyltransferase 
DAO D-amino-acid oxidase 
DDO D-aspartate oxidase 
EHHADH enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase 
EPHX2 epoxide hydrolase 2, cytoplasmic 
FAR1 fatty acyl CoA reductase 1 
FAR2 fatty acyl CoA reductase 2 
HACL1 2-hydroxyphytanoyl-CoA lyase 
HAO1 hydroxyacid oxidase 1 
HAO2 hydroxyacid oxidase 2 
HMGCL 3-hydroxy-3-methylglutaryl CoA lyase 
HSD17B4 hydroxysteroid (17-beta) dehydrogenase 4 
IDE insulin-degrading enzyme 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 
IDI1 isopentenyl-diphosphate delta isomerase 
IDI2 isopentenyl-diphosphate delta isomerase 2 
LONP2 peroxisomal LON protease-like 
MLYCD malonyl-CoA decarboxylase 
MVK mevalonate kinase 
NOS2 nitric oxide synthase 2A 
NUDT12 nudix-type motif 12 
PAOX polyamine oxidase 
PECI peroxisomal D3,D2-enoyl-CoA isomerase 
PECR peroxisomal trans-2-enoyl-CoA reductase 
SOD1 superoxide dismutase 1, 
SOD2 superoxide dismutase 2, mitochondrial 
XDH xanthine dehydrogenase 
Figure S 5.1. Map of DRL assay vectors. pGL3-basic vector (#E1751, Promega), and pGL3-control vector 
(#E1741) and pRL-TK vector (#E2231, Promega). 
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Publications 
 
• Costello, J., Castro, I., Hacker, C., Schrader, T. A., Metz, J., Zeuschner, 
D., Azadi, A. S., Godinho, L. F., Costina, V., Findeisen, P., Manner, A., 
Islinger, M., and M. Schrader: (2017) ACBD5 and VAPB mediate 
membrane associations between peroxisomes and the ER. J Cell Biol, 
216(2), 331-342. doi:10.1083/jcb.201607055 
 
• Schrader, M., Costello, J. L., Godinho, L. F., Azadi, A. S., & Islinger, M. 
(2016). Proliferation and fission of peroxisomes - An update. Biochim 
Biophys Acta, 1863(5), 971-983. doi:10.016/j. bbamcr.2015.09.024 
 
• Azadi, A. S et al (2018). The canonical TGFβ pathway induces peroxisome 
proliferation in HepG2 cells via PEX11β expression (Manuscript in 
preparation) 
 
 
Courses & workshops 
Scientific and laboratory skills 
• PerFuMe Workshop I ‘Systems Biology of metabolic pathways’, 
Wageningen, NL 2014 
• PerFuMe Workshop II ‘Peroxisomes in Health and Disease’, Exeter, UK 
2014 
• PerFuMe Workshop III ‘Science in Industry’, Potsdam 2015 
 
• RNAseq Workshop, Edinburgh, Scotland 2015 
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Transferable skills 
 
• Project Management 
 
• Scientific Writing 
 
• Learning and Teaching Stage I; 
 
• Researcher Development Induction; 
 
• Presentation Skills: Learn the basics 
 
• Health and Safety training 
 
 
Conferences 
 
• Oral Presentation, PERFUME 2nd Conference (Jul 2016, Hamburgh, 
Germany) 
• Elevator Pitch, ESOF 2016 (EuroScience Open Forum) (Modern science 
& Business Session, July 2016, Manchester, UK) 
• Coordinator of Organising Committee of BioCon-2016, PhD student 
Conference in Biosciences (Jun 2016, Exeter, United Kingdom) 
• Oral Presentation, Progress Meetings for PERFUME Network (Sep 2013 
Groningen, Netherlands; March 2014 Brussels, Belgium; Dec 2014, 
Exeter, United Kingdom; Jun 2015 Sevilla, Spain; Dec 2015, Berlin, 
Germany) 
• Coordinator of Organising Committee of BioCon-2015, 1st PhD student 
Conference in Biosciences (Jun 2015, Exeter, United Kingdom) 
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• Half time PhD Upgrade (March 2015, University of Exeter) 
 
• Poster Presentation, Health and Medical showcase 2014 (Jun 2014, 
Exeter, UK) 
• Oral Presentation, 6-months assessment for University of Exeter (March 
2014, University of Exeter) Poster presentation in PERFUME-ITN Kick 
off conference (Dec 2013) 
 
 
 
Activities and Societies 
 
• Founder of Bio-PGR-Network: This committee is organising events 
targeted to postgraduate students in Biosciences at University of Exeter. 
Postgraduate Researcher Liaison Forum Representative: Bringing issues 
in the department to the meeting with CLES (College of Life and 
Environmental Sciences) admin staff and with the Director of 
Postgraduate Research at University of Exeter. 
• Committee member of Early Career Research Network: This network has 
recently been established in Biosciences to help support postdocs and 
PhD students in their career development 
 
 
 
Awards and Grants 
 
• Best Presentation and Business idea Award Entrepreneurship and 
career Workshop (Dec 2015, Berlin, Germany) 
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• Biosciences Research Strategy Grant BioPGR Committee has been 
granted £2000 per year (2015-2016, 2016-2017) 
• Researcher led-initiative Award, Funding has been received for 
organising an event for PhD students career development: Beyond 
Academia: what your PhD can do for you? (May 2015) 
Other PhD training 
 
• PerFuMe Progress meetings 
 
• Weekly Biosciences seminars at University of Exeter 
 
• Journal clubs at University of Exeter, Schrader lab 
 
• Secondment I and II, University of Sevilla, 
 
• Secondment III, Amsterdam Medical center 
 
 
 
